var title_f37_59_38832="Thumb spica cast 3";
var content_f37_59_38832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thumb spica cast: Step 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cut a hole in the stockinette for the thumb. Cut the distal part of the stockinette covering the fingers at about the level of the proximal interphalangeal joints.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_59_38832=[""].join("\n");
var outline_f37_59_38832=null;
var title_f37_59_38833="Transection of redundant sigmoid colon AP view";
var content_f37_59_38833=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Transection of redundant sigmoid colon AP view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 639px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJ/AfYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACig8A1n/bZv8Anmn50m0gNCiqAvZe8IP0apVu89YmH0NLmQ7FqioRcqf4WH4U7z4/Uj8KdxElFME0Z/jFKHU9GX86YDqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooppdR1YUAOoqMzoPU/hTTcDsrGlcCaiq5uD2T9aja6k7Kv40XQ7FyiqP2mb/Z/KnxTSNIoYjB9qOZBYt0UUUxAehrK4rVPQ1k4qJjQZFODCm4oxUDJlenBqhFOFUBJkU07T2pKSgBwwDwSD7VIkjr0bcPeoKUUXAurOv8AEMVKDkZFUQeKVWZOVOPbtVKQrF2ioY5wxw3yt+hqaqEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFJkbtvfGaWoUObyUeiL/NqBpE1FFFAgooooAKKKKACiiigAooooAKKKKACiiigAooooAYZAJljOcsCR+GP8afVaT/AI/4B6I5/wDQas0Da2CiiigQUUUUAFFIzBRyajaQkelK4D2cL160wyHtgVCzgdKjZ6TkOxKz56kmmFx2FQlqM1Nxkm+k3GmZpdwoAWjFJuFG6kAuKfD/AK1frUe6pID+9X600BeooorQkD0NZeK1D0NZmaiQ0JilxRmlqRiCloxRigBDSE04000AJmlBppNIDSuMmFOBqIGnhqYh5wRg09JXj/2l9O4qLNKGppgXY5FkGVP4U6qIyGDLww/Wrkbh0BH41adxNDqKKKYgooooAKKKKACiiigA70UHrRQAVXj/AOP6f/cT/wBmqxVfGb3cuMBNr/nx/X86RS6ljNFJS0yQooooAKKKKACikJx+NLQAUUUUAFFFFABRRTHbAoAdkUuaqO5pFmOCAcHsfSlcvkdh0H727ml/hXEa/hyf1/lVqq1gcQmM43Rnaffvn8c1ZoQpbhRRRTJCo3k7Lz70SHPA6d6jY4FJsY1jjknJqNnpsj5NR5qGxjiSaYaM0HpSGFJmkopXAXNGaTFLigBOaOadijFADMmpbYnz0+tNxT7cfv0+tC3A0qKKK2IA9DWVmtVvun6VkVEykOzS5pmaM1AyQGlzUeaUGncQ8000ZoNADDQOtKRTehqRjxSjimg06mAuaAcGkpp4p3AlVqsW7YfHZqohuamRvTrTTEaNFIjblDDvS1oSFFFFABRRRQAUUUUABooNFADXZURnY4VRkn0FVbJmNsskgxJL+8I9M9B+AwKXVcfYJVbo+Iz/AMCIH9aUtnp0pPc0ivdJQ/NPzUI61KKCWh2cUbhTHNRM3PFFwUbljNKKqiUiniXNFx8jJm7fWkb7y/X+lRGTOPqKWSTDLii4uVk1FRCSneYKYrMfRULS+lIJDmlcfKyYmoXPNK0mRULNgZobKjEZIapyziP61LNLgGsi4k3MeazkzqpU77mppdwz6nIv8LRbj9Qcf1rZrmvD5aTWpiPux24B+rN/9ia6Wrg7owxCUZ2Ckc4WlqKRvmx6VTMBp4FV5n7U+V8CqrnJrNsoAck0tIBgUtSMKQ0ppKAEApQKKM0gFpcUlKKYC4oxQKWmITFPgH75PrTakg/1q/WmBeooorQkG+6fpWPWw33T9Kx6iZSCijNGazGFLSZozQA4GlpmacDTELSEUtFAxop4puOaUUIBaRhkU6koArucGnxvTJhgmoVbBoA27Jt0RHoanrO02TMzp6rn8v8A9daNaRd0SwoooqhBRRRQAUUUjHAJoAXvRmkHSigDL8TSeVpgOcZmiH/j4p9tJuUVU8bEjw7O69Y5IpD9BIpP6ZpLCYNGuD2rNv3jspwvRv5v9DVQ81MDVVDUytxVIwkiQjNQupFSbqMg0yVoVqKnZVNQvgUjRO4gPzAfjTnOCnNZ9zKwuIgvTDZp80pwpz0INTzGns3oXC1GTVeOYHrU4welO5LVh2aTNLtHrSMygUyRc9zVe4lAHWmz3AAwKoySFjUtmsKberEnkyDWfO4VSasTOAKw9UvAg25rKTsd1Knd2R1Hg8B4ryfuZBH+AUH/ANmNdDXKfDe4W50S5YHLC7kB9umP0xXV1tT+FHm4pWrSTCqTyZZj71bkbajN6DNZanKinJmCHs2aYOtBNArNlC0GikNAAelJ1oNFIAFKKKWgApRSUopiFpaKWmAVJB/rV+tMFSQ/6xfrTQFyiiitCQb7p+lY1bLfdP0rGqJjQUUUVmUFFFFABSikooAeDS0wU4GmAtKKSlWgBcUlOopgV7jpVTvVu5+7VSpAsWT7L+D/AGsr+lbtc3Hn7faY/v10laU9iZBRRTJjiMn6CrEOz6AmjPrmkFOpAFMm4jJ9Oafmq9wd0kcXZslvoKYEynIGKU03bg8cUp96AM/xFZtqOg6jZxnEk9u6IfRipx+uK4jw5q/n6bbT5+8g3D0NejA14xb3C2Ova5AoIs0vpVQf3ecn8iSK56zs0z1suXtIypv1/wAz06xvY5lGGGa0VcEcGvObS7KuGjbKmuistQfAyc0QqXCvg3HVHSZozVCK8yOal+0qRWl0cbptFhm96hkaoXn9KYJeeaGyo02En+tTPoRVS/YrEjD1Aqe4blG9DUF/g2Mh7qA1YzZ0QVmiWN/lFTLKR3qhaTLJCMHkVIWNWmEoa2ZdM5x1qCSYnvUG401mouJU0iRmz1qGSQKKjkmVe9UbifdnFS2bQp3GXt1gHmuXvpzLJnPSte5YsDWJOhVjWMnc9KhBROm+G96LfWLqxY4W5TzUH+0vX8SD/wCO16PXi+jzG38QaPODtxcqhPs3yn+de0V0UHeNjx80p8tVSXVEV0cW8v8Aun+VZYPA+lasy7onX1BFYgJAGauZ5yJweaeKhU1MKkYUhpaaaAAUtIKWkAClpKWmIKUUgpaAHUtJS0wFFSw/6xahqWH/AFi/WmgLlFFFaEg33T9Kxc1st90/SsIGs5lIkzRmkBpagYZozRRQIKXNJRQAtOFMFKKBj6cKZmlBpgPopM01mxRcCC5boKqSyCJCx69h61JNIMsx6CoIY/PfzJB8o6CpuMbbtOZknyMocgHoa111KfAJhQ/Q1SCHPA4qRI2pp2EzTgv4pCA4Mbf7XT86sXALQNt5OMiswRgjDc06Od7Q93h7r3H0rRPuTYvxSB0DDvUmazXkNuwkQ7rd+VYdB7VIt/CejZPoKdwsX81VmyL2EjptbP5imfbY/wDaH1U1Dc3cTbHVxlT+lDYWNOkzVaObcgZefaplkVvancVh5ANfP8kxf7XN1aa9nkPvmRq99LgDrXgaR4muYcf6u8nQj6SNXNidke1k1uaXy/U2tBV2X29K6i3ygFZWiwhVAxXR28AOMiogjsxNRXFjmwOelTJOh71P9nRkxiq8lkf4K1s0cHNFkodf7wpGlRRywqt9imzxmpE0+Q9TRqHuLqR3ExdCAcDtUqN9otyjdcYNTR6f681GLcwXGQflPBqJxdhqUWrIzYI5IkYEEFTipkmf1zWukQ8w5Aw4/WnLaID90VUY6CdeL3Rlo0rngVYW0mk6nFakcKL0UVMMAcVaj3MZV+yMY6bgZbk1m3lqVHA4rqHOeKy9Qx90d6UooulWk3qczJEKyb+PaxroLlQDWFqJyxrCSPUoyuzLOQ9sw6rPGR/30K9gvtVjgJSHEknfngV45dnEEY7tKgH513MZ3AEHJNVSla5xZqruHz/Q1zdXM7bmnYA9kOBUKs8L4YkoaW1jbbzVry8qQw4Na3vueQKj/lU6tkVSUGNtp6dqsR0CJiaKaKWgBR1opKKAFzSim04UAKKdTaWmA6ikFFMBc1LB/rV+tRVJB/rV+tNCL1FFFaEiN90/SsKt1vun6Vg5rOoVEUGnimU5azGOooopgFFFFABRSUtK4CinZptNJpNgOZqid/ekZqo3kzcRR/fas3IpIbI32m42J9xfvGrmduAOBUdtCIowo69zUjqcUrgTq3FPDVR3lakjmzw1UpCsXQ2abKCRkUxTUinIrVO4iC2uHs5SeWt2OXX+77ituIxsgeLaVbkFe9YsyYOR0o064FrKY3bEDnjPRT/gatSsJo2yaybu5F1uhQZiB+Zj3x2FP1q5MUHlxn534z6Cqca7IUx6UpS6AkTaY+EeMn7pxV9GGKyLBv8ASph6jNaCvgE1KYx0xOeDivH9YtzZ+LdVgbo8wuU9w4BP/jwavWTKCea8/wDiNCsOt6ZfL0mja3c+6ncv83qKusT0crny1uXui1pPTNdFE+FFc9pRBhUiteOTjmpiztrxuzVjcMKkB5rMSXaeDVpLgEc1qmccoNGgmMU7IqolwuKcZ1HequYODLYaql5gYb0NJ9pUCs3UrwlMA8ZqZSVjSlSk5GkzhVB/umpxKD0qg7/u6gWcryp4qYS0G6VzZDHFLvx1rNS/A4I5pXui4worTmM/ZMtT3CxjrzWVNIXYsalIB5Y5NVLxwiErUSZvSgk7Io30gANc5dvuY1fv7jORmspm+bNYSdz1aMOVFW4BfUbCHOP3nmH/AICM/wBK7XR23nB7VwupNs1fTZBx+92/mCP612mjHa5HrVU9jzc0vzx9P1OljOOlTrhhzVaM09HIatbnlEsseVpsZ4weoqVWyM1HIuDkUMQ4GnZqMNkU4GlcY7NFIDS0XEKKdTacKdwFpaSlqgCiiimA6pIP9av1qOpYP9av1poTLtFFFaEiN90/SsCt9vun6VgVnUKiKKetMFPFZjHUUgpaYBSGiikACjNHSmk1LYxS1MY0hNNrNyHYZPII0LH8Kr2sZyZX++36UuPPn5+4lWlFTuMcg70rUUlMRE65qMrU7CmEUhj4X7GrKmqYFSxvjg1cWJosMAwwarSxZ47VPu4prc1rckotEQhXuOn4VbkOI0+lBA71XmkwhJ6CkMXTuZ5m/CrzthKoaXxAznq5zU8zYQ0ICJn5rjvHbJdXulWbcmMvct7ADaPz3H8q6oNk1wGqzNceJ9WlJysKx26fQDcf/HmNTUeh35dT5q1+3/DGno1wvllAfunFaySZrk9LYxTA9jXSp90EdDWcHdHr1oWkXAxp6yEd6rxtng1MBVo5mkTCY0hmNR4pCPencnlQ9p2x1qrITKyr6kVISoojX9+hHcGk9S42jqjTnbZB15xSRhVQcZqrqLkRIPcUyG6UqFc4NEGYcjcbou4XOdopxfAxVfzkx94VFLdRgcHJq7k8jY+aXDEZrLv7rKlEp0rNIc5IFM8oAdKhu50wgo6sxZgc/NVWTqa17uMHkCsiXhzWTO6m7mfrbbHspP7s8Z/8eFdlpzFZlPauH8TPtt7f/rov867WzPzrV0+p5maL4H6nTq+VGKcpqOP7i/Sn9Kts8cmR8VLnI9qqg1IjdjU8wWFJ2t7VInzVG4yKWBuoouBNjFLS9RTc1QhwpRTacKYDqKTtS1SYgpRSUCqAcKmg/wBYv1qEVNB/rF+tUhF2iiitCRG+6fpWAK32+6fpXP1nUKiOFPFMFOFZjFpaSlFAAKKWmmpbGIxqMmlY0yspSGkGaZM22M46ngVJUMvzSov41FxjoE2R47nrUo4oHSimgFzRQKUCmhCGmGpDTGpgNpRSUU0MepNPzxUa9adWiEI5OKztQk2xhQMljjFaDVmx/v8AV4lPKqSfyoAuabxaRjuMg/XNPuD8pqC0/dXc8R/vbhU9z3poRUQ81wE6Mmua7G33vPDfgyBh/Ou8Q81yGvRiHxW7D7tzaqx/3lYg/oVrOotD0sslaq13RVtEy4rpbQHaBWZp9uA5Y9BW3bAAjFTFHp153JhanblajMbr2NbEAG0cVaEKY5Fb8tzz3X5dznNrehpyxOx4U1vm2QnpR9nUCjkF9ZRjJZsR8xxTkhxcIOwBrTkTbVXP+kD2FTJWQ41HIqanGX2KvrVQW/rWm2GuQD2BNTC3UjNTGN0UqnKkjH8gDrQIlFaM1uD04qq9uyjIOadi1UuRCMUyQAA0rMwOKhckjmkaJFa5A2sRWBP/AKw1vTH5TWPdKFbdWcjqpaHPeIB597p9sP8AlpMo/DcK7m24b8a5HSLc6h4ie6cZhs1493OQPyGT+VdZbn56qmebmc05qC6L8zqIOYl+lP70y3/1KfSpKcjywozRRUDJQcgGmZ2SA06PpTZqZJbU0h602E5QU89a0QgFKKSimA7NGabmm5oAkzTgahzTgapMRMKmg/1i/Wq6mp7f/WL9atCL1FFFakiN90/SufroG+6fpXP1lU6FRHilpFpazuULS0gopXAU01jTiajc1EmMY1JS0Vg2UFRDm4NS1En+uP0oAmopRRViCnUlLTQBTSKfSEUxERFFOIoxQhjRTgaMUYq7iI5WwCaz9KOdSXPUg1en+7VCyUwXcUrfczg+1NPUDR1GF0kW4iGSOoo3rNDuXuK08ZrJvoWtg0kIzGeWT09xVtEpmfI+08VxdxOb/W7q7JzHGPs0P0U/Mfxb9AK6TVbo2+nXVzFy6RsVH+1jgfniuWtIvJgiiHO1QMnvWVR9D2MspayqP0NvT3GNpPNasLYxWDbI4IODitaJ8gZ60os7asdTftpQVFaEbhlGDXNwzlDV6G8H0raMjz6lFvY2c0jHArO+24FRS3juMDgVXMjJUZFi4mBbANQxjLFvU1TklKqTnmrloQQKynI25eSI0nbeD/d/rVsONuKoX0nl3Ab/AGf61CtwWGQaIOyG4cyTNB+tRsQBzVT7U/Q1HLOzcHpVXBU2MmILnFV5TgU9mqvK1Zs6Yorz8jis91BfDVfkOASazHbdOfQVDOmBU8LHF5rKDoJlP6H/AAroYFIesLwku46pNjh7oqPcBR/Umumgjyw+tVB2R42Od68v66G7B/ql+lSCmRjCKPanihs4haKM0VID4z1om6UidadN93NMBbVv3dTsaq2h+T8asE8VSEOpDxQDTWNUICaAajzzTxTAcKcKZmnKaaAepqzbH96v1qsKntj++T61cRM0aKKK2IEb7p+lc+K6Bvun6Vz61lU6FRHigUCisihRS0lLSAQmo2NOY0w1nJjDFKBRS1kMCKgH/HwPpViq3S4T3oGWhRSilxViG0CnAUoFADaCKdilxTER4oxUmKNtADNtBWpNtLjihgU51qDywwZD0arsi5FVXGORU3aYy1YTnZ5Un30457iluX3HFVf9YAyHbIvQ0xrn59r/ACv/ADrVTYrHM+OkWCwhEeVa4uI0IHQ4O4/otZdhEJZwD0HNZnjrxOL/AMcaf4d05FkaxU3V9Kx4i3DCIPViCT7AitjRjmZ8+lS99T3sCrYe68zXjjHTHFNZCrVZjHFTxQeYcYq7A52KSk96kGRWl9jVRyKrzWrDmPmnytEKrFsgDmnBzUbK69VNRsW9DSLsmSzODE4zzir1i+Y1PtWQ+SCK1NP4hQ+1S9WTUjaJU1iZjMqr261RS4aPqa0p4PNLNVCS1JPJp2ZcHG1h63St1p/2hD3quLQY71G9sR90/nRdlcsWWmkB6VWkcZ61WlVx8uSKoztLH94kipbNI0yxdTjoDWdPMILaWZzgKCaQSKW5NVnA1PUoLKLmFSJJj22g9Px6fnUbmztTi29kb3h61+y6TbIww7DzXz13Mdx/nit62HzCq8Sk81es48uKt6HzNSbnJyfU0U6AU7FAFOAqTMbSilIpKAFXrSzf6s0KOaJ+IjTWwDbX7tTseKgtuFqVjxVIQ7NNJpuaXNUmIQU9aZTlqgHd6cKTvSimgHrU9t/rk+tVx1qxbf69PrVxEzSooorYgRvun6VzwroW+6fpXPCsqhUR4paaKdWRQtFIDQaTAaxptBoFZSKQopwpBTqzASqsnEyH3q1VWb/WL/vUAXV6UuKROlOqgCjFLRQIAKdikp3AFMBBS0xpBTN+adxkpNMLUhbimk0xAzVTnbnirJNUp25rNjRXeRkbKmqeqahDaWFxeXR/dwoXPqcdh79qnuHAUgda4Px7ctO9npUbcSHzpgP7oPA/E/yoTOjD0va1FE4zQtPuNPN3rl44kmv7x7mV+4Vjwv0UAAfSuu8E+ILfWbq/NqrGK1mNuZMfKzDrg965rxPbapfaNNp2kMsckoKb26ID1P1xmtrw9f6R4T8FKZStvY2Ue1+MkMOufUk/mTVrXU96UeRcsVaKR6PDyoNXIXC4rE0e/hu7SKSNuHUOoYYOCMjg1po9apnHUiaoYMuaadtUVmZTwciplnUjniquc7g0Sso9jUZhQnkCnB0P8VODL6imGqKt3bLsJUY4p1umyyU99tPmkG0gHJqXbi0T/dFQ1qXzPlSZCCFjP1pqQq3zGopSdv4n+dSQSgqATTG07XRJ5SelUryAK2Vq80iqMkiqE8vmPx0oY6d7lSSHcOaoXEIKEGtN2xk1nXbhI2Y1mzrg3cyI4189wVBwPSneEEVo79wBuNyyZ74AGB+ppquEWadzhFHU1Z8IRlNJhdhhp2aY/wDAiSP0xULcjHytSt3aOnhjwBWnZw4UkiqltztrXiACgU73PBY3ZxShMVNtoI4pEkBFJtqUrTcUDGqKjuf9XVhV4qK5XK0xEUfSnGhRgUUDClBptFUmIkpRTR0pwq0A+lFMzThVCHip7X/XJ9arg1Pan9+n1qo7iNSiiityBG+6fpXPCuhb7p+lc8KyqlRHClpBSisihaQ0tNNJgNNKKQ9aUVjIocKDSUZrNsANV5vvqfep6hn7GlcZajp9RRmpM1SYhacKYCKC4FUA8nAqGSX0pjyE1F1pXAfnJ5pwNRin00A/NGabmjPFUAyZsCs6eULkDrU15MEHv2rKLNNMI0POMsfQVEmoq7KirjJ5QDgZY9TjtXn0s/27WtQv5ANit5MYH91eP1OTXc+JblNM0WeRANyozD3IFefW0f2fToIurEZY+prOnLm1PYy2nvP5Fq2n2OWJ5zmuP1jTZNR8ZWU81q76Lbn7VOoOVeUHahK9wOTXUY+VR6nJq7aymD5SMoa2TselOCmrM6OW7s4NJN3JNFHBGu8yswAAHcmtDTNRt7+ygurWVZYZUDo69GB7ivE/E9rea7rMPh/TlmXTmJurxWyImVSCsYPbceo9BXqmjala/YkhdRbyxLgxEbSuPT2+lWmcsottrsdMr08NXK+DvEcfifSm1CzhljtvNeJPMxlwrY3D2JBroY5M/WquZct1dFvNKTUKsTTwQD8xp3IsSxLkjNaEnFsvsoqrafO/TgVckGY9pHXiktzKpukZ0gzHmqpbBqZHzGyH7ykg1WcEGmzaKtoKzZ71E5wKGJqB2qWzRIR3JHJrI1G43NsXntVy0uYb+7uLaGdN9vgTAHlM9BXCeKdXl0jxzoNvYXcU0N7JLBNDIoIQhNytu9QR096lps1jKMNWWdYvLp/EWmeGngCw6hDJK04bkBCCy49wRzXfWaYwFACjgAV57oOn3t78SpdUvpo5Le3s3itVTORuZdzN6ZwQB6CvS7dMHFS7LY8zHVJSnyvZGnZDGK00NZtvxitJRxSPPZMr07NQ0u6i4iXikxTN1KGoAcBxUM54qbPFVrhulO4gHSkNAPyilNK4xpFGKWkPFUmAopwpopc1omIfSim5pRViH1Paf69PrVcVPaf8fCfWqjuI1qKKK3IEb7p+lc8K6Fvun6Vz1ZVOhURwooFFZFDqaaXNIaljGmlpDSVjIY7NIaKKybGFRy9BT6RxlSKm4xyNgClaSoUOeO9OIqkwF8w0m4mm0CquIdSUUhouAuaXdUZNANO4iUGmythaFNVLubANK47FC9l3SHngcUmlrmJpT96RifwHAqncPhHY1ftCIraJD1VAD+VY4iWiRpFaHL/EV91nBbqeZpkj/DO4/oprmrn74A7DFbPiyUXGq2af3TJIPwAX/wBnrFl5mP1rSivdPfwUeWih4H+FW4kytVgORV+25WtUdLY5E8shlAHY4qj4stJ77w/fJYxJJeNC6QFx91iMDntW3Aox0rUWBHjAIwMVaRlKXRmD4X0CbQPDunWen3BTyIERo5BuXdj5iD1GTk1z11req3PxJ0/TUlmSzsoWudQW3BZTuysYPHrk49q9DhhMQPz5GOBVTSdJttP1G+vYIwLi8ZWmfu20YFUYNaWRopqFuYCyyxMqjOQw/WsD4b+JZ/FWgrqVzarbeZJJ5SqSQ0YYhW59QKteNrG5v/C+pwaTFF/aE0DRxMwAAYjGc496r+EvDVrpPh/T7JWkhubaBImkhO3cQACSBwfxoexmt79Dq4dZ0611m10ea5RdSuo2mihwcsq9T6d62ZD2ryO306+n+Lj30skrQWOmLBbzSqpyzyFmxx2AX867vVb+7ttJvJ5JoNsULuSIWzgKT/epnPKEm+Ys3kO91mtmVlfqQeDWRc6hBDq0OmyToL6aNpY4ieWUdSPpkVzvwdju4Phl4fUTRhWthJhkbI3Et1z71m+JdOnn+KvhS5Ek5CQ3YmmijwsabFwM89WNDWtjWEnypvyOs8RXE+n6JfXkJjM0ELyIrnAYgEgGsbwn4pGr+GNOv1tpJbu4t0leOJDtDEZIyeMZ961dW0+1nsbmESPJcSxsiNIxYKSMA46CqPg/TW8M+GdO0rPntbQrGz9Mkd6k6Em35HJaI8s3xQ8RreHyYmsraSaKByAWBkADH1xW1q+l2N9f2V19liX7DuMGBjazDBP5d61jbQxXM1wI0E82DIwHUDoKpahL5Vs79cAnHrUuVzop0lFFzwjCu+8nxy7BF+i5/qTXVW/365vw6Ps8cSHoVwT/ALXeuki4YVhTnzq54OKlzVXI0lXkEVoR/dFZ8RytXIHyuKq5yMlpppeaaTTuIM0BqaaSi4Em+q9w/IpzHAJqumZZc/wii4y0Ogpc03NGaVwHUlJmlqkwCjNIaK1RI5TUgqEHmpVrRCHip7T/AI+E+tQip7Ufv0+tXHcRq0UUVuQI33T9K5yujb7p+lc5WVQqI8UtNFOFZFi000ppjGpYATSZphbmk3VjIokzQDUeacprFjHilpBS1IDGXncvWhWBODwakxTGG7gDJpoBSlMcon3iKetsSPmcj6VJDbRxnJG9vVuaoRVNxGMc05ZI36MK0OCMHpVeazgkB+QK3qvFVYCsy9xTV60yRJLZwGO5D0NSqvOR0pAK5wmazbgbgc1oTn5cVQuB8v1poaMuePe0UX99wD9Op/QVpuoVGOOgzVW3TzNRHpGhP4k//WNXbpCLWU/7JrkrS941XQ831VjJ4jI/hjtQfxZz/wDEiqGcz/jV26Odc1Nv7qRJ+hP9aox8zfhXVT+BH0dBWpx9Cz/EKuWpxVEcuPpVuHjFaIpmtbDO2teIYWsm0OGHtWvGflFaI55jgcmpo0qFfvVbhFNGcnoKqYpGXBJFWNvNBTiqsZcxTRPnyaluAkkDo4BRgQQe4ofjpVaeTjGaRa1IVgjjjSOH93Gg2qo6AU0xIMg5OR1oVuaR2yTUmquJsjiX5Rz61Ulcs3Wnzv8ANjNVy3BNSzaKK8zHn34rNnU3N9bWy9Gfc3+6vP8AgPxq9Mf0p3hmHz9RluWGQD5afQdT+f8AKsK0+WDY68+Sm2dBHYBLM7F/eIN4+o7f0qzA4kjR16MMitKxj3E5HFZOnLtg8v8A55syfkSK5sLLVo+em7mtH2q1E6oMk4qoudigfeNX7S3Vfmkwze/QV1GDHCXIyiOw9QpphkYfeicD3U1e3dqM0WJKasjjIYUOVUZJqWW2jkbcVw3qOM1DJalW3RnPsaBldt83GNqfzqRVCLheBTgwJwRtPpQQRSAbRS0lAxc04Go6UGmIcTRmmk0gNbRYmSCpUqFTUyVqhMlUVYth+/T61Cg4qxbj98n1rWJJo0UUVsQI33T9K5yujb7p+lc5WVToVEcKctMFPFZFAelQualbpUEhqWNDGNMLc012pAawZRKpqRTUKmpFNQ0MlFP6daYOBzSxZlbP8IqLAPALewqRQAOKUiko2EOBpwNMzS07gPzSZppNGaaYhJkWWMqf/wBVVIchSp6g4q4DUEo2y7uzfzobGVp+tVJ+oFXZBk1TmHzn2pplIj0tQz3B7+YB/wCOj/GrOpfLYye4xUOhjdBNJ3aZ/wBDj+lWdVXNpx681wzfM2zXZnlMzZv9Xf8A6bKv5RrVOD/WMfarNx8txqfvdsPyAH9Krwjr9K74fCj6WCtBeiJkPzj6VbQ8iqmMbDVgHG2rGzXtGyBWtE2RWFZP0rWgb5atHPNF+H+dXYRVKI9KvQmrRzTJ1HND8CnJ0psvAqjHqU5mwKz5my1XLhqzpTzUM6qaHK3eoXc/nShsIahZsn6VJukMlbkmoS3FErcVC7cVLZrFFTUpvJsp5R94Kdv17frXReGLYQ28agcKMVyeskuba3H/AC0mQH6A5P8AKu70mPCIB6VwYt6pHDj5aJHQ2a4jz61jWg/e3WOnnyf+hGt+AbYlHtXP6ad0Uj/35Xb82NRhfiZ5EtjUgHRu9XozVOPotW1ruMWS5pc0wGloEPBpc0zNFAgliWQcjn1qswaI4flexq2ppJFDqVPQ0rBcqkd6bihcoxRvwpzCkUMNJS0hoAQmkBpHpoNaQYmTKeasR9arR81Zj610RJZYSp7f/XJ9agWprb/XJ9a1iSzSooorYgD0Nc3XSVzjfeNZVOhUQFPFMFOHSsigc8VUmbAqzIeKoTt1qJDRGTk09aiB5p6msmUTKalT1NRIO5ps8wCkCoYEu5ppBHH07mtFIwiBR2qvpKYtt56sauEU1ETYwimGpDTGqGhiUCiioGGaM0lFFxC5pHAZcGilFFwKuCGIaqkw/etWky5471nsP3zZ9aaZSMS606+1Xwdf2ulXzWF/N5ht7gDOx8kqT7Z61zF38T7XRtLS38cabqeiX8e2OSRrV5raV/WOVAQQeuDg+1eg+HgP7Lix05/nXKfF3wleeMNO0+yh1GOxsYJzcznyt8juo/dAcgbQSSfXAxXFBxcrT2NZXvocXa3kWoWU17b7/JubiWVPMQo2CxxlTyPoakhHX6UpAFtNtGFNzMR9PNaiDrXpR2R9NFaEh+4tSkdKjH3RUrdRVDLlr1rYtWB4rGgPFaFpJhhVIxqK5sRZBq5A+MZrPt5AwJq9DjNaI5JovRsMUyZuKaTxUErEg1VzJR1Kty3JrPlcZqe6as925rJs7acSVm+WmMcL9aYXHSo5pMVNzZIjlamA9fYUwsSaQHCH6UjS1kUcebrlmDyE3P8Apj/2avRdOTEa/hXnmmjzNcJ/uxgfmf8A61el2i4VAK83Eu9RnkY+V528i/ey/Z9PmmHVIy36VkaZH5dpEp67RWjrfGj3X/XI1Wtx8ij2q8J1Z5sti3GORVpeBUEK5NT11XMhwpRTRThTEOFFIKWgBe9OptKKYiG4i3jI+8KgRs8N1q7VG4G2fPrUtDQ4immlVsikNIYx+lQZwanfpVZzg1pERZiOatR9RVCFqvw9q6IkssqKnt/9cn1qFantf9etax3JNCiiityArnZOJG+proq5+fieQf7R/nWdQqIwU4U2lFYlDJjxWdMcmr83Q1ny9TUSKQwdakU4qMUkjYFZMZJJNxgdailyIxnqxpsK5bJqwU3zQL6tUjN63QJBGo7KKeRTgOKCK0sQREU1hUhFNIrOSGRUhp5FMNZWGJS02nUmAmactMpy0gA/eqhOP3zfWrzfeqpdDEmfUU4jRQ062+2+HpbXzZIfMEkfmRnDLkkZB7GvNPH2o+Lfhv4bt5Bqlp4hs3njtIEvYDHdbmztG9Gw/TuoPvXqegHENxH/AHJm/U5/rWL8QvD2keIrS2i1a286WBi8DhirRMcfMuO/A57VxQajP3lobtNvQ84sWnbRoWvBGLlmdpBESVDFznGecVPF1FNi505f95//AEM06Pqteotj6ZKyJR938am9KiHeplGWFMZZtq0IY+9Uo1wBVyFscGmjKRdhBRF96vRPjrVAPkrirYIOBWiOaSLnm8dahkkpjjaAM1VmcjjvQ2TGA25YEVmyN8+KndmY4qsw+Y5qGdUFYQtzTJaQ/fxRJUmyIu1Nlbah+lSAZIqvesFRzSGyTwvEZNSmkPTKr+XP9a9KtV+dR6VwnguHdbJNj77F/wAO36V3licvXlVnebZ4OLlzVGReIHLQRWy9ZnAPso5P8sU+2XLD2qjNI0+uz55SBAo+p5P8q07NfmJrqw8eWBxT7FoACg0ppprUzFFOpgp1VcB9KKYKeKYh1ApBS0xAaqXo5Q1a71DdrmIexoYIqng5pQ2RTivFM24NTYoG5FVpatkZFVZRVRENhPzVo27cCs6Mc1ft+1dEBMvKas2fMwqolW7L/W/hW8dyGX6KKK2ICsC6GLmX/eP8636wrzi6l/3qzqbFRIKdTaXtWJRHL0qjKOTV2U8VRl6ms5FIjFQuctUjHANQKctWZRbgHNWIx/plv/vVDB2qccXNuf8AapLcTN6giloNbWIIyKaRUhFNIqJIZEwqM1MRUbCsWhkdApaTvUsYGnLSAU4CoGMfrVe7GVU1Ycc1Dc/6r8aa3BGdpjFNWuov4WRZB9eQf5Cm+IR9xvwpEJXW7fb/ABxMD+BH+NO119zqmPfNcVVe+zojujyeI/8AEtT6t/6Eaki6Co4/+QbH+P8AM1JF91a9RbH0xMvVqsJ2quv3j9KsA4IpgXIuQKtovNUoTgA1oREHmqRlLQsQR5YVbVfnqO3xxVhBzmrRzSYh5bJqlO3zE1exjNUphQxw3Kp5NRTKO1TEc1G/NQboq4+emSHmpT1qCQ1JshUrK1eQ/Z3VfvMcD6ngVpqcIx9qynHnanZw9vMDH8Of54qJy5Ytik+VN9jvNBt1t7CNB0ACj8K6SwTCbqx7RMQoo9K2rhxa6bI56IhP6V5K1Z85N3ZjaWfMa5mPWSZjn2BwP5VvWa4iye9Y+lxGOzhQ/e2jP1NbsQxGBXopWikYTd2DUxqeaY1BAClpopRQA8U+milFWIWlzSUd6YDhTLgZiqRRSTfdH1qkhEG3ioytTmo2p2Abt4qrOuKtrVe4HFFhlZOtXbftVJfvVdt+lbQEy4lXbH/WMfaqUdXrDq5+lbx3M2XaKKK2JCsO/wCLuT61uViaj/x+Sfh/Ks6mxUStRRQaxLIpTxVGTrV2XpVKTrWchogkPFQIfnqaTpVdPvVmUaNuanHNzB/vVVtjVlm2SRP2VqFuJnRUlKpyoI70GtzMYaaaeaaahjGGmMKkNNNZtFEJFN71IwplZMYCnYptOBqGAjjiq10P3X41bIyKrXY/dfjTiMy+Bqto3fa4/Vabrf8Ax8L/ALtLMMX1m/ozD/x0n+lGuD95G3tiuOt/EZ0Q6Hk1vzpUR9j/ADqWP7gqGz50mH/d/rU0f3BXpI+nJozl6n71XQ4YVOOopiZeQfKoq7EMAVUTtViNuKaMpIvRPtIz6VbikBU1mxnINTIxWrTMZRuaJI8s1RnNP87CYqtKxIobFCNhhNQMetK5NRN0qWbpDHOM1Xfk1Kx4NQt1qWaxElbbEaoaEpn8RrnkIo/U/wD2NWro4jP0pnglPN1+cn0X/wBmrnxL/dsxxLtTkz0u2QZUYpdebdDBbD/ls4Uj27/pUluP3gqpI/2rWHcf6u2Uovu3Q/4Vw0o80j59vqXLdcyAVpgYUVTsly5arp6V3yMGRnrTTTjSUiRtPFJinAU0gFpwoFKKoApKdSDrTQD1ps33R9aeKjmPQVotiRh6VExqVqhY0DFBqC46VMtQT9KEMrD71XrccVSUfNV6DoK2ihMtJWhp/wB1z9KzlrS0/wD1bH3raG5my1RRRWxIVian/wAfj/QfyrbrF1T/AI/G+gqKmxUdyrmkzRSGsGWRS1Sk61clqlJ1rOQ0Qv0qt0erTciqr8SVmUXbY81bZd6FaoQNgiryGgRsaTcedbBW++nykVcNc9FK1rOJk5Xo6+oroI3WWNXQ5VhkVtF3RDENMNSGmGkwGGmmnkU0is2hjDTMVJikIrNoYzFAFOxRUNDFFV7oZiPtVgVHOP3bfSkkBi3R2tA3pKB+fH9adrY/dxn3pupKfsUrKMsmHH1Bz/Sn6sd1lEw6ZBrlxC9+5vDoeQWP/IIt/wDcqWL7gqLTTu0mEegIqWL7legtj6nqTJyRVlR8wqtH2q2n3hQBaBxips4PFVm421MG9aZDRZjbipo2yarJ92pYjhqozaJ2bBqJ2GBSSN8xqF25FFwURXpmOKGbim7u1I0SGMuKgf71WHNQSdqllorXn+rNTeAV/wCJxdH02j9DUV3/AKs1c+H651C/PcFf5Vz4n4Dmxn8KX9dT0K2/1orN0f5oGlPWVi35nP8AWtKNhEksrdEQsfwFVNMj22kC4/hFc+G3PAnsbNom2MHueamNCDCge1DCulswGGmmnmkxQACnUAUtUhBSikpaAA0LSGlSqQEg4FQk7mJ/KnSN/CPxph6VoIa5qFjUjniomNADl6VBPU4+7VaY800MYg5q9CMKKpxjmrsY4raJLJlrT0//AFB/3qzFrT0//UfjW0NyGWaKKK1JCsfVR/pX/ARWxWXqa5uAf9kVE9hx3M6mtUpWonFYM0IZOlU5Opq43Q1WkHNQ0NEIFVp1w1WxUU471NhjIeoq+nSqcIzirqDihoB/WpdMuTaT+TIf3Ln5Sf4TUQpHUOpVuhpJ2EdGRTSKz9HuWbdbzHLIMq3qK0yK13VySLFJipCKTFTYCMikxUuKTFTYLkRWkK1PtpCtJwHchApki5BFWNtMdKz5R3MWcfupB6qRVads6PDkdVX+VaEycsDVF13aLF6qo/SuTErY2ps8i0wYsdn912H6mnx/dNLarsa7T+5cyr+TsKavVh711x2Pqk76k8Jziro4YVRg61dPVaYyw/QU49qa3Kin9hTESwk7akV8NTIRwaP4qZmx7NlqYx+anMPmFNbG8UDQyUnFMU/MKdMajzyKRaJJKil6CnE5pJegpDRVueUI9qv/AA9H+m6if9pf/Qaozj5W+laPw6GbjUj6Ov8A6CK58V/DOXGfwpf11O11I7NGuz3dfKH1Y7f61Zs48CNfTAqtqS+a9hadnfzn+i//AFyK0LcfvR9axwsfdbPn6j0sX1HNNYU9OtDVtYxISKAKftpcVSQDKXFOxRiqsA2inYpMU7ANPWkZto46npSudqkntUKZY7j1NNCJFGBz1pDS00mrAjc1H1NPc0wdaYx54WqrnJqxIcLVY9acRD4hyKuJ0qrCOatp0rZCZItalj/x7j6ms1RWpZjFuv4/zrWG5DJqKKK1JCqF8uZvwq/VO7GZfwqZbDRRdKryJV8rUMiZrJoq5nMtV5Vq/LHg1WlXIrNooo96SQZWpGXBptSUQRHDYq/GcrWc42vVu3emInpRTWPNKpqGgJI2MVxDIvB3bT9DXRdq5yAefeQwr67m9gK6YCtILQlsZik21JijFVyiuR7aMVLtoxRyiuRbaXbUmKTFHKO5HimsuRUpFJis3EZl3SYkPHWsxEzZXEX9xm/Xn+tb9zDuXI6isoII7qRT92QZ/Hof6VzYineNzWnI8dlTy9V1SP0uWb/vr5v/AGaq/SRvrWr4gh+z+K9TTs4SQf8AfIX/ANlrLk4lNOHwo+poy5oRfkiS361ePRaoW5+ar5GUWqNSx/BTgfkFMTmMUqn5DTEWID1pf46hhbmnk/PTIa1JnPSoZD81K7fLUTHkUMEgJJppFLmjPFIsQUOcgUv8NNbtSKRDccI30rW+GIzcapkZ/eL/AOgise6OI3PtWz8MPu6nJ0zMB+SLXPivgOPGv90zrWk83Vrhx0iVYV+vU/zA/CtayjJ+Y9BWRpUe6ESd5CZD9WJP9a6KBdsSj2q6MLQR87Ueo9RQRT1HFLitFC5nciIpCKlIpMVXKK5HikxUm2kxRYdxuKNtPxS7afKK5RuzjYvqaRak1BMKkn9081EvTIpctmO48mmE0E1G7cUwGuaEqMnJqReBRYBspqAdakc5pFXmtEgJoRVqMdKgiFXI14rSKJY5RWla8QJVACtG3GIU+lbQRDH0UUVYgqtcjLj6VZqC4++PpSew0QEU1lqSgioGU5Y81SmTHatV1zVWaPrUSQ0zJlSqx4NaMyVRlXBrJotFedcjNMhbFTkZFVfuPz0oQF9WyKcW2ox9Bmq8bUtyf9HbHVsChoDZ8M22Ynu5B88hwPpW5io7CIRWcKAYwoqbFbqNkZN3G4oxTqSnYAxRiiigBMUYpaMUmgG4pMU6ipsO43FVL+0EkJaMASKdyn3q7RUON1ZjTseM+NkH/CR284Ur59sUIPYo5z/6HXOzjEv4V3XxQtPs17ps4B8uSV0B7Alckf8AjgribsfMp/CuZJrRn1GBnzUYsjg/1laK8xisyHiStKI/IaDsJo/u0IecUkZ4o6NTAfGcNTnb56j6NStyRQJoezcVGTSjpSYzQCEzS54oxSN2oGOLfLSE5xTGPSnR8mkNFe9P7p/pW58OUZNGv5hxud2H4fL/AOy1gakQsL12vgO18vwxaqRgzIhP/AjuP86xrrmSR52Plan8zptPg8uCNPQAVsRx8CoYouQKvAV1QgfOydxhWmkVLikIq+Um5HijbT8UYo5QI9tJtqXFGKOUCPbShafijFUogRyRCSNkYcEYrJiBXcjdVOK3AKyrwbL1scbhmhx0BELVXkapZWxVOVu3eo5ShyHLVKzcVHEMCl6mmogKBmpkTmiNKtRR5NUkFwijq2icUkacVMBWqRDY3bV2LiJfpVWrafcX6VcRMWiiiqEFQXH3x9KnqtdHEg+lJjQylxSA0oqRiEVFIuRU1IRQBm3EdUJk61tSJkdKozw8nArKUSkzIYYNQzJmrsyYqsw7GsiitHJtO1utTyHdGv8AvD+dQzR7vY+tRrN+7Mb8OpH41SA9DjH7tfoKdUVlJ5tpE/qoqauqxiNxRinUUWAbikxT6TFKwDaSnYoIpWGNpMU6jFTYBtLilxSUrAch8U7fzvCckwGWtZ4ph7DcFb/x1jXlt2uYg2PevcfEdj/aWgalZD709vJGvsSpx+uK8Ohk+0abHJ/fQN+YzWFVWZ7+UzvTcezKqffq/bngis9PvVdgODWJ65YjOGp7HmoCcGnA5NAyQnJFPWoe9Sr0piY6kFJmgUCFprdaWk70DQxvvU+PrTD1NSIOKQzK11yLOXbydpx9cV7B4cs/IsLWE/8ALNQPyGK8kmTz9Qs4D0knjQ/QsM/pmvbdFiIiZj9BQo80keLmk7KKNCNcDNSUAUtdiR4dxKMUtFFhDcUmKfilxT5R3I8UYp+KMUcoXGYoxT8UoFPlC40CsnVDi9X/AHK2QK57XJRHqDFugQYoktAW5UmlANRICTuNRxgyNvbp2FWQMVkWLUsa0yJcmrccee1CAWNMkVciTApsUeKsqOK0iiWwUU7FGKWrJG1bX7o+lVDxVtfuj6U0DFoooqhBVG+fE6j/AGavVl6o2LlP9z+pqZbDQ9GzUgNVYmqwpzUJjJaKQU4CqEMZaryp7VbNROuaTQzHuY+az5VxW7NHmsy4iwaxlEtMzyM1XurYTRsF4fHBq66VF3qRm94QvvtGn/Z5TieD5WB9OxrerhILltPvo7xPu/dlHqvrXcxSLLGrocqwyDXRTldGclZjqKKK0JCiiigApMUtFACYpMU6jFKwCYpMUuKMUrAGK8Gu7b7Ff6nZYwLe5lRR6LuJX/x0rXvWK8f+IEItvGl0AMC5hjnz6nBT/wBpj86xrrS56uUztVce6OQAw5FWozwDUEq4k+tSxH5a5D6MnalB5FN/h+lKDwKAJO9PFR96kHSgQZpwNM70oNMBSetIKCaTtQAAZqQ8IaRBTJmwDQDH+G7Y3viyyjAyIt85/AbR+rZ/CvbbWIRQIo7CvPvhPpgkl1PVJBkb1tov+Ajcx/N8fhXo5Fb0oW95nzOZVeetyroJRRRWx54UCinAU0AoFGKWlxVWENxRinUU7ANxS4paKLAHSuM1Bxe6nNMDmFfkT3x3rb16/EaG0iOZpV+bH8C/4msIeg6CsqkuhcV1HoMVMq5psS5q0qVnYpixLVyJeOlRxJ3q3GtXFEscq1JjFAFLitCRKaTTjTGoGNY1eT7i/SsyRq0ouY0+goiJjqKKKsQVi6ycXa4/uD+ZrarF1n/j5B/2RUT2HHcihersbVlxtg1dhes0ymXlp1RI3FSZrREimkNGaKAIXXNVJ4gR0rQIqCReKloZhzx4J4qqyc1sTxg1QljwayaLTK3lggqwypGDWl4VvTDI+m3DfMvzQk919Kojg1DeRO4SaA7biI7kP9KUZcruDVzuqKpaPfLqFjHMvDYw49G71drqTuZBRRRTAKKKKACiiigAooooAK82+L9psk0jUVHRntnP1G9f/QG/OvSa5r4jWJvvB2oBF3SwKLlMdcxncQPqAR+NRUV4tHTg6ns60X/Wp47OvcUkfBpwIeFSDkYxmmV559cidaco4pkRyKlFAxR2p46UztThQACigUCgBaWk96UUAPXjmqkzgbmc4UZJPoB1qzIcLgd6do2nHWdas9OxmOZ8ze0S8v8Anwv/AAKmld2M6k1CLk+h6v4EsRYeE9OjIw8kfnyf70h3n8i2PwrdIpQAoAAwB0A7UteilZWPjZzc5OT6jMUmKfijFTyiGgU6lxRTSEAoooqgCiiigAqvqF3HY2klxKflUcD1PYVYrk9ZuP7R1PylObW2PPoz/wD1qmcuVDSuypEJJd9xPzNMdzew7CpVTmnsacikmuY0JYVq7ElQQrjFXYh0q0iWPjSpgOKRRTq0QhRS5ptLVCA1DIcVIzYqrM9S2Mileti3OYIz/sj+VYLnJrctf+PaL/dFENwZLRRRWhIVj6thpyO4UVsVzVxOW8QXsB6KiEflUT2KiRirETYNU3bDke9SxtWKZRpRvxU6tms+N6sK9WmItg0uariSn+ZVXESk8VDIaDJUTNSbAZIM1VmjyDVonNJtzUMZkyJg00cVozQ5qq8WKhqxVyppt2NJ1QmQkWs/DHsretdqjB1DKQQeQRXGTRLIjJIuVIxTtM1aXRysF3mWzPCyd0+vtV0520YpRvqdlRUdtPFcxCSB1dD0INSV0GYUUUUAFFFFABRRRQAUjKHUqwBUjBB70tFAHz9Pa/2fdXNiwINtM8GD6KflP4rtP41XkGDn1rq/irp7WXiOG+jX91fR5Y+kseB+qlf++DXPRqrxBuxrz5rlk0fX4ar7WlGfcbABtBqbHNQhChyOlSq+cVB0hinCjPJ4oB4oAAKO1OAo28UANxwKkFKFyRTuFGaYmytcuI0JJA9z2r0P4WaObbTJNWuIys96B5QbqsI5X6biS30I9K4rw/o58R6/FZPxaRjzrn3jBwF/4EePoGr21VCqFUAAcADtXRQh9pniZribL2MfmLRRRXUeGFFFFABRRRQAUUUUAFFFZusatFpyBQPMuX+5EOp9z6Ck3bVhuM8Q6h9isikZ/wBJm+WMDqPU/hWBaxCCBUH1PuaRVkluHubtt9w/p0UegqyiZrnlLmZolYYBk1ZhTvTo4easBMCkkFwQVYj4qAcU9XFWhFtTTs1XV6f5lXcRLmmM2BUbSVE8nvRcB0klVpHyaR3zTM5qGxigZrctP+PaP6VhZxW3YHNpGfr/ADqobiZPRRRWpIVyEx/4q/UPZIx/46K6+uTmj2+ItTlP8WwD/vhaipsVEgkbMrfWnq9MZfnNKBXOWWUkqZZPeqQOKcHqkxF7zfegT+9UGlqMzYouFjV87PemmSs1ZveniXPei4WL4kyamU8VmI5z1q5G/SncCyRmopI8inq2akFPcRmyw1VkQYKsoKnqDWy8YIqtLD7VDiNMxoftOmy+dpr4XOWhb7rV1Ok6xbakmFPlzj70T8MD/WsWSEiqV1ZiUiRSY5l5WReCDRGbiDVzuaK5jStfkhdbfWMK3RZwOG+vpXTKQygqQQehFdEZKWxDVhaKKKoQUUUUAFFFFAHMfEewS98J3cjIWksx9qTA5Gz72Pqu4fjXjttP5TYbmM9vSve9djabRNQjT7z28ij6lTXhckAimBI/d9PXBrkxC1TPfyibcJRfRllcMu6P5lPpTCq/SkERVt9u2M9R2NWPO28TRsp+mRWB65Dj/apV/Cpw8T9NtGxD6D6UBcYozTwMdacAg7k0oZR0FAXGYJOB0qK5cLgZxxUsku37qlvoKht9Pk1K9ht5H8sXEixZ6kBiBn8M0bkykoptnpvw30pbHQVvGH+kX+J2JHRMfIv/AHzz9Sa6ymQxpDCkUShY0UKoHYDgCn16MVyqx8fVqOpNzfUKKKKZmFFFFABRRRQAUE4GTwKgvLuCzi8y4kCDsO7ewHeuev76bUMptMNqf4c/M/19vaplNRGlcu32tguYtPAkYcGY/cX6ep/SsdYx5jSMS8zHLSNyTUqR4AVRgDtViOGudty3NEkiKOPJq3FFUkcXrU2ABTURNkYXFKTxQxxUEkgqhCSPimeb71WnkOah3n1qbjsaSzU4z+9Zglo84+tFwsaDTUwyZqkJCalTJovcLE4OaXNMFOFMAZq29LObNfqawz71taR/x6f8CNXDcl7F2iiitSQrh9Xuzb+ILtX4VyuD/wABFdxXD68iS6tOkilSW4J78dqzqbFR3HK4cZFPDVkm2miP7qUgehpRJdr3VqxsWa26kJFZgurkdYwaDezjrDmmBdkaq7yGqU2qbR88Dj6CqM2rrnCRuT9KljRteYakjlP4VzX9oXkzbYIj9SKe11qUGGkClc4xU3Cx1STY61ILrFZv+mQRJJd2M6Iw3bguR+nSnxSRzrmJw3t3qtUI00vKuRXanrWCcg96ckrDvQpBY6dJA3SlZQaw4LogjmtCK6z1NWncViZ4/aq7w1cSRWFDID0oaEZFxbrIhSRQynsahsr270X5UBuLLP3D95PpWs8YNQSQ+1TZp3RW5u6ffW9/AJbZwy9x3B9CKs1xElm8MxnsZGt5/wDZ6H6itOw8RNGwi1aLyz2mQZU/Udq2jUT3Icex0lFRwTxTpvgkSRfVDkVJWhIUUUUANkQSRsjDKsCCPavLfEWgyabckKC0R+4x6MPQ+9eqVHcQRXERjnjWRD2YZrOpTU0dWExUsNK62Z4i1ooPylo29KcGnQbWKuPcV6Xf+FLeXJtnMY/uNyKw7nwpNGT+6JHqhzXM6Uke5TzCjPqcfnd1gXPsaXZn/lj+tdC/hxx0LqfcU0eHJ+0gqeSRv9Zp9zBEXqpFOVNv3Y8n1NdAvhm5I/14p8fhW4Y4ZpGHsKOSXYl4ul/MczIXHDED2FdJ4B0lrjWBdXKMYoFLpngb+g/Qk/UVs6f4QRSGmVV/3vmNdXZ2kNnF5cC4Hc9zWtOk73ZwYzMIODhT3ZYooorqPDCiiigAooJCgliAB3NY1/4gtbcmO3zdT/3Y+gPuaTaW4WubJ4HNYeo68kchg09RcTjgtn5E+p7/AErJnkv9SJ+2S+VCf+WMfA/H1qxbWqRIFjUKtZSqX2LUe5Xjgd5zPcu007dWbt7AdhVxYqmSMAVKqVFh3Iki9qsImKMqgqGW5C9DVWSEWCQo5qtNdKtZ9ze8YzWZNcsx4NS5lKJpz33PFVjfZNZxZmPc04LtXc7BV9Saz5mx2LzXG7tTd5PSoLaO5ujiytJph/fI2r+Z4qLV7PVbJoBJ5SCXONrZIx61Vna4rlsMe9KpOayB/aEeGZg49KtQ3UwxviP5UIZqxrVhSBWat45+7C34077RcnogWrRJpBqN1Zvm3J/uijNwesgFAGiWxya2tDcPaPg5w5H6CuT8l3+/KTXSeGYxFaSqP7+f0FVDcUtjYooorYgKy/EVolxp0jFRvQblbuK1KjuU8y3kT1Uik1cEcOrboFJ54pmKktlyjKeqkipPKrnRqV8VHIcDirRjAFVZlpgUp3PrVRnweg/KrMymqrKazZSLFqQzirWpQZsWZeqkNVCD5ZBWww821kX1WkkDO8tHElrC46MikflWbqWgWV8xkCGC4/56xcHPuOhqTw1OJ9DtGzkhNh+o4/pWnXZo1qY7HE3thf6crG4QXNuP+WsQ5A91qmjRyqGjYEV6FWLqmgw3Lme1It7n1A+V/wDeH9axlS7FKXc5flTU8M+OtMnbyJjBexmCcdm+63up7imle46Vjqi9zTinHrVyK49awUcg1bimq1ITRuAq44prJVKCbHer0cgcVe5JA8WaryQ5BBAI9DWiVBppQUnEEzCNg0Unm2Uj28vqh4P1FX7fW7+2AS9thcAf8tIzg/iK0AigdBSGJW7U0mtmF77iJr8R+9aXQ/4Cp/rUn9u23eK5H1jqE2y9qb9l9DVXkKyLK69YE/NI6/70bf4Vct722uMeTPG5PYNz+VZJtAeoB/Co302N+qD6inzMLI6KisBYLu3X/RrmQD+63zD9alttWkjk8u+TB7Og6n6VSl3FY2qTA9BVBtQZv9VCcerHFAvJ8f6pfzNXYRoYorPN7MP+WK/maZNqywRFpoWGOm0g5NLYDTPFUZ9WsICRJdR5HZfm/lWUwudUXdOxjgPSJDgH6+tPTS4o/uxqD64qHJ9CrEz+I7Mf6uO4kHqsf+NKNfjYZWzuiPcKP61GLQDpgUv2UdzU3kFkLJrr4/dWEpP+26r/AI1SudX1WQYgt4Ys9ydxH9Kui3UdaeIkHaj3n1HoYZs7u8IbULiSX/YBwv5VbhtViAVECj2FaYAHQUjKD2qXAdytHFUyp7VIFxQSFFCQhMAdahlnC8Cori44IHFZk9x1pN2GkWZrnrk1QuLrriq00pJ61CAWrKUikhXcuaQLgZY4FAkjWRY8NJK3Cxxjcx/Ctuy8OT3wD6mTbwZ4gQ/Mw/2j2+gpRi5DbSMez868mMOmwGaQcFzwifU10+leG44XWfUXF3cDkAj92h9h3+prbtbaG0gWG2jWOJeiqMCpa6oUlHcycrhXJeJW87XYI8/LDCW/Fj/9YV1tcRfS+druoSDorCMfgMUVHoEdyGfagqJZfSoryTnFRRtWBoaCtnvTwarRtUqn3q0xE2RSFgKZuAprEGi4DhLg1ueFZvMN4ufusv8AI1zjcAn0rY8CMXW/kPQuoH4A/wCNEH7wpbHVUUUV0GYUHkUUUAcYU8rUbqPtuJFPbiptaTyNa3EYEq5FVJX4rnlozREcrYqnK3WpJXqrI1RcaI3OajIBp5FIRzUsoYifN0rWtgPLFZy8VftGypHpTQmbvgyVRb3VoSN8UpYD/Zb/AOvmujrzqS5l0rUotRhG5ANkyDutegWlxFd20VxA26KRQyn2ropyurGckS0UUVoSV76yt76HyrqJZE7Z6j6Vymp6FdadmWxLXFt3iPLKPb1rs6KmUFLcadjz2F0nXKcEdVPUVKDiui1nQIr1zcW7eRdf3h0b6iubnE1nL5N/GY37OOVb8a5pQcTRNMnjkIq7BPg9azR7HNPRuaaYG/HJuFShgayIJSo5qzHPzVpk2NADNGDUCSg1Krg1Qh6jJqdIsioEYZq9CQV4qkDIjCaURc1ZxRiqsK5GIxisvVolVBJj7rA1sZrK1hwbdwPSlLYEWIsbBgDpTiarWr5hQ+1TseKoCJ2Oaz9U/eCGMD7z1dfvVG5bbdW2fU0pbAjct4wqAAYAFOeMGm20gZOKnoWwFbyKXyRirFIcYosK5RlTbUOKsXMi561UMoqGUSYx1prECoJLgDvVSa661LY0i80oFULu728A1Ve5JHWqMzksSahyKSJZrgsTzVZnzTCSabv/AHqxxI0szfdRBkms27lDyBjc5AA6k1b07SbzVMMmbazPWVh8zj/ZH9a1NI8OFnW41bDsDlbccqv19f5V1A4HFaQo31kQ59ihpekWemKfs0X7wjDSNy7fU1fooroStsZhRRRTAR2VEZ3ICqMknsK4G1bzEkmPWZ2kP4nNavizVDK50m0b52ANw4/hX+79T/L61nABIgB0UYrCo7uxcUULoZc4qNDinSnJqM5rE0J1eniSq4pc1Qiff70b6izSg80mwFuJNsDn0FdL4Bj26H5hHMjls1yOpvtsnA6twK9B8PW32XRrWI9QgJ/Gro6yuTPY0aKKK6TMKKKKAOf8Ywn7DHdoPmt2y3+6eDXPGYOoYdDzXfTxJPC8Uqho3UqwPcGvOby0m0a+NpcZNu5JglPRh6fWsKya1NIPoK5qIjNSGm4rFFDKSnEUgFUAhqxaPtfHrUFAODkUhmlOgeMgjIp3g7UWsNRbS52/cSktAT2PcUyCQPGPWqWp2zOFeE7ZkO+Nh2Iq07O6JavoelUVieF9bTVrTZJ8l5EMSxnr9R7Vt10J31RlsFFFFMAqlrBtU0+Z79VaFRkgjn6D3pdS1O006PddShSfuoOWb6CuSvbqfVbgTXIKW6nMUPp7n3qJzSRSVyjaLIkYZgQp5CnsKso4anSEBTmqrEqciuW9jQ0omyKlU4rOhl5HPFWjKMcGqTEWRKRU8c571mCbnmpklB71SYWNITelWYLsr1rJVx61IH96pMVjoEulYVJ5y+tc+JiO9L57etVzk2Nqa5VVODWNeyl4pD7Ux5uOTVeWVSmM9SKTlcaVjUt3CRRj0AqYzDFZTXIU4z0ppuxjrW1iTSMwzVHU2G+Bx2NVmuhnrUF5cgwhs9DSktBrc27S62dTxWit4hHWuUW5/dqQe1Ibth0NYqdiuU6xrxB3FVLjURggGubN257mmGZj1NDqAomrLelj1qu95xxWeX9TTGfFRzDsWpLlmPWoxKWqoXJ6VJETnmpuOxOTxzVdzk1K7DbgdagbkgVLYIFBkJUce9a3heaHTrySK5Cr9oI2TH1/uk1nREKR6VM6pLGUcBlPaqg+V3B6ne0VyGl63Lp22C/3y2vRZgMsg9D6j3rrIZo54lkhdZI25DKcg11RkpbGTVh9FFFUIKyvEuqjSNMeZQGnc7Il9WNaU0iQxPJKypGgLMxOAB6153f3kmuan9qcEWkRK26Edf8AaP1qJy5UVFXG6ZA6qXmYvLIS8jHqWNW7p9sePWnqAiVQuJC7n0rn2RoRE5NLSCl7UhhSgUYqJ3w6MjBgQRgHgnIobsBMOacKRBtAFRXlwLeLIG6RuEUdSalggSFr/V7SzQZ+cO/sBXp6gKoA6AYrm/B2iPYQNd3gzeT8n/ZHpXS100o8q1Mpu7CiiitSQooooAKo6xpsGq2L21yODyrDqjdiKvUUWuB5m8c1jeNYX2BOnKuOki9iKdXaeItFi1i1ClvLuY+YpQOVPp9K4QSSQXLWl+nlXSHBB6N7iuWcOR+RqncmNJinEUlIY0ikxTzQBQA63k8t+ehq+wDrVAJU8LlOD0oQFW4t5oblLqycxXSdGHcehrotK8XQFBFq6m2uBwWCko3vWduBFRSRRyDDoD9RVRk47Caude+t6Yke83sBGM/K2T+QrIvvEMtwuzS4yoPWaUY/If41iJaWyNuES5+lWM1TqNiUUQx2+Jmnnkaa4brI5yalLYpGao2asyhsjEmo80rHNJU2GFKrEU3FGKAHFj2o8wimjNB5FAEq3JHepFuveqZWkKntRdhY0ftPvSG596oq5HBFKXFO4rFs3PPPSql3c7ZIiOhbFMeQYqpdEnyz6OP50KWoWNCeZtxpqyMy02YfMaIhxXoWMxxZvWmXTH7E3PcU9uhqO55swPVh/OomrRYLckU4RRntThUCFtvA4FPEgrhuakuaRmxTPM44ppBbrQA4vTQSTShKcFxQABacDgUlGDQAuaM0mKWgABNTxtxioKerYoEWAQRg9KS3EtlIZNPmaFjyydUb6imK1SBqpaAa1t4n8obdUtzGe0kXzKfw7U6fxhp6L+4juJn7BUx+prHJBGCMim4QdABV+0kTyobqOoX2skLcKLe0Bz5CnJb03Hv9KdDEEApQwpHk4wKm93djGXUuF2r1qkATVhkJ5PWod6eaYs/OBnHqKTGRs6pncenWkt5PMDZxlWI/Wq0h/wBGuJBy5ZnA/wBw4/p+tNtiglY8kEo4I9wVqObUqxcuSRA+37x4H48U22hAAY59s/ofrjFRQB55S5BQKxzkfeGcjH4AfnVi4njt03SHnso6mhO+oPTQdPMlvE0khwB+tbXhTQZJZ11TUlwx5hiP8I9TUPhzQJdRmjv9UQpApzDAR973NdyBgYHSt6dP7TM5S6IKKKK3MwooooAKKKKACiiigArP1fSLTVYdl1GC4HyyDhl+hrQooauB5tqWnXuhPm4JuLInCyqOV+tNRldQyMGU9CK9JkRZEZHUMjDBBGQa4jX/AA7LpzPeaUpe2+9Jb9191/wrCVO2qNFK+5nU5RzUVvMk0YdDlTU6HmsyidEG3mnbBSp0p1UIjKUwqfWpWNMJqRiDpSk8UlJQAMajNSEU3FADKSn4pQoFIBmKXFSYFLigCEijFS4oxQFyHFIVqYgUm2kFyErkVGykVbCU1lB4yKB3KYUlwKju02jHoQf1rQWMKM1S1Ejy3x2FLYCxIPmNJHSvyFPqKRTjNekYiN1NNveIYE7ls/pTgpYgAdaS/XdcQqOwIqKrtBjjuPiGIc+tQgZq2iHYFp3kjPUVw2NbldU7mnYqwIx60eWKBXIAMUuKl2H0oxQBFg0oFSYpRTAi20hFTU00AR4oFPK0YoABTwcU0ClpgOzTSuTSilzQAKopzbUTceg/WkB5of5njHodx/z+NACQOs0SyICAex6j2rM1eEp5c0TFXVXXP1Gf5gVOGKxkKSBHI7HHs+T+hNRyM89iwl5kQjdgdeh/kalu6sUlZlW0k3AKR8pkdSPr8w/Q0+2twIY15ACCNs8E7eh/nUlvAApdgf3hEmOhBxg0+GG61O8+x6ePmH+slP3UFKMbg3YYHkklSz0+My3B+UY5C+5rrdB8LQ2brcX7C5u+uW+6p9hWnoej22kWwjhXMh+/IerGtKuqFNLcxcrhRRRWhIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBxHiXQ/7Okk1KwH+jk7p4R/D/tD+orNRwyhlIKnkGvSHVXVlcBlYYIPQiuA1nSX0W6LxAnTJT8p6+ST2Pt6GsakLao0jLoxI2qbrVNW96lWT1rNMolNMxShwTThzQAzFGKkxSYosIbikIpx4ppNACUUuM1A15bpJ5e4s/ogzUjJqXFSW1pqN1g21g6of45jsH68/pWrbeHbljm8u1Qd1gXP6n/CqUJMV0Y+00x3jj+/Io/Guti0GwQfNG8p9ZHJ/TpVy3sbS3wYLaGMjuqAH86pUmTzHExrLN/x721xN7rGcfn0q1HpGrTfdt4YB6yyf0XNdrRVqkhczOUTwtcSYNzqG0f3Yo8fqT/Sp18J24HN3c/gR/hXSUVXJEXMzlZvCsij/Rr459JEz+orPk8J6jMSjz2yoerAk/piu6oodOLHzM4qXS7y1QRy23nRjo8fNUmWFGw6yqfQivQqK1UiThLdWcgWlpNK3rt4H41ak8MXlzGJXuIoZwchMZH4n/8AXXY0Upe8rMd7HKW3he5IP2u+A9olz+pq9F4YsFH7xp5T/tSY/lit2ioUIoOZmK/hnTGH+qkU+olbP86pS+FnQn7HqEijssqBv1GK6eihwi+gXZxc2j6vBn9zDcKO8b4P5HFUJpJLfi8tbiD3dDj869DoqHSXQfMedxzQyfckU/jUu3PTB/GuyudJsLlt01nAzf3tgB/MVnT+FrFsm3e4t27bJCR+RzUOk+hXMjndppK1J/DeoRgm2vopR/dlTb+ozWfc2up2alrmwZ1H8cJ3j8utS4NDuiOgVDbXUNwdqnbJ3RuDU5GDSQxcUYoBpQc0xCYoxT8UYosAwCngDOaazYphkpjK5UefOrdHYj8Cq/4GkVNjFs5JUA+5HensFMhfHzYxn/P1NQXExTakSmSeQ7Y4x1Y1Fh3B1mubmOysl3XEvfsi9ya77Q9Kh0ixWCHluruerH1qp4Y0QaVbmSciS+m5lf0/2R7CtuuiELasylK4UUUVoSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTZESWNkkUOjDBVhkEU6igDgNd0uTRZi8YZ9Nc/K3Uwk9j7ehqorhhkYP0r0iREljaORQ6MMMrDIIritU8Kz2bNPpDGSLqbduoH+ye/8AnrWE6dtUaRl3KCnmrMfIrLF2I223MbwuOodSKnS/gA/1grNMovmo3YVBHc+e2LeOWYntGharcOlarckbLUQr/embH6Dmq32Fcg3etRG5UyiKFXmmPRIxk1vW3hPcQ1/eO/8AsRDaPz610FjY2tjHstIEiHcqOT9T1NUqbe4nJHLWXh68viDqJNrbf880ILt9T2rp9P0200+PZZwJGO5AyT9T1NW6K1jFIhtsKKKKoQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGXrGiWeqJ+9TZMPuzJwwP9fxrl7zStV04ElFvIF6On3se4rvKKiUExqTR5vFdxS8A7X7q3BFShua7DUtDsNRy08IWT++nBrBn8J3UJJsb0MvZJh/UVk4SRakimrZp3GKDpOsRfes1kA7xyL/AFNJ9k1AD5rC4GPQA/ypWfYd0QynrUJNWGtL9jgWFySf9jFWrbw3qF3/AMfLpaRnqAd7n8uP1pWb2Q7pGJLcEyLDbqZbhztSNeSTXX+GfD4sP9LvcSX7jk9RH7Cr2jaHZ6SpNuheY/elflj7ewrUraFO2rM5SuFFFFaEhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA2SNJBiRFYehGaiFnbA5FvCD6hBU9FFgAAAYAAHpRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the anterior posterior view of the transection of redundant sigmoid colon in preparation for a rectopexy for rectal procidentia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_59_38833=[""].join("\n");
var outline_f37_59_38833=null;
var title_f37_59_38834="Hypothalamic blood supply";
var content_f37_59_38834=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Vascular and neural connections between the hypothalamus and pituitary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the vascular and neural connections of the hypothalamic-pituitary axis. The paraventricular nucleus neurons have terminals in the median eminence where their hormones are released directly into the primary capillary plexus, traverse the long portal veins in the pituitary stalk, and enter the secondary plexus in the anterior pituitary gland. The primary plexus, long portal venous system, and secondary plexus comprise the hypothalamic-hypophyseal portal venous system. In contrast, the axons of the supraoptic nucleus travel down the supraopticohypophyseal tract and release vasopressin and oxytocin directly in the posterior pituitary.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Guillemin R, in: Neuroendocrinology, Krieger DT, Hughes JC (Eds), Sinauer Associates, Sunderland, MA, 1980, p. 45.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_59_38834=[""].join("\n");
var outline_f37_59_38834=null;
var title_f37_59_38835="Gentamicin (topical): Patient drug information";
var content_f37_59_38835=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Gentamicin (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/46/17123?source=see_link\">",
"     see \"Gentamicin (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/20/31042?source=see_link\">",
"     see \"Gentamicin (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8107115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Gentamicin;",
"     </li>",
"     <li>",
"      ratio-Gentamicin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to avoid or treat skin infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to gentamicin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14314879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11695 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-CA557B663F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_59_38835=[""].join("\n");
var outline_f37_59_38835=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107115\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031182\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031181\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031186\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031187\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14314879\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031184\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031185\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031190\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031191\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/21/3412?source=related_link\">",
"      Gentamicin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/23/28020?source=related_link\">",
"      Gentamicin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/36/37443?source=related_link\">",
"      Gentamicin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/47/761?source=related_link\">",
"      Gentamicin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/8/18564?source=related_link\">",
"      Gentamicin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/63/8185?source=related_link\">",
"      Gentamicin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/46/17123?source=related_link\">",
"      Gentamicin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/20/31042?source=related_link\">",
"      Gentamicin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_59_38836="Amphotericin B cholesteryl sulfate complex: Patient drug information";
var content_f37_59_38836=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amphotericin B cholesteryl sulfate complex: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/57/26518?source=see_link\">",
"     see \"Amphotericin B cholesteryl sulfate complex: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F134753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amphotec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amphotec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amphotericin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697798",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may need extra potassium or magnesium. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. You may be given drugs before this shot to avoid these signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698630",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cloudy or pink-red urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11489 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_59_38836=[""].join("\n");
var outline_f37_59_38836=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134753\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134754\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026633\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026635\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026634\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026639\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026640\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026642\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026637\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026638\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026643\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026644\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/57/26518?source=related_link\">",
"      Amphotericin B cholesteryl sulfate complex: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_59_38837="Primaquine: Drug information";
var content_f37_59_38837=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Primaquine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/37/30292?source=see_link\">",
"    see \"Primaquine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/26/14757?source=see_link\">",
"    see \"Primaquine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F213265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Aminoquinoline (Antimalarial)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F213247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The CDC requires screening for G6PD deficiency prior to initiating treatment with primaquine. Dosage expressed as mg of base (15 mg base = 26.3 mg primaquine phosphate).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment or prevention of relapse of P. vivax malaria:",
"     </i>",
"     30 mg once daily for 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment of uncomplicated P. vivax and P. ovale malaria (unlabeled use):",
"     </i>",
"     30 mg once daily for 14 days with chloroquine or hydroxychloroquine; alternative regimen (for mild G6PD deficiency or as an alternative to daily regimen): 45 mg once weekly for 8 weeks (use only after consultation with an infectious disease/tropical medicine expert) (CDC, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chemoprophylaxis (unlabeled use):",
"     </i>",
"     30 mg once daily; start 1-2 days prior to travel and continue for 7 days after departure from malaria-endemic area (CDC, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Presumptive antirelapse therapy for P. vivax and P. ovale malaria (unlabeled use):",
"     </i>",
"     30 mg once daily for 14 days after departure from malaria-endemic area (CDC, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Pneumocystis jirovecii",
"      </i>",
"     </b>",
"     <b>",
"      pneumonia treatment (unlabeled use):",
"     </b>",
"     Oral: CDC recommendation (as alternative): 30 mg once daily for 21 days (in combination with clindamycin)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F213258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/26/14757?source=see_link\">",
"      see \"Primaquine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The CDC requires screening for G6PD deficiency prior to initiating treatment with primaquine. Dosage expressed as mg of base (15 mg base = 26.3 mg primaquine phosphate).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment of uncomplicated P. vivax and P. ovale malaria (unlabeled use):",
"     </i>",
"     0.5 mg /kg (maximum: 30 mg/day) daily for 14 days with chloroquine or  hydroxychloroquine (CDC, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chemoprophylaxis (unlabeled use):",
"     </i>",
"     0.5 mg/kg once daily (maximum dose: 30 mg/day); start 1-2 days prior to travel and continue for 7 days after departure from malaria-endemic area (CDC, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Presumptive antirelapse therapy for P. vivax and P. ovale malaria (unlabeled use):",
"     </i>",
"     0.5 mg/kg (maximum dose: 30 mg/day) once daily for 14 days after departure from malaria-endemic area (CDC, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Pneumocystis jirovecii",
"      </i>",
"     </b>",
"     <b>",
"      pneumonia treatment (unlabeled use):",
"     </b>",
"     Oral: CDC recommendation (as alternative): 0.3 mg/kg once daily for 21 days (in combination with clindamycin)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F213248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as phosphate: 26.3 mg [15 mg base]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F213231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with meals to decrease adverse GI effects. Drug has a bitter taste.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F213229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of relapse of",
"     <i>",
"      P. vivax",
"     </i>",
"     malaria",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F213262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of relapse of",
"     <i>",
"      P. ovale",
"     </i>",
"     malaria; prevention of malaria; treatment of uncomplicated",
"     <i>",
"      P. vivax",
"     </i>",
"     and",
"     <i>",
"      P. ovale",
"     </i>",
"     malaria; treatment of",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP); prevention of malaria",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6704513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Primaquine may be confused with primidone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F213263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, dyspepsia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, hemolytic anemia (in patients with G6PD deficiency), leukopenia, leukocytosis, methemoglobinemia (in NADH-methemoglobin reductase-deficient individuals)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Interference with visual accommodation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F213234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in acutely-ill patients who have a tendency to develop granulocytopenia (eg, rheumatoid arthritis, SLE); concurrent use with other medications causing hemolytic anemia or myeloid bone marrow suppression; concurrent use with or recent use of quinacrine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F213218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolytic anemia: Promptly discontinue with signs of hemolytic anemia (darkening of urine, marked fall in hemoglobin or erythrocyte count). Moderate-to-severe hemolytic reactions may occur in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency and personal or familial history of favism. Geographic regions with a high prevalence of G6PD deficiency (eg, Africa, southern Europe, Mediterranean region, Middle East, southeast Asia, Oceania) are associated with a higher incidence of hemolytic anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Other hematologic effects: Anemia, methemoglobinemia, and leukopenia have been associated with primaquine use; monitor during treatment; do not exceed recommended dosage and duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with known G6PD; use of aminoquinolines has been associated with hemolysis. The CDC recommends screening for G6PD deficiency prior to therapy initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; NADH methemoglobin reductase deficiency: Use with caution in patients with NADH methemoglobin reductase deficiency; methemoglobinemia may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be prescribed by physicians familiar with its use.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F213260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (strong), CYP2D6 (weak), CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anthelmintics: Aminoquinolines (Antimalarial) may decrease the serum concentration of Anthelmintics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Aminoquinolines (Antimalarial) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Carteolol (Ophthalmic); Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Aminoquinolines (Antimalarial) may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Strong) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: Aminoquinolines (Antimalarial) may enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Mefloquine may increase the serum concentration of Aminoquinolines (Antimalarial).  Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of an aminoquinoline antimalarial when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F213242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (due to GI irritation).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13801098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Primaquine use is not recommended in pregnant women per CDC Guidelines. Consult current CDC guidelines for the treatment of malaria during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F213252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Primaquine Phosphate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     26.3 mg (100): $178.98",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F213226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic CBC, visual color check of urine, glucose, electrolytes; if hemolysis suspected, monitor CBC, haptoglobin, peripheral smear, urinalysis dipstick for occult blood, G6PD deficiency screening (prior to initiating treatment; CDC recommendation)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Malafree (KP);",
"     </li>",
"     <li>",
"      Malirid (IN);",
"     </li>",
"     <li>",
"      PMQ-INGA (IN);",
"     </li>",
"     <li>",
"      Primachina fosfato (IT);",
"     </li>",
"     <li>",
"      Primacin (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F213217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Eliminates the primary tissue exoerythrocytic forms of",
"     <i>",
"      P. ovale",
"     </i>",
"     and",
"     <i>",
"      P. vivax",
"     </i>",
"     ; disrupts mitochondria and binds to DNA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F213233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to carboxyprimaquine (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3.7-9.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (small amounts as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention,",
"      <i>",
"       CDC Health Information for International Travel 2012",
"      </i>",
"      . New York: Oxford University Press; 2012.",
"      <a href=\"file://wwwnc.cdc.gov/travel/page/yellowbook-2012-home.htm\" target=\"_blank\">",
"       file://wwwnc.cdc.gov/travel/page/yellowbook-2012-home.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States,&rdquo; Treatment Table Update, September 23, 2011. Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;",
"      <i>",
"       Pneumocystis jiroveci",
"      </i>",
"      (formerly",
"      <i>",
"       carinii",
"      </i>",
"      ) Pneumonia (PCP).&rdquo;  Available at",
"      <a href=\"file://www.dpd.cdc.gov/DPDx/HTML/PDF_Files/MedLetter/Pneumocystis%20jiroveci.pdf\" target=\"_blank\">",
"       file://www.dpd.cdc.gov/DPDx/HTML/PDF_Files/MedLetter/Pneumocystis%20jiroveci.pdf",
"      </a>",
"      . Accessed August 29, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Treatment of Malaria (Guidelines for Clinicians).&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf",
"      </a>",
"      . Accessed August 29, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lynk A and Gold R, &ldquo;Review of 40 Children With Imported Malaria,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1989, 8(11):745-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/59/38837/abstract-text/2594448/pubmed\" id=\"2594448\" target=\"_blank\">",
"        2594448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Panisko DM and Keystone JS, &ldquo;Treatment of Malaria - 1990,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1990, 39(2):160-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/59/38837/abstract-text/2183998/pubmed\" id=\"2183998\" target=\"_blank\">",
"        2183998",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White NJ, &ldquo;The Treatment of Malaria,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 335(11):800-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/59/38837/abstract-text/8703186/pubmed\" id=\"8703186\" target=\"_blank\">",
"        8703186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wyler DJ, &ldquo;Malaria Chemoprophylaxis for the Traveler,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(1):31-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/59/38837/abstract-text/8505942/pubmed\" id=\"8505942\" target=\"_blank\">",
"        8505942",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9810 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-15E18CE5C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_59_38837=[""].join("\n");
var outline_f37_59_38837=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709346\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213265\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213247\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213258\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213248\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213228\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213214\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213231\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213229\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213262\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6704513\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213263\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213234\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213218\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213260\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213223\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213242\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13801098\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213252\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524693\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213226\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038777\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213217\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213233\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9810\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9810|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/37/30292?source=related_link\">",
"      Primaquine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/26/14757?source=related_link\">",
"      Primaquine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_59_38838="Capillaria hepatica life cycle";
var content_f37_59_38838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Capillaria hepatica life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 442px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAG6AjoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorF1vxZ4c0G7S11zX9I025dBIsV5exwuUJIDBWYHGQRn2NAG1RXK/8LH8D/wDQ5eG//BpB/wDFVv6VqVjq9hFfaVe219ZS58u4tpVljfBIOGUkHBBH1BoAt0UVBBd21xPcwQXEMs1swSeNHDNExUMAwH3SVZTg9iD3oAnoqEXdubw2Yni+1iMSmHeN4QnAbb1xkEZ9qmoAKKKKACioYru3lup7aK4ie4gCmWJXBeMNnaWHUZwcZ64qagAooooAKKKbI6xxtJIyoigszMcAAdzQA6ivNta8ezeb5tk8UOnAnDDmZlA5fBBCjg4BBPTJUnFY0HxB1klkS2vJ23BVdFVldslTtxH0GAecfe7daAPYqK8w8OfEuSSd4dbtQsKtsNxECNh+U4ZT6B1zggg9jya6e/8AHfh+ytWme93sG2CGNCZWbGcBfXHP0oA6iiuEl+J+jIZglnqkvknD+VCr45C9A2epxxW/o3inStWmjggmkhuZFLJBcxNE7AdcBgN2PbNAG5RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUV5742+LXhvwxLLaRzNqmqocGzssMVP8Att91fxOfavKtY+LfjfV2b+yobTR4OwSLz5Me7Nx+S0AfS9FfHc3i7xsjtI/ijVic5IWRQB+G2tjS/jD40051L3ltqMS9YrqEAkem9MEH3OaAPqyivP8A4X/FDSvHayWojbT9bgXdNYTMCdv99G6Mvv1HcV6BQAUUUZoAKKM0hIAJPA96AFoJrgdT+KWgWd3NbW4vL2SJyjNBCSmQP73cZ4yK568+KmoXVvjTdIWzkP8Ay0upPMIGOyrjvnqa5K+Pw9BXnNHZQy/E12lTgz17IpCwAJJAA714RN428TzKQ2qFARz5UEa4+mQSKwbuW6vd32+7urssMEzzM36E4H4V5VTiPDRXuJv8D1qXDOKk/fkl+J9EXusadYxCW8v7WCNuQ0kqqD9MnmscePfC5k2f2zbZ9ecfnjFeCx2cUKqI41UIoVcdQB0A9uP0qQoeev51xz4n19ynp5s76fC0bfvKmvkj3jTfHPhrUbq5gtdXti8ADOZD5a4PcFsA9e1dDDNHPEksLrJE4yrqchh6g18wS20cilXRHB7MM1s+F/FWteE4HisRHf2WMrazfKynH8L9h0GOmB6811YTiGlVfLVXKcuM4aq0o81CXN5bfqfROeKUcivGdF+NCtcTLrGmiOGMjc1qSzx/VT1H0P4V63pt9b6jY295ZSebbToJI3APzKRkHmvco4inXV6bueDiMJWwrSrRtct0UDkUVscwUUUUAFFFFABRRRQAUUUUAFcrpv8AyVPxD/2BdM/9H39dVXFahJqukePtS1K28O6lq1leaZZ26yWUtquySKW6ZgwmmjPSZMEAjr6UAY/gDxB4hvPix470HXdRt7y00uOze2W3tBAiebGWPBLMe2cseRkYzitvwJc/YvBuq3XlSzeRqusS+VChd3239ydqqOSTjAA61z2i6XBo3iK513T/AIf+NF1W6wLiaXWoJfOABVQ6vfFWwDgZB29sV1XgWC80zwncPqlm9jcPe6hem3mdGaNJbuaZAxjLrna652k496APKNEtPHvhK01S+Gksb/xBaG8lktGe8eG6Eu92eNo1CN5MpVUywJt1XnPN/wAPX2vaL4ovtURfEt7oV3rY+2T3OjsLq4h/s1VRvJSFWCiZFXKIvQbu9d5Z/Erw7JBp/wBqvTHcXVvazsYba4kgi+0AeVumMShVYnALhCe4B4qXxx4sm8NajYrstTZvY395O85cbfs8auPmQMQOTnCOcdATwQDyjxFY+KNf0ldRv7XWo746fYvM0VgPN/d6oXK+X5ZBdYwH2hcnaOCCQe38Mav4hk8fxWlxda9qGjSR7o5ZtNNpHGoiBBnD2iZct/zzl+82PLUKa66LxpoLKgfUI0kN39hZCjjbOIvNK8qDgR/NuIC7ec1Sh+JHhaWMP/aE8YJi2CaxuIjKJSVjZAyAujEEBlyvvQByfjnxD4vtPiFZWug2usnTku7OOcC1822mhd1ErKVtWxtBOS06EbchSOtX+0viLaabHeQvqGoXl3Y6m/2O40+NEtpYpALfbtRWyy5wHYh+2Otev2dwl5aQ3MSyrHKgdRLE0TgEZ+ZGAZT7EAjvU1AHmvwqjvH8TeKb26m1y7huI7IR3er6f9jklKpJuATyoxhScfd79Twa5D/hIvif9o1gmO4SeNbgfZTYSyrGBKAj25FqqMyx7iFM8u/jAB4r3moL60tr+0mtL63hubWZSksMyB0dT1DKeCPY0AeKWfirxHc3moQQ6v4ll0O11f7NLqC6IjahDH9jSQKYBb8AysfmMJIG3pnNP8N+KPFuoP4Ou5LzV760vYLc3Mdpp4QFjKwaSSU2rxFdu3IWWEqFOMlhXqT+D/DMmkR6VJ4d0ZtLjl89LNrGIwrJgjeE27Q2CecZ5NbNvDFbW8UFvEkUEShI441CqigYAAHAAHagCSuF+I3iKOK3l0a0kJuZQonK/wACHnaTkAFhxyeh7kqD3ErFI3YAkqCcDvXgKiR4pp4N8mo3s5M7yoWbDQh2Kf7vmFthzwGI5xgA6H4c6Dda7vvr95EsQ+GV49skrgnJz1XPGehH3ePmrvtRi8MWMsFnfwaZC8oHlxvEgyMgDtxzgVqaLb2lrpVrBpziS1SMCNw+/eP7xbuT1J7k15D8YI7y58XQnTZogIooYplk3ZyzPwCBjGHyfqo5zQB6Pc+C9FkUCCCS0ZWDg28hQA/7v3f0rLn+G+mSsD9omUhmO4Im75sZ5x7Ae1dxRQBwEfwn8NJMJ3W+kn5PmG4Kk855C4B6dwa5bxDp8+l3t3awyPNCJfKgTP71p2CujqeMNlsDHfJAAzj2iqI0jTxqx1T7HD/aBQR/aCuX2jPGe3WgC1biRYI1mYNKFAdh0JxyakoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACigkAZPSsHxn4ms/Cuitf3rLlmEcSFtu9z0Gew4yTQB514t1zVr3xDr1xHLfx6b4cngVbSzfa9y+Fdyem/wCU8LnBrjPiH8Q/FPixDpuiW0WkabIPnR7rZdzA/wAJIGEGOoBz71S1PWNU1fW7wtK/2ieYPctAcJ8o2qFHoBxzya7Twf4Y03XL0f21KZobTEnkt1mbP8WOoHp3pbFr3rJHk+i6M0LwRxwCBm+YK4xkg8j616CAB0AA9hWFJr8Da/qcRjV7OK9lS1kjX+AMQMe3UZFbbyosJlY4QLuJPpTJas7HGeIpEfVJTGoG3Cn3I61z0lgUhaVyRkFlAHFdFp9o2qai7HIi3b3NN1wf2hf/AGW1GETESBR+dAjj4pbmyvrXUdNma31GzcS28ynG1h2PqD0I9DX2R8O/FMHjHwjY6xAAjyrsniH/ACylXh1/A/pivlvU9CFh5aSgMHGQynv6V6P+zBqElvq/inQXYmEeTfxDsN2Uf89q0AfQJryfSPiZeWHjK88PeLraCHZOyQ3sIKrtJ+XepJ7Ecj16V6u3SvmH4p3ya38SLwWCNJJZn7M+V+XhR3B6ZBBPv7Yrjxtd0KfOjvy7DwxFV05rRr7j6N17WLPQtLm1HUpDHaxAbmCljz0wBXh3jHxVeeL75o4Zbm20JQY1gBMZuDxkvg5IBBxjHaqt7rXiPXvDlrpb3UI05Ag6MssyDjY7An6HjnFV/KvEB3WMjkHGUdTn35I4r5/NM59pH2eFe+/RryPcyzKI0Zupiltst0/MbHCAoA4A4AxjAqQIBjgAnp7/AErGuNXmlWVrSBoII8K884+bc3AVV+v8R471P4l8Mz6boh1K6vmnuHO0gHOAVJGG65BXsAOeleHRy2rWTlLSx9BLMKakox6msIvoKXymPTrVq1jLW0ZZfmKjOfoKm8knqK8xxaZt7YzxGT0PX/P9aaYzjse/9a0fKPv+dRzRlY3YDkKSB+v9KOV3sP2xnGMdxUTx8cHI/wA//XrRiCyxRyDhWUN+BFUbBGe2D4x5js4B64JOP8apJpNvoVGvqkYGtWghv7a9QYYt5MmAOQehPPGDXpPwY1qax1ptDmkZ7O6VpIFb/llIvJA9ARk49V9zXF6zZTXNuDF5AjhkjmlaU4wu9QMe5J/LNdP4J0W5m17TdUidUhtr5YsZO5yUOcD0Ck5r6PKZVva0nHrf/wABT/Q8nNqlCWFqwn0tb/Fb9T3de9OpBS19sfAhRRRQAUUUUAFFFFABRRRQAUUUUAFR3MK3FvLC5IWRChI64IxUlFAHEW3w10e30WXTEudQNvJb6fbFjIm7bZkGI52Yydo3cc9sVqeL/CFh4qULqE11GBZ3dj+4ZR8lxGEc8qeQBx2z1Bro6KAOTPgHRX8SSazKtzJNJY/YXgaX9yw27DJtA/1hT5NwP3eMVi+H/hFoGhNAbOafEE8E8e21s4mBibcqtJHAruCcZ3sxOM5zzXo1FABRRRQAUUUUAVNW1C10jSr3UtQl8mys4XuJ5NpbZGilmOACTgA8AE1wP/C7/AH/AEGLr/wVXn/xqt/4sf8AJLPGX/YFvf8A0Q9fLfhjwymp6Nqus3941ppummNXMcImkkd2wqqpZR9SSPxrWnBSvdm1Kmp3bZ9LeHvir4O8Ra3a6TpOqTTX90WEMb2FxEHKozkbnjCj5VY8ntT9S8HXSTvLol8sURfzBazjKI/PzK2CQRuJHBxx2GK8smsbTTv2o9EttPtYLW2SRysUEYRBnT5icAcda+iKiUUnoROKi9Dz5/DWvynLSQQNu3n7NdNGCe4PyZIzzyc9voujeBbxr+OfxFfRXFtBcC6htId2PMU/KzMcE4/u4x65r0CipICiiigAoorJ8SaKNbs44hfXthcQyCaC5s5SjxuAQCR91xgkFWBU56UAa1FcUnibUfDTiDxvDGLPO1NctEP2ZvTz05MB9ySn+0OldnFIk0SSROrxuAyspyGB6EHuKAHUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAIeh4zXg3xD07VdZ8czR3ghns9GjElnCqlhFJKP8AWMD1IC8dgScYr3qszUNEsb+6W5miK3IXZ5sbFWK9cHHUfWgD59uvBWpz20Q0jVf7PuUJM7+WJXbOMHAYYI54IxzWtdytA8wiMsfyeW38JbjByPc84969Fu/hf4clvZL+G2mi1B23mf7RKSfY/NjHHT615X4oOoxePbvTtNW0FlbMkJt7y7bzHZgD5iFgfl5PBJ6Z4ofmOKbehzo0WOGGZ5mZUiizx0D+g9hxW5bxi90y2EzFlZAW5+9WVPJq/iGKO30bQ9TuFf5meGLch5OPnOAAcZ5x2osLjUtMguLK80W/S6hYgJIYwudwULu3YHJpXBRb0RpWcDQWt1HGoWcsxGOAc9MVT0DTGtN91eALIeFDH7o9a0AmqzwAQxxPeH/llbWs91g+mVUD9aqS+AvH+qAyxWkcgJ4juwLUAfTe5/TNCdxuDW5Q8Q3cd/JDbWn711YnI6E+grc+Fznwt8TNNNyw8jWbd7Evj7soIdFPpn5h9arW/wAIviGZkmjm8P2rI4ZVeWSTgdjhag1Pwj4l07VdDt/Hc622meeTHfaXKcNc5zEHJAKY6j1IobsKK5nZH0vqkzW2m3c6FQ0UTuC3TIUnmvmfTrAXX2a6d2+0YMhl4LEty2fxNe5WWoSeI/DOsaXIcatDbtBLsIXzC6HZIvorfoQR2rwq2vRp9osbW8puIQI3t1ADxkcEYJA4I6Zr5viL2koU1T7s+l4eUIurz7pL9TtdKsl2gbQCeTgetbb6SHgYEYDArkcHmue8L6ul9ZJOox8xQg8YIJB4robrXLeztd9xKEXO0DPUntXz9CnBNxnuehiKlRu8djhPFumx2Hha5SSRYd75dtgYAFgOh4wBj8qp+JryKfSrTTbK6gu7W1tDI8sOFBc/KgwCccbv8muhk1zTNcMsUUkM0kWGeLcGK56ZArmfEcUAs7t0WNJNu7P3QWGSC30NdEcWqV6DWsnv9xdHDSqtVU9EjsUhwoyCDgcHtThD7VW0iKSPw1bP/qZRAHzLnrgt82ex781a0a/h1O1R0HlTlQZIWIyv+I4PNcbwkmnJK6TH9ZSai3qxDD7VV1JNlhdOSRtic5HUfL/OtxovVf0qvcwCSGROoZSDkZ7VmqVmi/bXTOSuJUHhWGQEIJoI4w3ZN4C5/DNXordbeCOJMlI1Cjd14rmkvHi0W8sYYjdmKWLBUAJb71DDceTwysenQ11tu8mFhvAsd/Go86IHODjqPVT1Brqx2X1aEW7e7d6/l+plhMdTqySvrYqOpFvqS+Usy/Y3k2EDO9HR1IzxxyTntmuk+HJH/CSRIyyAxzFgMnALQtn2JG0fnWTFMbG9hulj81Yj88X/AD0Qgqy/ipIrs/hukM0VlFbOki2KzSTOpJzJI2EBz32An8R617OQRVVRlfWF1b1s1+p5edTdNyi1pOz+7RnooopBS19UfNhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVV1PULPS7OS71K6htbWP70szhVH4mgC1RXMp4j1DUWQ6FoN1PbNyLq+f7JGR6hWBkP/fAFKX8Y+ZuEHh8J/c86Yn/vrZ/SgDpaK5mXXdZ0986r4ele2Ay1xps4uQv1jIRz/wABVjW3pWo2erWEV7ptxHcWsoysiHjg4IPoQcgg8gjBoAoeN9Kn17wXr+kWbxJc6hp9xaRNKSEDyRsoLEAnGSM4BrwrRPhT8StFhu4dOvfDCQXaqs8UlxJKkgU5GVe2IyD0OM19H0VUZuOxcZyjseH+Fvh145HxS0nxX4svdEuPszyNM1tO5kcG3kiUBfJRf4x3HA717hRWdr+s2eg6Y99qMvlwqyooHJd2OFVR3JJApOTe5MpOWrLtxPFbQPNcSpFCg3M8jBVUepJ6Vy8nj/QicWMl5qRPQ2NnLMp6dHC7e4796801/WNX8SeJ7yx0i1tNTu7CVTNc30mzTtLPOEwP9dIRtbjn6Dis77BpMzx23iPxt4h1y7Me8W2lSC1txyFAUJyBwB8zdOTSEes/8JzB5av/AGNqwBGTvEKEcE4w0gOcA8U4+NohA039h600anDFIonI+92WQk/dPQV4T4jtfhrpClZPC0+oSqrv5l5fSs2QBs3ZcEZ54wcDmklk+Fw0+5mHhC6ieJIyo824UFmxnkPjjP4/jQB75beOdFkXN0b3TxnBN9ZywKOo5Zl2joe/Y10lvNFcQpNbyJLC43I6MGVh6gjrXzto2ieE9ZRh4M8TeINCuFDlVknkltN3IwY5uSMOehHU81oaFr2veCtfGk6tZQR39wzTQw2r/wCh6uhxuNuP+Wc4POz+LOPQ0Ae+OqujK6hlYYIIyCK4ubwrfeH5HuvAs8VvGWLyaNck/Y5SeT5ZGTAx/wBkFPVM811Wk6jbatptvfWEgktp13o3T8D6EHjFW6AOd8O+LLTV7p9PuYZ9M1uJd0um3gCygDqyEErImf40JHrg8V0VZXiHw/pviG1SDVLYS+U3mQyqxSWB+zxyLhkb3BBrnftniDwj8uqrP4h0JeBfQRZvbZf+m0Sj98B/fjAb1Q8mgDt6Kp6RqdjrGnw32lXcN3ZyjKSwuGU/l39u1XKACiiigAooooAKKKKACiiigAoPHJornvGni/S/CGmG71SX52yIbdOZJT6AenqTwPyqZSUFzSdka0KFTEVFSpRbk9kjL1f4o+ENLd0l1eOeVeNlsjS8+mQNv61m+Gfina+KvEcOl6DpF5Kpy8087LGsUY6tgbs9gBxkkdK8P8Txa543Gp+LzpUVtp8JVCYk2hsuFABxmRvmGW/lwK96+D3g0eE/DStdRgare4luSRyn92P8M8+5PtXnUcRWr1bLSPe3T59z7PMcoyzK8D7Sd5Vnpy810pWTfwpfDf8ALudtfXlvYWz3F5MkMKjlnOBXE6t4ql1CZU0LQbq+KnKXM1i5Qc9V3bQf++hXeMqtjcoO05GR0PrS16Z8QnY8xjt/HF6yPO17GgORHHJBbKPY43tj8aLnwHfapqMGoavbWM95AMRTyXjtIg+oiFenUUrFe0a2S+4851Dw14ijKmz1LVRjp5Goggcd1kTBqsl/4105wJLiadAcD7ZpXmD/AL7gf9Sten0UWH7S+6R5ovj3W4VIm0vSbhh/zzv2gOfQrIgwfxrm/GniHxB4t0p9Ik0nS9LsJZI2lvH1ETOgVw3yAKAD8vUmva54IrhNk8SSp/ddQw/WsXUvB/hzVD/xMdD025/66W6n+lKz7jUoJ3cfxOE+G+qx698SNau9H/f6PZadFZNeRn91LOJCxVT0baCeR3NUfiV4Ouo9Tk1SwAdppTKCRn5+ex4Bxkc8HgcEc+vafY2mm2kdrp9tDa20YwkUKBFX6AUajEJ7G4hKB98bLtPfis6tGNSHJIuniZ06ntI/8D0PmfQrS60BJLC7md5SftH7wgsA+TjI4Pr+OPrc1C01LXjIukukb2sTSGV2ICMxAHTjON3B7elUPi7rejeGtR0oIpQPpcbPsTHmSKzIw93HQ9+Oa9A0Tw7Zv4S0u3t5HGs6vEt1lSUbawB+cddiAjr3+tfNRyussbKq9u/e59HVzDD/AFCEV8b3XZJnJaB4e1/VcJP9sSMKGe6l3RwBQOTuIye5wCevBA5rOvbd/tnlR2rmGIq6tdHb5q44bYp4U/3WJJ9ea+h7PQFWTzdSvJ9RdceWk2PKjx0wg4J/2jk1wHxQ0g2/imy1JJV8q/j+zvE3USICysv1XOfoK7MZgVhKE69FJzWt2l+CtZHHg8weIrRo1tIPSyb/ABd7s5XRNFfUtHn1CRrEgysht4rc7N4cKNx3ZODz16H2rv4/hy8l6Li61WSP7OqC0S1jCpHjOSwbdnOcdelZeiQCbwGbS3jRpoL6OCRnUqgzMrbiRjPDAcd69YFevQUalGMnrdK/3Hj124VZKOlm7Hi/iKLWfD2t6XZXV3YTx3+9UcIYyGDDAwT6EY9Tx71rSR4PA57+9P8AjhZrPY6NMRylw0QIOGBdeCvPUFQc9qpeHNQGr6Hb3LBlmGYplYcrIvDD8+fxr5zM8PCFXlgrK39fke3ga0pU1KTuYlnpVit/rekzhEfWgqWzlsFZ0UvHj2LZH4Y7mq909lqV7FNdQlrtrX9zInyvE4PJ3dgMnOfSt27lGm69Y6qcYtirSZGcIHCsRyB92VuTVi48F3ureM9Xtk82x0PzlmNygAZ9yqzRx5z/ABZycYAJHWvbwiWIwsVL0+48rEN0cQ2jmYJX8x7SdxJcRAZlVcLJx19AeeV7dehFdV8Nb2LSLu5imnkMOoXgXY/3YpCnyEegYKQc91HrXQeM/DkFv4Kkh0iArLYZuoVUAtIwB3BieTuBOTnNeBj4i2DRylYr623lRuESSHAIZXXJwGU8j8a86lgZ4HHe0pRbpyWvl/wDvqYuOMwnJUdpx/E+sl6UtZXhfUZtW0O0vbizls3mjV/KkYMcEZByOx9wD7CtWvoTwwooooAKKKKACiiigAooooAKKKKACiiigAooooAjuJo7eCSaZwkUal3Y9AAMk1ynhXTF1lLbxNrafaL25Hn2cMnKWUTcoqL0D7cFn+8SSMgYFXfiHOkHgrV1eTY89u1vEB1eSQbFQe5JA/GsG1+JujiRY007U10xT5cV7FAJImA43BUJfZxwduCOelROrCnbnaV+5cKc5/ArnoFFUtH1Sx1mwjvdKuorq1k+7JG2RkdQfQjuDyKu1ZAVyWoQp4e8V2OoWg8u01if7JewqPlMxUmObHZvlKE99y5+7XW1zHi9/tWqeHtLhIa5kvVvGXukMPzM59txRfq4oA6eiiigArxr4zXWpT+OfDdhZXVzbw2drc6oq223dJMiMqD5gRgZPUdzXstcF8WvA6+L9Os57eSaHULCQspgk8p5oWG2WHf23L0PqPc0AeF+LdS1TQfh/pFlpcflWLWFtezTop825ubhDJJIW5xzx68Y6Vx+kSXDWFtcSXkvmNNtjCMpldiCTnowGOMZ9hXrelavY2uiW/hTx5JDbeQhtNM1pyBbTRAriN2/5ZTKo2kHHQjOazrv4S3Rk8zRxHdWDXJaHy3EoCgDDEYwQeM8884AoA4PVtKh1S7ihkaVHmU/K04KiUk53O49AcHn6gU+bwBK9hPBFdbzCY4hyn7rcuS2B1B+U4GTjJ4rptL8DatcSRQ3+k37tAskgWQNGDjnnnBJ6ZHoB2OJdd8Ea1/a7x2WlX9yqCLyztZVLbeAcnovocc88UAeO/bdU8P6xbW8k7XHkyfKrsxXJI7fgPr3r6G8Uvbap8OfDNx4muYorYa1AIJoX2tEgiOQHJ+U5BBOe1ZUvw+0/SWj1Pxjc6Vo+mKxV4ruY5Y55KhjlsjOMYPNX7ic+PdU0IabaTp4U0yQvplrcR7ZNWuhj98yn7sSBi24jnnjnFAHoHwSMI0zxDFpoRdGi1aVLERyb0EexCdp9NxY/UmvR6zfDukxaJo8FjDtJTLSOqBPMkYlnfA4GWJNaVABRRRQByeq+EAuoy6v4Yu/7F1iQ7pWRN9vdnj/AF8OQGPGN6lXH97HFGl+LzFfw6T4rtP7G1eU7ISz77W8P/TGXABP+wwV/YjmusqrqmnWerWE1jqdrBd2cw2yQzIHRh7g0AWqK4g6fr/hH5tEabXtDXrptxLm7t1/6YTMf3g/2JDn0fotdD4d8Q6Z4htpJdLuN7RNsngkUxzQP/dkjbDIfYj3HFAGtRRRQAUUUUAFFFed/FX4kW3hC3+x2IS51uVcpGTlYQejP/Re/wBOudSpGlHmk9DqwWCrY6sqFCN5P+rvyL3xK+INh4Lsth23OrSrmG1B7f33PZf1PbuR5t4I8B6r491MeJ/HMsptJDuigbKtMvYAfwR/Tk/jk6Hwz+G1zql6PE/jnfcXE7ebHazjJY9nkH8k+mfSvbxxwK5IUpYl+0q6R6L9WfRYjG0MkpvC5e+aq9J1O392H+f9LkrnxT4d06e40VbTUZf7PZIZIbLRLu5ihbYkiruiiZMhWRsA8ZFP/wCE80j/AJ8/En/hOaj/APGKpaR5Ju/iOt1etYQPqio90koiaEHTbMbg54UjPB9a5L4ezalpnxs1zw9f318bQaRHd21m2pzalEB5m0yNLNh0kPHyAYwxOeBnvsfKOTe7PWNL1K01TSLTVLGYSWF3AlzDKQVDRsoZWwQCOCDyBVXRvEuha5NNFoutaZqMsPMiWl1HMU7fMFJx+NcXo+kXOv8A7O+jaVYNGt1deHbWOMSEhGPkJ8rEc4PQ+xqDxG3iTU9FMWl+BJ9Oukhig837fDFKiB1LJCYJ42KADIBliBxggUCPUaK8O0Xwn46vNPSDXbnXIRBY6mIPK1donM7TIbTeUnZmwm/G53AxhmPfWtvDvjJtV/tS5uNV+1LqemlYxqZEH2UQQLd5hD+WfnE2QVznleuSAekWWvaXf6j9hsr2K4uPI+04iO9THvaPIYfKfmVhjOQRVvULyDTrC5vbyTy7a2iaaV8E7UUEk4HJ4B6V4dqnhXxo5+0fYtcm1d9Kmtbe8ttXSEW9wbqZ4nmPnKzxqjIduHGONuRxJqmgfEG/8TanutLxNOng1C2kUX5a3uFaB1hcK90wUs+w7Vhj2bsZIyaAPadO1Oy1JHawuoZ9gQuqNlo9yB1DL1UlWVsHBwQauV4rq3h/xotjeJbprcipcWzWttaXypG0a2MKOrFbqB0XzhIflf73zFWB5szeEfFV/fz3V3c63al9Q09VhtddmESWn2aJbkKPMGf3nmfMRvJG4cnJAPYaQ1xGjaX4ltPh/rumpdTJrIl1CPS7i8uPPdYzJJ9mZnJYnClPvEkd+mK5XTdA8XyZjhTxDpunvdaduhvdZFxcYVn+1SCQSviNlKDZu5KkhRnFAGj8UPhxfeJ9Tt77RNSSydVKzQuDsck58wY6P2zxx3ro/AfhQ+HbRmupRcX7qEeYsXYgerNySTz2A4AHFbOqaXLN4an0zTry5tZvs/kwXJmZ5EIXCsXYlmPAySSTzznmvKvgF4iuoLzVPCetO4vbeV5YhK2WyDiRM/X5vxauac4wqpNfF1PWw+CqYrA1KsJL9203G2tn1v2Xb5ntQri/ijGjaXpkjnBS/jAO0E/MGBH612UhCozHoBk18i/EX4tax4qne2tm/s/S4Zw8KQj94xGQpZ/XvgYArStT9rTlT7qx5tKXJNS7Hr1nq9mINW0Eahblr6CWRVWQFoZETLZwcgEAc9iPevVdOnFzYW84jlj8xFbZKu11yOjD1r4s+Hfha58V+LbXTbGRrcnMs9ymd0Uan5myP4jnA9z7V9sW0YhgjiDOwRQoZzljjjk9zU4ei6NNU272Kr1FUm5pWueKfF/wh8QvE+tyf2Ve250KLbJbW6XHksrhcFn45Oc85715doHjbUPCMGp2F0V1O8aYFGa5DRQsMhssB8xPHQ46c19X+I7GXU/D+pWFvM0E11bSQpKvVGZSAfwzXwhPBNpk91Z3sbw3Fo3lTo4wQ4yDkfXGKdShTrK01cVKrOn8LPWdF+IUOtvcWviE2tgXjEcLRxu4l3Ou8bexABxzyeK+pYyDGpXpgY4xXyv+zr4Yg8QeL7i/1BBJb6SiSpGwyGmYnbn/AHQuceuK+qhV06UKUeWCsiak5VJc0ndnmXxz8W6z4Y8PomiaY1wLxJI5bsoXS3GMDIHc5PJ44r5FZJVURhlA243ZI59Oc5r9ByAQQeQaoXmjaZfQ+Ve6dZ3EfXbLCrD8iKslGV8ONXk17wLompzxeVNcWyl1x3HBx7HGa6SmxRpFGscSKkajaqqMBR6AU6gQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeMftH2WoLZaNrP2tzoljcql3ZrC7j5/lMrlOdqqTxwOSOd2K89/4SrX7iSWPwz4Yn1q3hOwy20MqIvAwMbTg4xwcEZ6Cvfvijo39veCrzT/ALI92ryQO8UZ+cosyM5TkZYKGIGeSKqaL4j8I+HdPXTrdm0aCHLiG8tprcnJJZsyKC5ySScn3rjxOBo4pp1Ve3r/AJm9HF16GlKVk/JHh3hnxw1j4pR/Jn0bVBLGbu3yyrcIrDzEljZR8wQkhuox1HQ/U9eBftJaPaTPoviC0kthK8NxHMwYbpIBA7h19QvIz/00Fe5aTN9p0qzn3B/NhR9w6HKg5p4akqDlSjsrW62/qwVqk6qVSe+uu1/P8St4j1Y6Rp6yxW5urqaVILe3DhPNkY4ALHoOpJ5wAeD0qt4c0WaynudR1WdbvWbwATSqMJEgzthiB5CLk+7EknrgVPE5P/CV+D1b/VG7nPP98W0m39C1dRXWYBRRRQAUUUUAcx4k8HWOspO0ZW2nmO6U+SksUzbSoMkbAh+CfQ+9edXnwYtoJvP0/TLOCYAAy6Vfz6ezfdGdg3Lngnr1avbKKAPGLX4d6zGj/wDE18ZQPyAF1/zBjDbeT/wD8jVZvhlqsl3JJ/a3jpACSpPiFeeWxkA+m39a9wooA8e0b4RWtvqP29NPtILotu+16jK+pXI5ByN52KevPPWvTNE0K00ndJGZJ7t1VJLmdt0jKOg7AAegAFatFABRRRQAUUUUAFFFFABXPeIvCllrFzHfxSTadrUK7YdSsyFmUf3WyCJE/wBhwV9s810NFAHEr4pv/Dbrb+OoYYrUnbHrdqpFq3p5ykkwN05JKH+8OldojrIivGwZGAKspyCPUUSIsiMjqGRgQysMgj0NcY3ha/8ADbtceBZoYrXJaTRLpiLV/XyWAJgbrwAUP90daAO1ornvD3iyy1e4ksZo5tN1mFd0+nXgCTIP7y4JWRP9tCV988VHrXjvwtoqM2pa9p8W3qomDsP+Ark0AYvxg8bXHhDRoV062kkv70mOGYpmOL3PYtzwv4npg818KfhnNFdJ4l8Xhp9TlPnRW83zGNjzvkz1fuB2789Nmf4yfDi5VRPrcEyo4dQ9pKwDA5BHydQehre0r4keENUUG01+ywf+erGL/wBDArmlh+epzzd0tke1Szh4bBPC4aPLKXxS6tdEuy7/APDnW0VDaXVveQiW0niniPR4nDKfxFTV0ninCzaV4jtNX8Ti00fw/qulaxdpc7b7UZIW2/ZYIWR4xbSKRmEn73IbpUeh6Zr2gJKmheBvBWmJKQZBZ6rJCHI6E7bIZrvqKAOQsJl+HvwosX1oGcaDpESXP2T5t5hiVW2btuclTjOPwqpJ8SbKG6FlcaLrUWqteRWS2DJCZS0sMksbZWUoFYQuMluCPmAGSN/xtoX/AAk/hHWND+0/Zf7QtntvP2b/AC9wxnbkZ+mRVaw8EaBZTQzxWk8lzFdrfC4ubyaeUzLE0Ss0kjszAI7KASQM9KAOYX40eFhrF1p1wbiCS1Fz5rtJA+17eNnlQxpK0gwEf5im1ivyscjMFt8Rrm21zxNc6xp19Z6ZZWmnyW9ndzWUEimY3G6Te0wQAiNPlZwRtPyjv158FaGbu9n+z3QW9837TbC+nFtMZQRIWg3+US24knbnJz15rPj+GfhaOKRVs70u7QP5zandNMphDiIpKZN6bRI4G0jhsdKAOf034qnWtStX0XSbqbRp9KuL03GIWaCSKYxsWHngMgKnOzOcqVJGSNXT/iVYzrZhrHUpoGNnBc6jFBGlvBPcpG0aMplLgnzY/uhwu8AtWlbfDzw1apbLbWdzELdZkUpf3ALrM5eRZD5mZAzEnD5Gacvw/wDDSX9pdpp7rLbeQY0F1MIi0KhYmePfsdlAADMCwwOeBQBX8JfECy8S6haWsOmarZfbLaS7tJbtIglxHG6o5XZIxGC6/eC5zkZFdlWLpnhfR9Ll06Wxs/KfT7eW1tj5rt5cUjKzryTnJRTk5Ixx3raoAKKKKACvA/jRYT+EvHmleMdMQhZZF80DgeaowQfZ0yPwavfK5n4j+Hh4n8HahpwUNcFPNtz6Sryv59PoTXPiqTqU2lutV6ns5Dj44LGRlU+CXuy/wvR/dv8AI3NMvoNT061vrN99vcxrLG3qrDIrz/XPgr4M1e9lu3sri1mlfzJPss7RqTnP3eQOeeMVl/s6eITe+HbrRLl/9I0590Ybr5TEnH4Nn8xXr1XQqqrTU11ObNMDLL8XUwz+y9PNbp/cc14L8EaF4NhmTQ7QxvMR5ksjl5GA6Dcew9K6WiitTzwrn9a8G+HNb1OLUNW0ayu7yMBVlliDHHYH1H1zXQUUAUtJ0nT9Gtfs2k2VtZW+S3lwRhFJPfA71doooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKRgGBDAEHgg1na3rmn6JAkupXKxGRtkUYBaSZv7qIPmY+wBrHiTxHrrCaWc+H9OYfJAiJJeOD3djlI/wDdAY/7Q6UAeE/FrTdRg+3aPahpY7CJbSzGSRJCrC4+zk9dzRttx3ENej/ATx9Y+IPDdlo0s23ULOERwiQjNxCoABH+2owGHXjPQiu2m8G6PN4en0iSGV4Zn8552kLTmbjE3mHnzAQMN2wB04r5o8feE73wj4kmuYbnyLuCRLmSaAbPORmKx3SAfckV+HUcHk9GxXFUbw9R1Psyt9+i/wCG8/XTSd5wTjvFPTut9PNa+qPp/wAXabc6jpG7Tiq6laSLd2hboZE52n0DDchPoxq1oGr22t6al5a7l5KSwuMPBIOGjcdmU8H/AAwaZ4XvZdT8M6Rf3IAnurSGeQDgbmQE/qap6p4dd9Rk1PQ75tM1OVQszCMSQ3AHTzYyRkgcBgVbHGccV2mZ0FFcxZeJ2s7mOw8VwR6XfOQsU4fNrcn/AKZyHGG/2Gw3puHNdPQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVx3xG8cW3g+yhAhN3qdyG+z2ynGduMsxHIUZHQE+1AbnY0VwPww8QeIdZl1SHxPb2sE0JR40tyTsDZ+RvUjA596h+JnxT0nwbbvb27x6hrbD93ZxuOPdz2H60A1Y7jVdTsdIs3u9Uu4bS2T70szhVH4mvEvF37QNsjvbeCtOOpSDj7XcZSEHPOBwW/A143rt/rXjXUBe+KLw3W1i8cC8Qw+yr/AFrQ0iyt0uoIimVZgp/OgC3L4u8Ua1qMd14huVvoo23xW4QQ+Qf70Ui4kjb3DexyOKmuvD2la2ZLtIFe5ILyXEdupuE6nM0KACUf9NYRnu0fVq6yHTrSEARwRgjvjmpvJjypCAFTlSOCp7EUAeW6hoM2nrHL5cEtrKN0NzbkPFMvqjDgjj8O+KypLaF8+ZDEef4lBr0ufUok1G8huWWKSV8yTeX5kVwccGeLI3Nz/rEKyD+83SsDxPo8EUf2y2K2wbkRNJ5kUvPWCXA347owWRe6kDNAHNafe6ro063Ph/VLrT7iMkoEkJjyR3Q8H8q9p+Fvx5N3qMWh+O4Y7K8fCwXy8RTH/a7An8u1eLtFIE3FSF9ap6hZQ39sYZxkHow6qfUUAfeisGUMpBUjII70tfPf7N3xEuJJP+EL8R3LS3kCE2FxJ1ljHOzPcgZ69hX0JQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8/XQ/4QH49JKP3em6q2TjgbJTg59lkGfoBX0DXkH7SOifavDNlq8S/vLCbY5H/POTAz/30F/M13vw91r/AISHwZpWpM26WWELKc/8tF+Vv1BP41xYf93VnS6br5n0+cf7bgMNmHVL2cvWO33o6Kiiiu0+YCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDG8Q66mlG3t4LeS91S63C2s4iA0m0cszHhEGRlj0yBySAaI0bXdSV21nXHtEccWulIIwnsZWBdvqNn0pPDuy/8WeI9SIDG3kj0yJj2VEEj4+rykH/dHpXUUAY+i+G9K0eaS4srXN5IMSXUztNO495HJYj2zipPEmuWXh3SZdQ1F2EakIkaDLyueFRB3YnoP6ZrUrxbxFqjeJfE814WJ03T3e2sU7M4ysk3uScqp/ugn+KuPHYuOEouo/l5s6sJhpYqqqa+foRajqWua7M1xqepXdhGeYrLT7hoVhHo0i4aRvfIX0X15Pxtqd3qvhx49Sma5nsre9s/tD4DyosluVLEY+YBsZ74z1NWNN1W/t/FMuh6u0M/mW5u7S6jj8suobayMuSNwyDkYBB6Vk+IyP7G1ZcjIe+OPxtf8K+cw+JxFWVT2srppNdviWx7WLoUadOPso2auvP4XuXPBKvr/hjS9V1C4u/tphEcUkVzJGbdEyiLHtI24Cg+5yTmvVvA/i+6S+h0TxJMss0x22V+QF+0EDPlyAcCTAJBGAwB4BGD5J8LruCHwT4ftpJAs1xHKYlP8e12Jx9Ac11l/ape2jwSM6bsFXQ4aNgcqynswIBB9RWcczrYXFycm3G708r209DZ5fSxGGiopKSS1+XU9wureG7t5ILqGOaCQbXjkUMrD0IPBrnY/B1tZNnQtQ1LSVAO2G3n3wD6RSBkH0UCj4e6/Nr+gBr8KuqWkhtbxV4BkUAhwOyspVh/vY7V09fYxkpxUovRny0ouLcZbo5M6xqvh5418Ti3udNZgn9q2yGMRMTgedESdoPA3qSM9Qo5rrKhvbaK9s57W5QSQTxtFIh6MrDBH5GsP4fXE0/hKyju2L3NoZLKVm6s0MjRFj7nZn8aoR0VFFFABRRRQAUUUUAFFFFABRRRQAV4j4tsZrr9orSRcq32IaZ9oiY/d3xFiRj33DNeteI9csvD2mSX2oyFY14VF5eRuyqO5NfO3iPxLdaxrx1rVC0N3DG0dnZoeLdG67j3Y4GT7Cgadncu+O7HWn8S3cnh7xFJaaTfhWvbaJAHZlJ+7J1XIPavO5PCmgxXLSXekXbzuTule6l3sT77q6bRkvr6R5ftjIuckZyTXa6P4RfxbdpbXRZdKjIa4K9ZfRM+nr9aWyKb9pK55xpXhu0ilZNGvPP085BjMm9oH+vUjpwa1dEsU+0PBcxkTQOHVumf84ruPjKlt4Os/DkekwRRW3mmB4Y1Cgg4AP8AOsCxvra8TdGVDngqetCYpJJ6Fw9+lR3UvkW8svHyqT+QqX8azvEEvlaXKc4LfKPxpknFzSGWSSQnJZsmpLC2nu3aCEuUYhnGfl46Ejpxk1FDG80iRRjLMcAV1bQx6Po0hGDKwwT6k0AcZqWUhlVvvZx+tY351sXcL3G0Ajk5Pqalk0lraJWmgYK3Rm70AcxePPaS2+p2DMl9YyCeJgSOh5Bx2IzX2z4F8QQ+KfCWl6zbkFbqEM2BjDjhh/30DXyBdWKtGxjGB3U969Z/ZH1eRtL8QaDcTFvsNyJIIz/DG2Scf8CP60AfQdFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZfinSk1zw5qWmSYxdQPGpP8LEfKfwOD+FeU/s16q/8AZ+saHcZWW1mE6K3UBvlYfgVH/fVe1V4FpOPCf7RF1bAbLXUmcDsMSqHAH/bQAVxYj3KtOp52+8+myb/asBisE9+XnXrHf71oe+0UUV2nzIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc54AIl0B7rbte6vLqdx3yZ36/QAD8K6Oua8Hb4LzxHYFt0NrqbtF7LLHHMV/BpH/SuloA534harJo3g3VLu3JFz5YhgIPIlkYRofwZga8avdN1CHTrW28P38Fn9nj8sCe385XAAAzyCCMdffpXoHxS1C31Lw1octhcLPa3GrRLvRvlbYJGI/76T9K811PVPEC3Ew0zRbX7JETm5vrwQhsdSFAJC+5x9K+Yz2U5VoU420V9bW106+h9Dk8YxpTnK+rtpf9DGuvD/iaPUbLWJNSt9Tv7UsscSwCBUR8BgBn5s4HVhjHB7HnrxdSv9J1PVlZ/K+0rFPAwCRyLKxTyVIZvvbXbdng+WemM6GneJPEfi1rrT7SxtYLYHy5Ly3mZkYdwJCBgf7oLemPvDtLLQtnwR8Twq5kk0/V/tZcKFysXks2AOAAgYAdgAPejL6UpVJQq25ktl27aabu5nmdXko89C/q+9vP7jy1dTtv+FeWNvp4kkk024Sa1vN4V0+cn51zuVuSp4KnqDjp6d4Z8TWuvPcQLFLa31vgy20wwwU9GHqp9ap+FvBhvvh/bajZW9rqVrZiaO4snYpPbshO/wAiQdmGG2HH3uvQDj7/AMN2+kazoupWWpXkGkXeIre7Rx5lkzjcg5BDRN0Kt3P41hjMLG/LPRu7i979f6Vl5ee+CxfPBVKburK6/r8/v8vbPAN3/Z/j0QDiLVbRlb/rrCdyn8Udx/wEV63Xhvh83Nn4i8Lfap1uLkXxjeVY/L3BopRnbk44Ne1W95b3FxcwQTJJNbMEmRTzGxUMAfwIP417GS1HPCJPo2jzc2go4ltdUmWK5rwi2zVfFNqP9XBqe5T/ANdIIpCP++nb866WuY+Hjm60O41F/wDXX99czye2JWjUfgiIPwr1jzTp6KKKACiiigAopGztO0gNjgkZr5s+LnjLxZZa9caRLrdqkSjLJpZZNoP8LsfmDY6jOOa58RiFQjzSR6+TZPUzas6NKSTWut9vkv8AI+hn1bT01OLTmvIPt8oJW3DgyYAySV6gYHU1erxL9m/w6Us77xHdKTLcMbe3ZupUHLtn3bA/4Ca9tqsPUlVgpyVrmeb4KlgMVLDUp83Lo3tr1t6beoHkVVa6WGdIrghPMOI3PRj6fX+farVef/GSC+/4QvU723ultobW3eSaPkicDHDdOnPStjzDyP4h+KdV8U/FHUNL0hBHZaJmKS5nwYoG/iZR0LHAxnONv1rn7onUdVnmAAizvdidqqo6knoBW1onhqfSfDMGmyM4eVvNuZsZaVz1571uL4Tj1DRrvTpILiG1uojG8sWA2D160AZ+hHTZZPs2myxG627jCx2ysPUKfmI967DwhrA0i9kWVykMow3sfWuN8L+ANP8ABmvHWXvtSvr1YjDELhQFVTWox3OW9aTVyoy5XcwPixrcviPxNDG25bHT2Yxg/wDLV2ABb6cDH41zMDqkysxbaD2POK6a9tEmurq5lj3Iq7EH95sf/qpk1hDaaC/nqPMIzn0J6UJWCUnJ3ZuWpDW8ZVy4wMMe9c7r8r3s7RQ/6mAEu3bNbGindo9vzj5TyO3Jpb2yV9Omt4AFLDj3pkmb4X0/y4/tcgBZuEz2HrVPxVdmS5W3U/LHyfrXQ6W2bKNSMOg2svoRXM3Ol3dxqsilG2lslz0x60ASeGtPE8xuJh+6Tpnua6LVIFn0+ZGA4XI/DmpbWBLa3SKMAKoqhrOqQ21vJGrB5WXGB2zQBxgxjkcZ611H7Na/YfjB4giYjF3pwdfqrrxWJplg13cRI4ZYnz84HtWhocy+Cvij4W1WeQ/YrlpLCdlGOXDbM/8AAttAH1hRRRQAVzXxE8TP4S8L3GqRWj3UqMqIgB2gk9WI+6uM8+uB3rpabIiyIySKrowKsrDII7gipmm4tRdmbYedOnVjOrHminqr2uu1zlPAfjzSfGVpusn8m+QZltJD86e4/vL7j8cV1teIfEL4WXOmXf8AwkHgEyW9zC3mtaQsQwPcxf8AxH1x6V0Xwp+JsHilV0zV9ltriDpjalwB1K+jeq/iO4HLSxEoy9lW0fR9Ge7jsoo1aLx2WNypr4ov4oevdef/AA56bRRRXYfOBRRRQAUUUUAFeD/tCRPpPivw14hgB3p8uR/eicOv57j+Ve8V5Z+0ZY/afAUdyB81pdo5P+ywKkfmy/lXJjY81GVumv3Hv8MVlSzOkpbSvF/9vK35nqEEqTQxyxMGjdQykdweRT65f4YX/wDaXw/0G4Lbj9lWJj6lPkP6qa6iumEueKl3PGxNF0K06L3i2vudgoooqjEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAy9C0k6ZJqcjTedJfXj3THbjbkKqr+CoozWpRTJ5DFBJIEZyiltqjJbA6D3oA8D01nl+E0jSP/AMgbxE8x5/5ZSTk5+gW4P5Gm+IdGg12xWzvJZktfMV5Y4m2+ao/gY9ducE4x0rsNG0VNOsdP03W4hDZ+INKW2vAflaO7VGcjJ4BKM+D6xCvAtZE/iO8nabWNRm0PcUtoAwh89BwJJNgGd3UD0I/Dwc3wcqtSFaMuW2nn5WPZyzFKnCVJxvf7vmepaUDcldN8Laeb14RsCW4CW8Ps8n3V+nLexr1Twf4VXSPDNzp2pSR3ct+8kt5sBEbNIMMqg87QoA55OM98V8yWk0+kwD7Dq2p6fEnAMWoSxqv4bsVv6f488YWUI+zeJ5p4cbgbuCKbjHXdtBP4mjARw2EvJXcnu2PGvEYmydrLoiho2vaj4Qsdb0VCI7G7mNjeTEnfbCOQxPMB3zGCCeMYDdsV3M9hZX+kmxlhim0+WIR+X1VkxwBj8MYry2x1KXV7nUr+4uI7qa4u3d5o4wiueMkAcf49akgtIraVpLUzWzN1+zzPED+CkCuTH03iJJKVuW9jwMuz2GWTqUK0OZX3Xbt5nrPgLTGh8XeH9NjmuLqKySe7aW4YO6oqGNATjnmUYJ5+XvXXfCiVrnUPG12z7xc628kZ/wCmYijRf0SuZ+GRl0P4Zza8wmutd1aY21k9w5aSUeYyQJz0XJLngcEk+td34M0V/D+o39gkcn2Nba08qYj5ZGVGRuf73yAn/eFe5l+HeHoKEnd7v5ndisSsTU9pFWVlY6yszQNL/si0nt1kDxPdTXCDbjYJJGcr17FjWnRXacwUUUUAFFFcb8UPGkPgzQDOu2TUbjKWsR7t3Y/7K5H6DvUTnGnFylsjowuGq4utGhRV5SdkYHxi+Iv/AAjsP9j6I4fXLgAFlG77Op6HH989h+PpnH8DfCGJ/D17deJ8yazqMDBBJljalhwxz1kzyfTp6034LeB57u4/4THxPvnvbhvOtVm5PPPnN7n+H0HPpj2uuOlSeIftay06LyPpcdj4ZRD+z8vl7y+Oa3cl0Xkv663oaBpUGiaLZaZaDEFrEsSnGC2ByT7k5P41fooruSSVkfKTnKpJzk7t6sKoa9pVtrmjXmmXylrW6jMUgBwSDV+imSeeWvhvWrGyWyuI7fUYo2/dyqwViO28Nxn6VyPiTwZ8RL3VJZ9I1PTdPiADxxNI7lyM8Y+6Md+xr3GggEg9xRaw3Jvc8Z0ex8XzvPZai+iz3KDKrIkkYnXHVeOD14PI47EVyt/qSQ+IJdGvbV9N1JV3GCRwwYeqMOD9OtfRE9pDMdzoC4OQe4PrXyC/h/So4b0+LtP1Cx1y3heVLq6Do1xOzHhTk5AAU8Y60m7DjHmdjvvKTCDAwvIFc14qvQ7raoeF5b61YvNC1WDXpLHwydfvbe3tA8jugmjeZhwgIA244yeetWtF+E3jvVJA+qSaZpcTjcWYmdx7FQR/OhO4SjyuzKvhW73xPbEH5OVPtXQYJ6Vy2seEvFHhLULqOHV7GVhMiL59oY45FfATB38Etke2KcujQ63r8x1PVV1SOzAjSx0pWLPJwWyoPzdSOCOlJySKjTcjoJ3hhBeSSOI92YgZ+tY2p+LdHsVAGoWcsp42rOvH15reXw3qciLDpXw+adCMCTUrswgfVcE/rWhp3wt8QXxB1Cw8J6SndYrR7h/++t4H6UJvsNwivtHms3iN9RyLe6iKHosLg/qKzLi9t4jKZZlBjG51zkgeuK9nu/2e9F1KVX1TVtQG3nZZbIFz+Rq5Z/s7+Brdw8keo3TY25nuN2R6HAFUZPyPHdH8ZaTYaTcSPdRyeWUcKrjJRmCkj6Z5FSfEnUYrrTbHSbCH7ZqmoyI1miHBXBB357YxXtU3wC+H0kWwaMUP95ZWzXB+Mvhanw1nj8XeGprq+srYCK7tbphI8UTEDfGQBgLkEjHQHmk9tBxSbSZ6v8JPEF1qnhxNO1pPI17S1FtdxFs5wMK4P8QIwcjua7qvFLjWJbjSrXxRoEgF5ZossgC5FzbnlgwHsSfYgV7BpF/DqulWeoWpJguoUmTPXDAEZ9+aUZXRpWpezlboW6KKKoyCvJPi38NW1J28QeF1MGswnzZIojtMxHO5cdJB+v16+t0VlWoxrR5ZHdl+YVsurKvQevVdGuz8jzH4QfEYeJof7K1lli1yBcZI2/aVHUgdmGOR+I7genV4p8Z/A81ncf8ACY+F90F5bN510kIweOfOX3H8Xr19c9z8L/GsHjPQRMxSPUrfCXUI7Hsw/wBk4P6jtWFCrKMvY1d+j7o9bNsBRrUVmeAVqb0lH+SXb0fT/hkdlRRRXYfNhRRRQAVyfxWsxffDrX4iM7bVpv8Av2Q//stdZVPWLb7bpN7a9fPgeL/vpSP61FSPNBx7nRg63sMRTq/ytP7nc89/Z3vPtPw8WEnP2W7lix6A4f8A9nNenV4l+zDcl9M161zxHNFLj/eVh/7JXttYYKXNQiz1eJaXsc1rx87/AHpP9Qormrvx94Os7qa1vPFnh+C5gdo5YpdRhR43U4KspbIIIIINRf8ACx/A/wD0OXhv/wAGkH/xVdR4R1VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHn/xyLv4AuLe1JW+mlQWzDqrLmRiPT5Eevn3QrG/vtItZ9M0i/uLMRIFkSIKpGBjbuI3D3XIr6Q8aCC517TLW+OLOOxv7qQkgDARIzyeAdsz15zJq17ofwptNTt4YpLy30+BlhkUgMSqgLjIOefz7dq8DPcROiqappNydtfkehgN5M8dSKTUtRuYxbA6mtwlnbWt/+6VCxRCxDDj52wTzwAOM1QtJLO8s4ZkElre+b81mi+YpmXqGhOVZcrzkYPevTbX4h+F/E0kOneKtGZLyNS2ya1+0oj4wcBQXXjpuUfmKh+wfDHNvJFqslolurso+2TIFDkswyxyDnnAIPcisI4/lUVWoTi11iuZP9DhxOXOdWVSnWSm33tp29DkrW5tYbdl3tEYz86zAq+4/NyD1J56cHnFdb4O8LPr85u9Xt7iDRUU7UkLQPcPkcleGEYG7rjJx1AyVPiP4d+GglzZ27anexqpE/lmabdyUBZ+QT6gYHtxUvh7xVqXj7W4rS5tJtP8ADk0cjB7dmzcOmzdE0/AI+Y5VOeME4JrhxdWvOMp0oSjHfmlo7eS7iwOTUaVT2tWXPLt0u/zOr8AajajXLGz08zp4es76E2aTBtqma3uEXy93Pllk+UdMsccEV7jXi6wJb6V40v4EjQWN1YSwqgAUNAI5B06HkLj0x617RX0+XScsLTk+qW+5pXVqkku4UUUV2mQUUUUAVtRvbfTbC4vb2QRW1vGZJHPZQMmvn/wvY3PxZ+IlxrWqxsNDsmGIW6bQcpF+PJb8emRW58fvEFxe3dh4O0gNJc3Lo9widWJP7uP8/mP/AAGvT/BHhy38K+GrTS7faWjXdNIB/rJD95v8PYAVwT/2mtyfZjv5vsfV4Z/2Nl31r/l9Wuo/3YdZer6ff3N1VCqFUAKBgAcYpaKK7z5Q+Zv2hbG0vfimv2y1guNmjWu3zYw+3M91nGfoK5bWPBWk2Hh/Q9Q/smxH9oLK2dqPnYwH3fLG3r/ebPt0ru/jrpupzfElbq00fV7y2bSbaMS2dhNcJvWa4JUmNSAQGU4PqK5fU7nxDqGj6Vps3hnXlg00SLEyaJeBm3sCd2UwenYCg+SzKliJYmq4xk1ZWsna/u3/AFPaf2e40i+E+lRxKqRrc3yqqjAAF5NgAV6NXA/Au0urH4Y6ZBf2lzaXH2i8cw3MLRSKGu5mUlGAIypB5HQiu+oPqaN1TjfeyCiig0GgVg654l0rTl8uZnupWJCwwRNKSw6qcAgH64rO13TvFWskxW1/Z6RZMCrBIzLOfcPkAflWPB8K7Z5/N1XxBreoFuXV5EiVj6/u1U/rSd+g1bqVdT8d+IgU/s/QbHTbcrkvq94kePThCaxh4t1g3QkvfHOjQj/n2sYY7jPPrjdXdWHw38J2Lh4tJV3HeeaSXP13MRW7b+H9Gt2DQaTp8bDoUt0BH44pWfc0U4LaJ47ruoaf4lsjp/iDVL3VYM7lVtBcqCPQiPirGh6ZY2FqLbQNR1jT4SeEhsJYlz6kbQPSvbERUUKihQOwGKWjl8x+1X8qPEribWY2P2T4hXFi+cKL6zQAn/tpjNWtO1/4gwputL3w34ijHXEhic/98Ltz+NetXdhZ3ePtdpbz4/56xhv5isTUfA/hzUHVrjTI1Zehgd4f/QCKLPuHtIPeJyS/EjX7AY1zwRqQGcGWymilX8t279Kt2/xh8LbtmotqOnSf3biwmx/30FI/WtAeAIreUHS9b1exiAIECSK6f+PqT+tQv4W8QKrxnUtMvIcfL9qtGLk+5DAfpR7wWpPq0St8VfBKJufxBaoPRlcH8iK5Hx18avBs3h7UdO0i5m1m/uoHt47a1t3OSykZLFQMDPrV668J3rtJ5/hDSLgjpIk6Lv8A+AlD/PtWFfWFxpLb4PA2pPIP+fJUIP4hQf8AJpcz7FKlT/nGfC+zk0r4WCDVUWN4bWTzAx+6uwnb+ANdT+zddG8+Emlz7iyNPchCf7gncKPyArznWdL+IXj+1/sKy8PSeF9DdgLme8k/fSLntj+X61714O8O2XhTw1YaLpqBLe1jCjH8TdWb8Tk/jRBNasK9SMrRj0NqiiirOcKKKKAEIDAggEHgg187+LNPufhP8QbbXNHjc6HeMQYh0AP34v8A2Zfw64NfRNYfjTw7beKfDl3pd1geauYpCM+XIPusPof0JHeufE0XVjePxLVHs5JmSwNdxrK9KfuzXk+vqtzS0u/ttU062vrGQS21xGJI3HcEVarxD4Ca/c6bqV/4M1nMc8Du9urn7rA/vEH/AKEP+BGvb6rD1vbQUvv9TDN8ueXYqVC91vF94vZ/11CiiitjzQooooA8H/Z//wBD8beKtP6bQeP9yUr/AOzV7xXg/wALf9F+O3iuDHyv9rAC9B+/Vh+le8Vx4HSlbs2fS8V+9j1U/mjB/geVr4wtvBXw4vdQna3+0z6/qlpZpcSiKN531C52h3PCIMFmY9Ap74rkPBvjHU/F3wK+J51/WrXVdSsY9RtxJAsaDyPsx8tgqAfIxEm1j1weTivRPDd9rfh+0vbCXwdrd3/xM7+4Se2nsfLkjmu5pUI33CsPlkXgqCDmsHUtNuLbwH4s0Hwx8PPEFlJrkN2zGW8smQ3M8RQuxN2xAztyAMDHArsPmj12iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAyvE+tR+H9Ia/ltbm7/AH0FukFts8ySSaVIkA3sqj5pF5LAAZrK/wCEo1f/AKETxJ/3/wBO/wDkqj4l/wDIuWf/AGGtJ/8ATjb15r8d9G0rxX4r0Lwdp+k6c/iDWJFuL/UvssbXFrYxHk7yNwLY2jnsR3oA9P0nxTLea/DpF/4f1fSbme1lu4mvGtmSRIniVwDDNIQQZk6gd/Sulrj5baGy+I/he1tUEdvBoWoxRoOiqs1gAPyFdhQB514xnk1JPEl98qWGh6fdW0ZK5M9xJEC//AFG1cd2J/u842p6S994Pm0pGaOaSz8lDK+4q23A3MBzzjJxzzXW+CrZNX8B3CTswGpS3pkYdcSTSD+RH5Vyvhl3i08addBVv9NP2OdApXaU4VsH+FlCsOoIIr5TiiNRRpVo7Rb+/S35HpZc1eUX1PNfiNd291OPEMN9HMddtYp3sIHzfWxEQjO1VyCmVJByMHPB7ch4d0O71+0uLiCXUJ7RJjE73cy2sUcowdpMr9sg4wSMivQtT8AXd94g1z/hGbieW6VoNTazMiRoWkkkDpuK5+bZkAnA2kdxjmbLw7Fdahq32yO00e5trlreVLi3+1XFxcBVOyOOIsSu3bucZxnOO9fU4TGQxGGjXvZNdT5vE4SpTxMoxhe/Z/5rT5GXFp+p2fiDUIpJLWGC0nMckdq3nNcuFyS0rgE8t1//AF13XgG/t2tNHtPNaPVf7UuLieyaM5t4ngK8dmUtGCXU4DNjvmuL0DwFqGvXOpx6Z4euoHguFNxEZorZegw/z7ZQhAPQYOD3zXX+E9Lg0vWNR8T6je29xbWFs1sJreTdDvyCwiOAX7Lu43NkAcAnkznEU1gJ635lZW6t6KxtlmGqxxvNy2XW/T8dfVno3h3SZdetvGcEMggSa7gWCdkyBNFHG3zIfvKGCZ9QSM9K77wzqb6xolteTQfZ7ht0c8O7PlyoxR1z3AZSM96zfh7pdxpXhmJdQj8vULqSS7uVLbiHkYkKT0yq7V44+Xijwon2bWvE9mpJjW+W5QH+ESxIzD/vsOfxrTB0XQw8KT3SS/A9CrLnm5LqdLRRRXSZhVTVb+HS9Mu7+7bbBbRNK59lGat15T+0XrZ0/wAGw6bG2JdRmCsM8+WmGb9dg/Gsq9T2VNz7HflmCeOxdPDL7T/Dr+BzXwQ0+fxR401fxjqi7jHIwizyBK/p7KmB/wACHpXvdcr8L9CHh7wPpdkybZ2jE8/HPmP8xB+mQPwrqqzwtL2dJJ7vV+rOrP8AHLGY2cofBH3Y/wCGOi+/f5hRRXH/ABWtoLzwlFa3cMU9tPq2lRyxSoGSRDqFuCrA8EEEgg10njHYUV89eNrrwdpfji/0K08KeENMsdKtop7/AFO88MtfIjScouyELsXGCXdgOcV6DpOhaBo/xJ8Pz+G9L0mxjvND1B3k062jhWcCaxKk7B8w+Y469T60AeiUV4gut7fiv4igu9RtpZbfVIFtLO48V3NnKV+zwMEislBjmBYtgEgMxINQWfxe1iSwmuftXhy8Y6ZFeyRW0Mq/2W73EUTLcnzWLeWsjM42ofkPAHNAHu1FeG3PxX1aDSby6TV/CtxBbatNZfboY1CzxJbwyBoYZLtPMO6VgdspOAuFJNeieJtXmgt/CMseW+36lbxOT5sPytE7E7QwPb7r7h6gkA0AddRXh1p8UfE8Hh2y1LUotFkOoaNFqkbRW8sSWe64hidpcyMXRVm3nG0gIR7iK8+LmtQWErW9xoN9Cmrz2A1i3iRLQolvDKvEt2i7maVgD53ROATQB7tRXi4+I+u3mp6fpz3Gh2c2o2Mbxw2hjv5RM8JYk+XdKypnlWWN1K4JcZrnrL4qa/pHgvwrHDqOi6lPNpgeW+uWjRROkcY+yzPNeRjzwWJd9xb5gfKHNAH0TRXh2p+MbzxB4x0CyvbrSbI2uvwKukAGS8K/Z2bzzIJNpjJcgEIQePm7Vb+J/ie48KfEK7v7HUNIt7pPDytFa36M73zrPIRBCFdTvY8AgNjI+U0AezUV5/pfi3XLvxwPDU9hbwXEcj3k8hjbaunmMeUR82PNMrGM9v3UhA6Y9AoAKKKKACiiigAooooAKKKKACiiigAooooA8I+O2mT+HfFGkeMtJGyUyKkxHTzUGVJ/3lBB9l969p0TUoNZ0ez1G0OYLqJZU9QCOh9x0rL+IOhDxJ4P1PTdoaaSIvD7SL8y/qAPoTXB/s4a2bvw1eaPM2ZdPm3xqe0b5OPwYN+Yrhj+5xDj0nr80fUVn/aOTRqv46D5X/glt9z0R69RRRXcfLhRRRQB4R4P/d/tF62qfKG8/IHfIB/nzXu9eEaRx+0xe44zv/8AScV7vXHgvhmv7zPpOJtauHl3pQ/U8+sPGuo3HhzQ794bQT32vy6VIoRtoiS5miBX5s7tsSnPIznjsKMPxisJdMXUF8M+JPsracdWDlLb/j0X70v+v6Lx8v3jkYBFdVbeB/D9trf9qw2UguhcPdqpuZWhSZ87pVhLeWrnJywUHk881Sg8N+ERcS+GIrT97BogsXtvMm+WwlZk27s85MbDOdwx1GRXYfNmdJ8XfDKeKToavLJOJvs/mrJDjzfL37fLMgmxjjd5e3PG6qi/GLT/ALAL6Tw34kitP7Pj1YytHbYWzckCY4mJxx9373cKRzXWR+DNFi1GS9givIJJTmSODULiOGQ7QmXhVxGx2gAkqScDNMk8DeHZNMbT307NmdMTRzH58n/Hov3Y87s8Z+9nd70Ac1pXxAls9b1iz1201CS0GtS2FpfJHD5KERK6wnDByeG+YqRkgFvS/B8TtJOk2Op3thqlhp99YSahaz3UcYEsaRJIVAVyQxDnAIG7Y2MjBOp/wgnh46zLqj2c73Ukz3JV7ydoRKybGkEJfy1fbxuCgisa+0Xw1rvhDwrJbXdrb+E9HmhuYvtCMA0cKNHGm+QgoAcZLAlgCD94mgC7Y/EGzu9ShtjpOsQQSXS2DXkscYijuigfyWAkL7hnaSFK7uN1UNJ+Kumajp32z+ydVtIn07+1Lc3j2sIuIN6oWVjNtXBdf9YU68ZroT4M0I+IP7Z+xv8AbvP+1Y+0y+T52zZ5vk7vL8zbxv27vesDU/DPgeG40jw1dWE7T/YRa2kEBuXaK3SWNwTIhPlgSJGRIxByMBuooAzdN+K667rOiR+H9Iuruwupbu3uyJLZmieERnKuJ/LZQJAxKlsgjHORS6Z8b/C2pySR2Ed7cTFFe2ihaCR7rdKkSqqrKTGxaROJRGcHPQHHTW3w+8O2phaC2vUmhunvVnGpXPnGV1VXLSeZvYMEUFSSDjkUi/D3w4tlNZrbXospAuLb+0rnyYdrh1MUfmbYirKCDGFI7YoAr+BfEl3qGneJr7XVms47DUp4xDcLHvt4UjRtreUWU4yxyC3XrWLpPxp8N6tHILCC+nuv3PkWsL280lyZXKoF8uVlQ5HIlKFRyQK7fQvDml6HYXVlp9u/2e6laacXE8lw0rsAGZmkZi2QBnJ5rA1L4d6Y3h+fTdKe4gLGJoPtl7eXUVsY3DKY089DGRjAMbJjjqBggFX/AIWhZshSHQdcm1CM3Xn2KLb+bAluwWR3YzCPblgBhyT2FWtG+I+mav4jtdGs7K9E9xbxXIeWS3jCpJEJRhGlEjgBgCURlB4zwcc7P8Imbw5b6fDrEa3wku3nv3iufMYXDAuilLlW28DIlaUMQC2ec9jYeB9GtJ9LnYX1xNpqRrbCe+neKNki8pXEJfylbbnkKDyT1NAHT0UUUAFFFFAGL4x0afXtD+x2d3FZ3KXVtdxTSwmZFeCeOYBkDKSCYwDhh1rP+w+OP+hh8N/+CGf/AOTK6qigDldL0HXP+EqtdZ17V9Nu/stlcWcUNlpr23+ueF2ZmaeTOPIAAAH3jzW5r19/Zmh6hfgBja28kwB77VJx+lUvCviWw8TW15Npr7ltbqS0kz/eQ9R7EYI+tWPE9k+peG9VsocebcWssSZ6bmUgfrV1Kc6UnCas0KMlJXRH4Q01tI8MaZYynM0MCiU+shGXP4sTUGu+EtG1y7S7v7VheIuwXFvNJBLtznaXjYEjPODxV3w5qSaxoGnajGNouYElK5+6SBlT7g5H4Vo1nKKkrSV0Um07o5o2WneCfDupXek6e7lFa4lHmM8s7AdXkbcx+pzgD8K8o8K6ZJa+PvEmq3E9teTaxBDfK1nkxRAtImxWJ+bOwHd8ucdOK98NeTfEKy/4RDV7jXNF0syRalbtHPDbQEg3SZMJIQZzJvKk46hfx8rOcPUrYOVOiu2nzR0YWcY1VKRzlzeaJ4qj0+/i1ZLDZvS8iaUQyyQFW3wPyGC7gCe2AfWuy8G6L/b19b6xe27xaNabH0q2dVVZWAI88rjIABAQHH97H3TWn4B8EaTpfhPSkvtJtpdTaCOS6luYlllMxGWyzAkYYnA6DtXb1lgsmhhpqcpOSj8Ke0b7/PzKrYt1E0la+/mFc5pBCeOPEMR+89vaTj6HzU/9kNdHXLw5PxOvCv3Ro8If6maXb/Jq9s5DqKKKKACvA/ikP+Em+NOhaF96C38pJU+p8x//ABzH5V75Xgvgb/icftC67eN832M3BU9fukQj9DXFjPeUKfdo+l4a/cyxGL606cmvV6L9T3qiiiu0+aCuV+Jok/4ReOSK3ubjyNT024dLaB55PLjvoHchEBZsKrHABOBXVUUAeM+LNM8IeJNX1DUJW8cWEmpWq2eoR2egXqpeRKQQr77ViOmMoVOMjNdLod1Z33jvQE0TT9Vt9N03RL213Xel3VpHHuls/LQNNGu47Yn4BJwpr0GigDlvEPjbS9I17StFS6srjVr68jtmsxdos8KMrN5hj5Yj5R2H3utclr2reBvD2g69qunatFqV6PLsZj/wkcrTIzy4WPzzKzwLuJY7cYCscHFaV38OrmfW5Zl1qJNJl1b+13tvsR88ymLyyvniQDbySPkyOmcVjaR8HDYaf9jk1pZ1iW1it5mjuXkSKC5inCESXLx8+UB8iIATkDHykA6DwlrvhXw/4eLz6hpOkxzXDPJLPrSXS3MpVCzi4kffJwyDL7Wxt+UDFX9e+Ifh7QbmCPU72CGGeaGFLg3UHl/vUZ1c/vMqgCfeIGcjGRkirbeAUi8SnV3v1k/0u9uhEbfp9oijjxnd/CIzzjndjjvjad8K7nTLCwSw12IXliun+TLNYl4y1rE8eWQSgkOJCcBhjHU0Adius6Prtre2T3yRACUMIdQWOUxxsA0qvDJuRQSOcqRkZAziqvhi68I6ROui6Jq2nte3Z+2eQ2o/aLm43qG80l3aR8qAQxJ+UDsK5/V/hauqWJim1hobiTUbm6nmht9vm29zxPbYLEhWGPmzwQDjinW/wwjtfGjaxBqCtYG+GorYyi5/dShAmU2XCwjGON0LEAkZIxgA39V8baXo/i9dD1i6stPSSzS5iubq7SISu0jJ5aq2Mn5c8H8K1h4g0Y6w+kjV9OOqxqXez+0p5yqBnJTO4DHOcVz/AIx8DJ4kuNbma9WBtS0R9HGYN5i3MzeZncM/eHy8fd61mr8OJhqYZtWt5NKTUJtUS1exzKZ5I2Qh5fM5j+cnaFBxgbsCgDRv/if4Ns73Trc+ItKmF7O9v50N9C0cDLGznzW3/KDt2jr8zKO9dpXmGmfDbWNPl064h8TQmfTboT2UD2c8trAnkSQsipJcs4BWXPEgUbVAXGc+n0AUbXSrK11W+1KGHbe3ojWeUuzFlQEIACcKBluBgZJPUk1eoooAKKKKACiiigAooooAKKKKACiiigAooooAK8C8MD/hFP2g7/T1+S11BpFUfw4kUSqB9GG2vfa8F+Oo/sX4i+GNeTKj5CxHcxSBj+jgVxY33YxqfytH03DD9tWq4N7VYSXzSun8tT3qiiiu0+ZCiiigDwjSf+Tmbz/gf/pOK93rwjwh8/7RetFPmC+fkjnHCj+fFe71x4L4Zv8AvM+k4m0q4ePalD9TxjV/C3jb/hGLSW1vNWk1NtUuWvbf+0XZmtPOnMKx7bmFRgNGTiRGxhSSFCVSvPCnj37M9xZzXjXraXY2s08rpHcTCO7uXkiGy5yGEckfzeeNwz84JONnwd8QtRmW4n1PTPEGoXuoXd59i02COz2w29tM8bMhEik4zGreYxJf7gI5ML/EW5uNftbu01Er4en1Oz27oV4tZNNmuGB+Xd95Fb1GMdOK7D5sw9d0H4jyeFbez0+PWpLxY7p4rg3xhmhkZgY42C6htZR2kd5yOhTrnXv9G8fyaxqkmmjUlmuLKUR3d5e7IbeYwAKIo47lkYF+heBSuS244ArqoPiZpxgjmvdJ1jT0kW2mj+0xxfPBPKsSzfLI2FDMu4HDAHO2mat8TNHECf2PPJcljCzTpbeYiK91FAAys8bZbzcqRxtBf5hhWAOL0nQPHMMEA1OPxNdaZ9qVrjT4dQW2uSPKYBknN/K5TftLL5qeoUjIrqtN0HxBYfA+DRrOKe18QxWgjSOO5AdH35wJQ2M477qtQ/FPSD5st5p+q2Ngi3rJezxxmKX7IzCYKEkZ+NrEZUZxxzxW14V8Wx+INS1CwbSdT0u6s4YLh474QgtHN5mwjy5Hx/qmyGwRxxQBzGm+HvE1t4qtdUe51VlfXbs3EcmpM8A09opfKxCXKD5/Lxhd4z2HRnjzwlruoeKNX1jw7LdW96dDFvZzrfOkf2jzHypjDgH5DwSMBiDkEZG0fiDbHT9R1KLRtTfSLJpE/tCSa0ggmaOTy2CGWdCAGDcsFU7TgnjOba/FzSb6ys59L0rVtQe5F4fKtTbMYxalBKS/nCMj94pBVmBHTtkA5jTdA8bRWcA1FPEt3pv27zLjTob9ba62eSVBjnN9K5TeASpmTk8DHFS22g+OR4yFy82vQaWJA0AS4WfZb+QFEMm+9CGQHOX8mQlxu8xgc11kvxQ0pZEaLTdWnsfLsppb2OOPyoUuyBCWBkDnJIyFUkVhJ8SryLWFumtb/UdJj0+/nuIrO2hiaP7PeNEZSHlyQFQjCuS3UIM7VANv4S6fr+nW+pReIbfUEXdGIJ9QvGmmmwDuLJ9pnRO33GUEk/IoArv6891H4p6LFrsOiRCUXV5Hm0uFntnViYTKpMQlMyjAxlowM/UZx9C+KaWPhLTr7xCZ7y4aw0x5WiihgHm3Fu0jO0ryrGFJRuojAOANxIoA9aorz7U/ijZWDuG0HXJ0ijtXnkt/s0iRG5YLCpIm+YliBlNw75xzXT+FfEEXiKzupY7O7sprW5e0uLa7CeZHIuCQSjMpGGByGPWgDaooooAKKKKACuS+KviL/hGPAmqagj7bkx+Rb46+Y/AI+nLf8BrraxPE3hfSvE/2NNbga6t7WQypAzkRs+MAsB1wM8Hjk9a6cHKlCvCddXindpdbdPnsRUUnBqG581/s6+Kf7D8Z/wBmXMgWy1UCHk8LMM7D+OSv/Ah6V9X18x/Azw3pGseJvE2naxZxzPbFXgdWKPCySMMowwRzt6egr6cAwAMk+9e/xbKlLHXgrSsr9norP7tH6HHlykqWuxzXgNVtbHUtOXgWOo3EYHorv5yj/vmVa6WuZ0lVs/HevQb/APj9gt71V9wGiYj8I4/zrpq+XO8K4f4sXgtNP8OgnHn+INOh+uZ1P9K7ivN/jOd1vofU/ZLiXVMD/p3hZ6APSKKRGDorKcqwyD6iloAK5rw263nibxPeryEnisFPqIowx/8AHpnH4GulrC8F2txa6ErX0H2e8uZ5rqaPglWklZsHHoCB+FAG7RRRQAV4P8B/3vxC8WTucyHfz65lJP8AKveK8H/Z9HleMvFUKf6sevXiRgP51x4j+NS9X+R9JlH/ACLcc/7sP/Sj3iiiiuw+bCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8X/AGm7YNoWi3WBujuXjB/3lz/7JXtFeUftJoX8B2hHRNRjY/Ty5B/WuXGq9CR7vDM3DNaDXe33po9H8O3Bu/D+mXJ5M1rFJ+aA/wBa0K5/4euJPAfh1l6DT7dfxEag/wAq6Ct6bvFM8nFQ5K84ro3+YUUUVZgeEfC//Svjv4rmH3U+14I5B/fqo5+nNe714N+z6ft3jPxVqOQdw6/78hbtx/DXvNceB1pX7tn0nFXu49U/5YwX4I5e88BeHbuxt7SSymjit5LiWJoLyaGRTO5eYeYjhtrsxJXO3pxwMSR+B/DkbwsmlxKIZIpY0DvsVo4GgT5c4wImZcYwc5IzzXmd/oHxAex1eOyGtx6s9pfrLdvrCmC6kdv9G+zR+Z+5IGOdsWACDuzmu1+JMU2gfCzXm0y91IXKRGRbg3btPvZxkq5Py9TgDCjoABxXYfNl62+Hfhi302/sF0+WS1vbYWcyz3k8xEAztiRncmNBk4VCoHarLeBvDbSXsn9lxK959k88o7rv+zMrQdDxtKr064AORXC6Z4b8VXWs2iyN4g07w4+pu72txrJkuorf7E6HfKsrsVaYrhVdiv3ht6jJj8OfEqLUtcMOoaik7R3q2sxlD28oYN5ABe7by2X5MMLdTkHcW5YgHokfh7wvdyXWiWttE9xpyTs0Mvmukf23e0m4EgOHJfIzx0G3is7wD4Ws/BF/rU1/rtvcX1zbQPKhklVbe2hDhWxPNK4XLP8AMX2jGABiuMbw54qto9bm0jQNchS/mslAvdbaa7VI45fMfel4hb5ig2GdRhs4421FpHhHxjClvfaraa5ca2+h3FitzDq+wwXCyzGEyj7R8wKNHjmTDcnn5qAPSn8AeGL5J5VguWt7uQXeyDUrhIRIXEgmjRZAkb7gG3oAck88nNnTfAvh7TmV7Wyl8xRcjzJbuaV2+0bPOLM7ksW8tMkknjjGTnirLRvGieJLSS5GrPILy1f7YNTH2OOzWJBNC8HmfPKWEnzbDksDvGMVe+GPh7xNot3osmt3GqTLLom3Uxe6k10BfCRMYDOwB2+Zynynvk4oA6pPBPh5LGWyXT8W0kdrE6edJytsQYBndn5SB9e+ap3nw38L3caRy2NysarOhSK/uIldJpTLKjhZAHVnYkq2RzjGOK6+igDk2+HnhltTF/8AYJVlFx9rEaXk6wLNsMfmCEP5YbYSMhali8C6DBaLbWcN9ZxLFbwA2epXNu/lwIUiUukgYgKxHJ56nJANdPRQBzNv4E8N21g9lBpix2ri1DRrLIAfszh4f4v4WAPv3zWzpul2emteNZQ+Uby4a6n+YtvkYAFuTxwo4HHFXaKACiiigAooooAKKKKAPnr4YH+yP2hfE9i3yrcm6CKT6yLIv/joNfQtfPHjE/8ACN/tK6RqBwkd+YST0GHUwHP5E19D19BxB+8lQxC+3Tj960Zx4PRTh2bOY17ZY+MPDuoN8q3Hnaa7f76iRM/8Chx/wKunrJ8T6S2s6S1tFMILlJY54JiM+XJG4dT9Mrg+xNa1fPnYFcj4z05tT1S2h8t2jOmX6FgDgM6xKAT6kFvyNddRQBl+FXeTwxo7yhhI1nCWDDBzsGc1qUUUAFFFFABRRRQAV4P8Kz/Z3xw8U2TggS/aQmep/fKw/wDHc17xXgmtn/hHf2jrK5I2w37R4z0IkQxZ/wC+wTXFi/ddOfZ/mfS8PfvaeKw3WVNtesdT3uiiiu0+aCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8l/aVcDwPYJnDNqKHHqBHJ/iK9arxL9p2626ZoVpnmSaWXH+6qj/wBnrlxrtQke9wvBzzWgl3v9ybPT/ASeX4H8OoV2kadb5GMc+Wua3qp6PbfYtIsbXGPIgSLH+6oH9KuV0QVopHj4maqVpzXVt/iFUdeu/sGh6jeE4+z28kufTapP9KvVxvxgvvsHw31yQHDSQiAY772CH9GNKrLlg5dkaYKj7fE06P8ANJL72cN+zFa7NH1y7xxLPHFn/cUn/wBnr2uvN/2f7H7J8OLaUjBu55Z/12f+yV6RWODjy0IryPR4kre2zSvL+9b7tP0Ciiiuk8QKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8I/ak0t1s9B123yslvM1u7r1G750P4FW/OvZPDOqx654d03VISNt3bpNgfwkjkfgcj8KyfihoB8S+BNX05F3TtCZYB38xPmUD6kY/GuD/AGZPEAvvCV1o0z5n02YsgP8AzykyR+Tb/wAxX0U19byeMl8VGVv+3Zf8HQ4l+7xLXSS/FHstFFFfOnaFFFFABRRRQAUUUUAFFFFABXiH7SWnyQNoWv23yyQSG3ZwOh++n6h69vrmPiXoR8R+CdUsI13XBj82AY58xPmUD64x+Nc+Kp+0pSitz18hxiwWPpVpfDez9Ho/zubGg6lHrGi2Oowf6u6gSYD03AHH4dKv15L+zpr32/wrcaRM+Z9Ol+QE8+U+SPybcPyr1qroVPa01PuYZrgngcZUw7+y9PTdfgFFFFannhRRRQAUUUUAFFFFABRRRQAUUUUAFc14j1zVbPX9M0jQ9Msb65vLW5u2a8vntkjSF4VIBWKQsSZx2H3TXS1yupf8lT8Pf9gXU/8A0fYUAZFj401m/wBVl0yxh8D3OpRZ8y0h8Uu8yY65QWmRjvxVweMr628MeMtR1XSbaG98N+b5ltbXrTRz7LSO5GJGiQjIlC/cOCO9eZ6ZNqHir4xaRc6l4e1Xw34d8OzSppkA0a4Bu5ZMqZHkSPy44z1OWA+uSR1nib/kTvjb/wBvH/pntaAOPH7RGoE8eD7X/wAHDf8AyPXSeE/i9qurePNM8M6x4QOkTXjOpaS+dni2wvKCY2hTghMdR1zXk/w+0Gz1Lw/4hvzYf2tqliIfs1hucAqz4aQhCGbA7A8d67rVf+TrtG/66N/6b5a6JwirpHVUpwV0v62Pf6KKK5zlCiiigAooooAKKKKACiiigArwX4yE618WvDOip8yp5IfnoXky3/joBr3qvAvBx/4Sj9oDVNUHz29iZWU9iEAhT887vwrixvvKNPu0fTcM/uqlfGP/AJdwk/m9F9+p77RRRXafMhXj/wC0rqIg8K6dp4OHurreR6qinP6utewV4F8UT/wlXxn0TQE+eC28uOVevU+ZIf8AvjH5VyY6VqTit3ofRcL0lLMI1Z/DTTm/RL/Ox7D4H07+yfB+jWJGHhtYw4/2yMt+pNblFFdUYqKSXQ8GtVlWqSqS3bb+8KKKKZmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfNmoN/wqv46C6P7vRNUJZsDCrFIfm/74cZx6AetfSded/HDwb/wlvg+R7SPdqmn5ntsDlxj50/EDj3Ar2sjxdOjXdGv/AA6i5ZfPZ/JnLi6blDmhvHVHoYIYAg5B70teU/s/eNB4i8MDSb2TOqaWojO48yQ9Eb6j7p+gJ616tXn43B1MFXlh6m8X9/Z/M2pVFVgpx6hRRRXKaBRRRQAUUUUAFFFFABRRRQB883zf8Kz+NX2kjy9G1IlmxwqxyH5v++HGcegHrX0KCCMjkGvP/jX4TPibwk8trHu1HT8zwgDl1x86D6gZ+qiqvwK8WjxB4WXT7qTOo6aoibJ5eL+Bvy4P0z3rho/uKzpPZ6r9UfVZkv7Ty6nmEdZ07Qn/AO2y+ez8/Q9LoooruPlQooooAKKKKACiiigAooooAKKKKACuf8Q+G21fVbDUrbWdS0m9s4ZrdZLJYG3xytEzBhNFIOsKEEAHr610FcH4qnk0X4jaNrs9jqN1po0q8sXews5Lpo5Wlt5EDJGrMARGwzjGRzigDS/4RfV/+h78Sf8AfjTv/kWiHwVb/wDCPeJNKvtU1K//ALf8z7ZdT+Ss3z26QfL5caoMJGuPlPPJzXmVjF480fw40WmtqtiNP0SG+gsYrGKYT3UlzOXhcmNmJEfl5RGBGQeM829X134iR+K9bit1uIbeFrsWsAspZYpIlhcwsjLaFfMLBT81xgnK7MkUAS/8M8+Hv+g/4l/7+Wv/AMYrQ8DfCHw3oniOz1/Sde1bUZtOmmRUknt3iEmx4XVtkSnK7mBGRgjnpiqLP8QbU3so1rWrr7Jb6ZcxRPplvtuZJpSLmI7YQdqKucKQy7sljWZpVx4u0m+1uDRBrmW1DW7iW1m0rbbxoWnkt5YZWizI7SGPCh3BDfdHWqc5PdlOcno2e8UV5Nr2o+MtGj0KKHVJry88RQiyRZraFDp94wV/NVAgJjSMTsVfdyijnNR3eseNIvEV1DA+syTJd3EYtTpamzFmsLGKdZxGN0pYJ8oc8sRsAGakk9dorxe41bx1pWmEXMviDUXutLsbkzQ2ESSWlzJIwmQbLaT5VAXcvlSOAePbJ8PT+MrvxFomt60NdivY7TUbCErpuUncXUTQJPm3UxxyKozIVi4jBBTLZAPfqhtbu3uxKbW4inEUjRSGNw2x1OGU46EHqOorwzRfEXxGk0ueTUJNSUE2ouSulSyXVpukxM8CGziRwAQNo88jGcsK7L4dx6tZeBvEc1tDfT6k99f3Fn/adv8AZ5bkkkxs6bU27jj+FevQUAej0V4To3iD4hSaXI+oT6msJntFuZU0qWS8tEYv5zRI1lEkgyEGFWYryctxVOTxr4qbwxcX76vr0Wn26aqYNQg0iOSWaWG4ZIUuB5BWFdi5JKJzuyy4xQB9BUV5X4Q1vxNdeN7WHUZtVu9NngEmUsTBbQ/uVPzs9sN5LZwY5zkkfIADXqlAGH431keH/CWq6nuCvBAxjz/z0PCD/voivOf2bNHNv4e1HV5VO+9mEaE90TPI+rMR/wABqt+0drMjwaT4bssvcXUgnkRTyRnai/ixP/fIr1Twlo6eH/DWm6XHg/ZoVRiP4n6sfxYk/jXEv3uJ8oL8WfTy/wBhyRL7WIlf/t2P/BNeiiiu0+YIL66hsbK4u7pwkEEbSyMeyqMk/kK8M+BdtL4i8c694svE6Mwjzzh5DnA/3VGPo1QfE34oJrHhrUNCs42jvnv5LaTZnDW6P8rA+rfKCPZuxFerfDDw3/wi3gyxsJFC3bjz7n/ro3UfgML/AMBrg51iK8eXaOvzPrvq9TJsrqusrVKz5Uv7q1b9Ht9x1dFFFd58iFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB84/FHQ774a+Orbxn4bjxp9xLmaIcIjn78Z9FcZI9DnpgV7v4T8QWPijQbXVdLk3wTLyp+9G3dGHYg/49CKta1pdnrWl3OnalCs9pcIUkRu49R6EdQexr5xtJ9X+B3jc29z5t34ZvmyCP40z94dhIvcd/xBH1FO2eYZUm/wDaKa0/vxXT1X9dbcEr4SfN9iX4P/I+m6Kp6TqVnq+m29/ptwlxaTrvjkQ8Ef0PYjtVyvmJRcW4yVmjuTvqgooopDCiiigAooooAKKKKACvnnx1p118MPiFbeJdGjP9lXjnfEvC5PMkR9AfvL9P9mvoasrxPodl4k0S50vUU3QTrjcPvI3Zl9wea58TR9rH3dJLVHr5LmSwFd+1XNTmuWa7p/quhY0bU7XWdLttQ0+US2twgdGH8j6EdCPWrtcv8O/CMXg3QBp0d3Ldu0hlkd+F3EAfKv8ACOK6itabk4pzVmcGLjRhWnHDy5oX0e10FFFFWc4UUUUAFFFFABRRRQAUUUUAFYuseJ9J0fU7bTr64lW+uY2mihit5JWdFZVZvkU8AuufQZJ4BI2qyLzw/Z3fiGLWJzK08djNp/lZHltFK8bNkYznMSgc4wTx6AHK638StNOiSXPhyb7RdLPZhVurSaJJYZrqKFpIywXzFw5wyErnHUcHbtvHWgXV5Pa21zczSxJM6+XYzss4iOJBCwTExU8ERlj7Vzmj/Bzw7pNpNa2ks6wu0BXbbWkciCGeOZV81IFkcbolB3sxI755qvH8JfCcF/qNpbXj209/BM32eKKzWeOORvmdJfJ88qCcfM7Lzg5HFAHSL8RPDbRkrc3zTC4NqbQaZdG5EgQSFfI8vzPuENnbjHOanfx14ej1MWE17LFPuRGaS0mSKJ2TesckpTYj7SDsZg3I4rkX+EnhvTtKuNNfVp7WHU7xJCrW2nqJJhHsVY4zb7FbClvkUNnJzV0fB3wyNZGoBZGYrGJI5re2nMhSMRhjLJE0ykhRkpIvPIwSTQBb8P8Ai3T/ABT47EOn2yT2drpgu7a9uLCWGXdJIVbynkUbo2VV5QEH1NdCvirRWlEa3nznUTpQHlP/AMfQUuY+n90E7vu+9Z/hPwTB4c1EXi6tquoypZR6fEL1oiIoEJKqNka5IyeWyT3Jqu3w9sD4iXVF1PVEjXUv7WFirxfZ/tJj8sv/AKvfyO2/GemMmgAsfid4SvbKS7h1OVbdLZbsPNZXEXmxFwgaMOgMnzsq4TJ3MB1IFPk+JHhiOKJzd3hkkllhFuum3LTh41VnVoRH5ikK6tyo4Oelc54W+EkVt4V06y8R6rfXmpWunxWUcsMkapZbJI5QYCIlJxJFGwMgYnaAeMg9JpXgKwsNVTU5dQ1K91LzJ5Zbm5ePdM0sccZLBUVRtSJAoUKBjvQBrXXibR7Xw3Dr0t6p0mZI5Ip0Rn80SYCBFUFmLFgAoBJJxiuX0X4l6dLBqM2rG4hVNRntrSGLTbk3DxRJGzO8IQyDG/klQBlemedl/BOnnwVpnhpLm9ittNW3FrdI6+fE8BUxyAldpYFRnK4PPGK57Ufg/oWpRI2oXl9eXq3U12by6htJ3ZpVQODHJA0WD5aEfJkdiAcUAa+u+JfCOpQ2ena3Ab+w1LymtzPpU09pcFxvjAkMZiLHggZznA61wMXi7wnrFn4La+8IWiaS8V3stpdBmuGtCgRgLZRFyp6syKR8vJGK6hvg/oLeIdP1c3V759lJayxRiG1Cq1uqhApEO6NDsGUjZUyThRWvofgCy0iXTmTUtTuYtOFwlpDOYtsKTAbkBWMMQMcFiT6k0AdRpl9a6pp1rf6fMs9ndRLNDKnR0YZBH1Brmvib4pm8H6FbanDCs6/bI4pYzxuQhs4PY8cVueGtHt/D3h7TdHsnle1sLeO2iaUguVRQoLEADOB2Arzv9pDefA1jHECTJqUa7QMlv3cnH5gVhiZuFKUo7nqZJh6eJx9KjVV4t6+hw/g3UrTxh8X7nxHq9zBaWFofOgW5lVOnyxLyeo+8cdx719GghgCCCDyCK8X+EnwnXT/J1nxRCGvPvwWTjIh9Gf1b27d+entNY4GE4wbqLVu56XFOJw1bFRp4WV404qK7K3bv5sKr6ldLY6ddXb/cgiaU/RQT/SrFV7+0h1CxuLO6Tfb3EbRSLkjcrDBGRz0NdjvbQ+bhy8y59up8j+BfBOteM9RL2KmG2V90t7ICEQ5ycf3m9h+nWvqnwtog0DSks/t19fOOXnu5mkZj7ZPyj2H/ANetCytLextYrWzhjgt4l2xxxqFVR6ACp65cLhI4dX3Z9BnvEVbN5ctuWmtl/m/6X5hRRRXWfOhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFY/irw7p3ijRZ9M1eAS28nII4aNuzKexH/1ulbFFXTqSpyU4OzWzFKKkrM+ZIZfE3wO8RGOZW1Hw1dPwRkJJ7r/AHJAO3Q+/BH0D4U8TaV4q0pL/RbpZ4Tw69Hjb+6y9j/kZq9q2m2Wr6fNY6nbRXVpMNrxSLkH/A+/avAPE3w38SfDzVX1/wCH11cXFmvMluvzSovdWXpIn6j04zX0vtcNnaSrNU8R/N9mfr2fn/wEcPLPC/DrDt1R9F0V5J8PvjVpGveXZ+IAmk6n93c5/cSH2Y/dPs35mvWlYOoZSCpGQQc5rwsZgcRgp+zxEbP8H6PqddKtCquaDuLRRRXIaBRRRQAUUVm6/rVloVj9q1CRgCdkcUal5Jn7IiDlmPoKANKkYhQSxAA6k14z4h8a+KpoxcXeoaH4H0iQExvfsLm+cfNgiPIRT8v3ct1rk9O0/R/Ekoff408fzSn/AI+JGkgslOBkctHGBktxz0oA99ufEuhWrFbrWtMhYdRJdRqf1NU28c+E0co3ibRAw7G+i/8Aiq8Vk06x0qeW2Pgn4daZAHAB1TVIWkjO4nBHlsc8gYz2rQgsormQz6XovwrkhjZSzQ3q4ByMg4h45HSgD1hvHnhFR83ijQx/2/xf/FUQ+O/CMzqkXijQ2dugF/Fk/wDj1eXLp8Nrthm0b4cf2gPniSO9jVifl5+aLJ6H86k/4RrU7uJpG8GeC9ViYfvIbO5Qyff3HBaMLntyR0oA9rtbq3u4vMtZ4p4/70bhh+Yqavmy50bwrpF55sUGv/DrWCVH2lN0Vu5+YAFgWgYEhRgleprvPD3jnWPDuq2ejfEBre6tLxlj0/xFaR7ILhiTtSZekbsBkEHac/jQB6vRRRQAUUUUAFFFFABXlvxp1zxVpawx+EINZ+0C0mmWS0tvPhkkGNsbKLWZt3oC0SkE/PnGPUqwfEni7RfDc0UWrXMqSyRPPshtZbgpEmA0jiNW2IMjLNge9AHCQX/juTUJdQ83UPLGsw2iaY9jGsDWzWsbNIW8vzMCVmG/dgFSDnoIfhk+t6h44tdS11tdluToZjuzf6Z9khtrgzIzQxERrvUc4O58gfePNdT4P8XXHiXxh4itYGjXSdMlFtEPsM4aZ/LjcyfaCRHt+cgIAWIw+dpGavg74k6bqVnMmt3CWV/FLf7s200UBitp5FLLKw2MRGqswDEjJOAOAAcz4km8Saj43tYpk1lzZa8klrZJp2LD7MsDbZmuBGSWLNgjzBjJ+XjNZei+IfiXLpV5Jf8A29JgkH2hBpsjz2pM6iZrdTaRxybYy+EDznKggsOvpSfEjww9uZReXm7zI4ltzptyLh2kVmTZCY/MYMqOQVUjCnng1JoXje11fxbqGhRWWoRNbQwTpNLZToriRC+H3RgRkAAYY5JyMZUigDhfEWt+K4E/4kd/4quYhYeZp8kmgrvvbzzXDRXQNunkxhRHg7Y8hmbcSKuKPHV74htlfWtZsrK71q8tJEi0+3KW1okbvFIrPCT8zIqh2JU7hxnk+tUUAeBXfivxyz29kt5rEeupoNrdRWUGkK63F21xOjfaCYj5KMsaZ+aMdSpHIrduNa8ajXr2KObVopRcX6PA+jGSxtrZYpDbTRypHvmcsISUDsTucbVwK9ZW0tlvXvFt4RdvGsLThB5jIpJVS3UqCzEDoCx9anoA8FuG8W+IdBFrdW+s3FwV1CA3d1YRhjmyOzyi9rC8as52fMgJJIDMMVZtrrxNZ2NtLpC65MqaVZwzXtzoipeQD7TiZY1MCFykeSqFWB+9hiefcaKAPHIb3xzqM1tBb6jrtrp4XUnjvX0uGO4uFjFv9n81HhwjMzTADYhZVzgHp6f4Uub288L6PdatE0Ooz2cMlzGyFCkrIC4KnlcMTx2rUqveXtrYx+Ze3MFvH/elkCD8zQBYqtdWVtdTW0tzBHLJbP5kLMM7GwRke+Ca5TUvij4L0+VYpfENnNMzBBHak3DEk4AxGDVO6+LXhiB9oGrSng/u9MnIwTgHO3HWhq44ycXdM9Aorz8fFzwsu4TSajAy7siTT5h93738Pbv6U5fi74M3hZ9TktSRu/0m1liGPX5lHFAjvqK53TfG/hfUmC2HiHSp2PRVuUz+Wa6FWDKGUgqeQQetAC0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5/4++FPh/xeZLlojp+qN/y926j5j/tr0b68H3rysad8S/hS7HT2OraGnO1QZogPdPvx+5GB7mvpSivawmeV6EPYVUqlP8Allr9z3Ry1MJCb54+7Lujx3wp8edA1HbDr9vNpNx0L4MsRP1A3D8Rj3r1PSNZ03Wbfz9Jv7W8ix96CUPj646fjWH4o+HvhfxMzyappMBuW/5eIf3UmfUsuM/jmvMNV/Z/NvcfaPC/iGa2kU5RblfmH/bRMf8AoNdDp5Pi9YSlRl2a5o/JrX7yL4mnulJfcz3qisvwvYXOmeHNMsb+4a6vLe3SOaZnL73CjccnkjOevatSvn5xUZNJ3S6nYndXZV1S/ttL026v7+VYbS2jaWWRuiqoyTXhsd3q3inxndXkLNZayloHaaVBInh+xkDHaFzhrqVQGP8AdHsuD1Hxv8TR6ZdeFtGazvNQj1C+E91aWUJmme3hwxAQckFin5Gj4Yi6uPBFvrtqI0m1aSe/uXdijPI7sAW6gBVVQBnjFSM5XxNeeGfh74ag1uw0/wDtbxFczSpaTX5864uNh/1ryNysaqMkAKOQOOtY/wDwrz4geKvEiat4j8TmTQ40iuGTz3ht5lIDlUiQjao6ZJBPWp/FM0XiT496NpczE2Ey26sjrkS28YklKjA+60qjJzzt9BXafEuzm8X/ABE0DwUbiSHQo7OTVdUhibb9pjVwkcRI/hLdR6fhQB5r4p0z4U3EEMMmo+fq1l+6UeH7LzSMfeLkLiQkk/Mx9PxSa/8AhPb2sEWuaHqNrp6IkSSzaB5AZwOSZANxJwepr2fV4tG0fwjPdwrDomkaaQ0yW9use9FAIQrjOSxUADkkivD/AO2Y/EkNz47+KLSNpV3I1roGgRAvI5DYYonAJ427+eWJGMLQA6+8S/Cp/Ec+sWejXLWohQS2w0FPLjjU53qeAu7P3iD+Faeh6p8OvE2vG18PzQaVcLAEs4oreSwunlAYhklUhTkseOMjAx69PC3xH12wvJtK8JeHPC9pPEIMavI8sskKgjayKCBwT94Dj14rhNd8C3x8QRWnjuxsGbVi0sGp6Wx2S3CQHyrfLYMQ+XK9icgH0AOx0bxTqGm6zonhv4o3cE8V0ga21CMK0FyQQpiuVI4YE7d3AJPIzVzxbolj4WvZdNuFMngPW38i4tJGyumyMQoljz0iLFRtGNrAEYBrh9ClvPEvww8VxT/Z9V8Q6GBpH22MfNJYuVYggjnowyADgde9b/hnVotZ+FWvW+sKt3qaw3Oki5Gd08cUW6OVj0PAj59eRQB6L8GNZvZtL1Lw3rc5n1fw9cC0eZjlp4CN0Mp9SV4J9VNei14p8O477RPiXY3Gq6uNXfxfoqXKzeSsXlPbhSEAXgrtl4PXiva6ACiiigAooooAK5jxV4Nt/EF4Lsalqem3DWsljM9i8YM0DkEo29GxyOGXawycGunooAxfDHhux8NrqCaaZRHe3AuWSRgQhEMcQVePu7Yl65Oc81jSfDjRJtNt7C5e8mtIvt/yPIvzi8ZzKGIUHjzG24wRxnNdnRQBwNz8MbO7tbqO/wBa1W+nuRDHJcXsNncMYoQ+yLZJbmPaDI7Z2biTy3WtPw14JtfDmox3WnanqhQWkNnLBNJHIk4iVgjuSm8MAx+6yj2rq6KACiiigAooooAKpa1qtjommXGo6tdRWtlAu6SWQ4Cj+p9u9WLu4htLWa5uZFighQySSMcBVAySfbFeQeJvFuiaho1r4x14LP4WhedbS3bqzhf3cu09XYhgoPQMD3yADUu9f8T+I7uGO0ZfDGjSSIHmmjEl60Tq5V9p+SLOw9dxGR9K8j1LX/hTpEkf9pG58Vaz9nmWQzs98xlYjYCWPl8AHoOKsaN4Y8Z/F+xhv/E+onw94QkWKKG0T/W3UaZ2k56nk/MeDnIFdtYRfD34c6VKdL06xlkR1ia4lKTXEzH7pUDJ6gjHy8igDh9J+Jest5a+FPhlfFSbXOI/JDtFz/CnckVNcan8brqxcaf4QtbOObykwwBkCoxYZ3v6nnivUH+JcrGRBptxDDEhilneMgrMV+TCDPBJHc1yuo/EvW7XUdMihsVndF3Szz3XlpMOflAUhSex4JGR1oA52Wf44y+aLnw1prFxMPlA580AOc+ZjOBx+NTXus/Gabet54F06eN4Y7dlUH5kV93I8wjnkGqmj/GPUrXStV+1215cmSbzLWZOQgxgwtye3IzitjVvjCtvYadG1vf2A8xWZLkGDKrk4Hl5YjIAbjBzQBy9742uNIus+PPhFFDEbkzyyQ2isNmzbtGVxwefvVq+BPEemX1pFL4C1yXR9TgtUefT5GZ7aWd5tgjML5I4I+aPpXb6H8aNFvpJbC1mN8yjeJ5kMcRVjwGZufl/iYgDH0pfGvwn8N+N0TVPDc0WieIogs8N9YHC5ydpO3API4YYPegDsfBXjUazdvpOsWy2GuRBz5avvhuAjFGaF/4gCOR1Heuzr5S0C81SO9i8A+P5P7J8Qacyy6PqcJCksWY7kY4BZ2IyTgFVYEZr3j4Z+LJ9f09rLWUEOvWaL9pVVKpOhJCzxg87HAyPTNAHa0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHn9+kUPx20ma52KbjQbiG2LDlnWeNmC++05+n414roumrrGpaRb3Wt6hp08GhmXSHtpMosy3kqS7ozxIPu7l6lQa9c+PGhQ6jo2i6rczXNvb6PqCT3M1rMYZUt3BjkKuvIxuUnHYGuFsvDdpqWmQ+CpLpdN1zRrh9R8M6oXDfaYSxfr/EQW2uvcYbBoA5D4heKJtK1jSrnWbN9D1uxUadez20BEV1bGXd9os24H97K9cOcdDXqI1O51240v4keD4INUaC2lsbzS45laaa0Mm5Sp7Sjbu2N1BxwazYfHc+k6gdD+Illa2VxKqxsLyMGwuWxzLHIRtAwB8h59gazP7K+E+q27XbeGktvPl2iSxuHQlzKEQRhWA5zuwAMCgDudXjufHfgu2ufA17aSFdRhuni1B3Xds+/BMACyMGwcc8qO1X/DvhKHR9Wi1nxE1vfeIpgLe3EYxBYxZG2K3U9AB1Y/Mx9M4rjrj4Q+C4Gur/AEXxB4i0W4jZxcXFrqDhlKNtJbcCxAPANdNN4L1CC2aUfE7xFHDCMM0jW7BccHcTH1+tAGvq6asumzJbW89zJ5/XKxMcgDJBIBGfTGePx5b47X+n23hrSLLWL+O0uZ7mGZVLAFEgHmyOAe+FKjB5LADmpT4RluxIj/FfxC6mT7O4jnt0+cjO3ITg4PaspPhr8MtOmOua3c3OsvGrusuo3zXIk2Y3HaPvYJxg557UAcp8H9Ik8P8AwP8AE2t6sy2EWuEtF5w+7AF2KcnoWy2M+3rWp4IMei/AXxpd27hljE9tEzkAsVt44fz3giqnxA8ef8LCNn4W8IaVNdKwjmW3KAKcHK+aQcRxrgEg8nAGOanfw9aWFrH4WTWY30PRVW78Q3xRdnmqxl8kY6kyEuwP3VCjjpQBv+BNSm8R/E7RraXSrnTk8LaHsJulVHmecRqCqqThcRtjnn0Fe2V518G9EnistT8VatB5Or+JJlu2hIwbe3AxBF9QvJ929q9FoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPEv2oPFcuneGrTw1YQfaLvW5FjkQSbD5O4AjPbcSFz6Zrk4rVfiJ8TbfSdT0Sbw94f8O2cd9qOnSTK6ySqu2MZXI2hOMjkgGtT4zwNP8AGnwyHUOFji2ITt3jdJkAnjPNO0DTbx/EPxlszeFr26sopkmt87lDxyFUGT1x6evY8UAUviT8S43nMWgP9oNuhDFUEcVugBGEJGSSCOx4PbFeXaZqX21HkutNKRtiO2jtHGHGGDFnc/MSQvAI5ApvxC0C40+3srazsdkDQo2HfO5jktlD8wHHfk81B4PTT3lWXWLpLdAhdostHHNIvKZ2jAYFR1KqMcgk0AdR4b8Qa0bKW10v7NCwRvIluZtsiAOp3EEkHCkbuMbeea5rXLW5jubWxt9LlHnOJUaAsHkbrvbGVOTkrwpOelaGmSzanY3F095ZBolXeLaMQzLMp+RMAfdbZgMMfeyav6rcS2Wo313HDe2sD7VukTkyqeDiRSUI55wT+lAHC2H9paTJfNJFqUcilZPJdjEjqWx5hzxxkfTJp3iS8vBCkr39wEeV3WOeFpPs3CD7/IK5OM9DgH2r1a707RtM0m8ki1GW5sbeVftSKv72U5ICsy9trMDzg88cGrmo6FZs2nGG6fULJbdIWtHlzEsWMoGcZGcEZGAnTgEGgDxrTvF2pQ2F9GIoiT96TywH3EDJGBwSB6gYzmvWPhX4sEd3DqN9qRe5h/eTMz7yYlDb8/w5+U4OCcMcdK8l8aaTb2k58lYU25ClJhvjy33X2HGce3+FXvhGLe38QWl3foJbOKTdLuTeXByp+Xpg4I9aAPcf2jrTT/Fnwv0bXTEwu4r+OFJ41DSbWYoyrg8gkAjnqB0zVK0Hijwx4j8J+MvE2pNLeXxg0e5tRbrGFifLAEA5LD7xPvW58X1j8H/BTSFhi2JDqMDoEUER5ZmGc9vr61yut+I9L8fa54L07SdQa4u49SjcIEKjywfnbZngYUkZzhdvPNAH1DRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8peGvHvj7WYNLH/CXXqz3iRn5bC1YBmA6KtuzHr0AJ+tadl438bWvi3SrK88UXdzE2r2tnPFJZWyLIj3KRuD+4V1yGPoR7GuP+Gt/FpR8M39wrtDbLbyuEALEAKTjJHNatxeR6j8QdOvYA6xXPiKzmQOMEBr2MjOO/NB8bRx9d14xdR/Ha3lc+sbmCK6t5be5jSWCVSkkbjKspGCCO4IrwHXvD1j4LH9h+K/tP/CINP52ia1HIwk0mXPyRPIOUwT8r/dI4NfQVR3MEN1byQXMUc0MilXjkUMrA9QQeCKD7I8gkfxRFp5g1zTNK8daM2FWaKSOGedCpxuifMchwQcqy5PauGvNB+HyRLd3Phnxp4Qmj2y+bDBN5aEnqNhdR+Q7V6s/wyGlszeC9dvdCTeZFsyi3NojHqViflforAe1Z8vhn4loxVdb8K3cZVUYzWM0TOFxjO1zj7o6UAeatF4dMUQtfiR4sMKghFl0mSXaCQe0Q4zz6dKv+dp39j39vqHxJnnhupFeeSTw7IrOQQ2C2B17/wBK9ANl8TLZY44LPwjOgULkXNygUDbjgqc/dHOaljs/iUcq9p4RVdmz5ri5bjbj+6M0AeYWcnha3QR2vxHn3JdSXaldDZ1M0gKkkbM8AAAZGMU2PQ9Mvw0ATxt4ihWIWixWFgNMgmAY8SSOVJDEc8j6V6dD4f8AiZIS0/iLw3BkklY9Okk6knq0g/vHtSH4e+Lb4t/avxEv0RmVjHpthDbYxyMN8zfrQBxZsm0DQWj1K70z4f8AhmYqFtNHJl1C43DGGnIJL4I+4pPPXvXSeF/Ccnii3s4b/Rm0XwZask0OmzLtuL+Qch5xk4Tdltp+Zict6V1vhj4b+HdAvhqC282oasMf8TDUZTcTj6M33fwArs6AAAAYHAooooAqarqNrpVhNe38hitYRukfaW2j1IAJxXA3/wAaPCFsD5NxeXmP+eFuRn/vvbXpBAYEEAg8EGvFfib8HYrzzdT8JRpDc8tJY/dST3j7Kfbp6Y78uJlXjG9Gz/M93I6WWVqvs8wco32aaUfnpdet7d7He+AvGqeM0urix025ttPhOwT3DKC78HaFGegPJz3H4ddXzl4Y+EWq32g2WraVrjWF5KGEkEsbxNE6sVI3Kc5BB7CtQeD/AIr6ZxZ6+bpV6YvWcf8AkQCsaeJrKKc4N+lj0sbkuXTryjhcVCKTtaXMrW0ervf12PeaK8Hz8arXqPOReP8Al0bP/s1L/aXxm/58/wDyFb/41p9cXWEvuOT/AFbk/hxVF/8Ab/8AwD3eivCDqHxmbgWmCeM+Vb8frSG3+NVxxJN5QHQ77Rc/980fXO0JfcH+rbXxYqiv+3/+Ae8UV4P/AMIb8V73An8Rm37f8f7p7/wCk/4Uz4l1DjWfFKsD1+aWf/0Ij3o+s1H8NN/kP+xMFD+LjYL0Tl+R7Pf67pGnZ+36pY22OvnXCJ/M1T0XxfoOt6k9hpOpwXd0kZlZIskBQQCd2MdWHfvXmth8A9LTH2/Wr2f18iNYv57q7fwf8OdA8J3v2zS4rg3ewx+bNMWO09RgYHYdqqE8RKS5opL1MMThsno0peyrTnPpaNlfzvrY7Giiiuo8E8n/AGifB93r/hSLV9DgWXXNFkF1BGUD+cg+8mO/qB7Y715T8N/EM3w8+IEE/iXUrbUtG8V20UlxqSwkJBc43CNmPB278HnoQcDBFfV1eM/FLwlpVppNxa6rp3neGLnIScFiNGdnLPIsa/wkkncBweD8tAGh488KQzab8klrvv7olrswfaJCh8zYDuyGA8wdxjkj0rw+48PTaFrtzbRXdsPLtXt53kgJjk3RtnyiQWIHGSMkZzjGa6XQ9f8AGXwgZbCXTrjxP4LKfa7Yjm5s4Sx2lsAhc4J2nj0I5FdLp3xe+HGuvcPcarcWF9PGqINWtSywYJ6bOASGIJ3c4GaAPHzZzwac7wW1sxumja2nRAjCHLKytt4DHPHT5V5NaNxox1mO1kMmoizhjKwx3EyxlEywkfYTgg4xz2PU4r2RvDvgzW9PntdE8UWLrcXP2mVLTUFiaR8HJ+XoTnnjGOMd6i0n4Yae2p2ctzqunajHCGE04m2zSZO4EbeAQSQc53Bj0oA84udHNjot2um3N4izqgluFDeXEwLIw7htwTAzgjc2etYDW8aTw6pdR309pAn7m38/yZVVWZXZTnhDjOP9o84r3/WvCVnHoeo2NxrlrBb3t01yYDcrbICQQwDDnDbskeo/Guasfhl4Zub20a78Rabd+VGyvPDchZ5STuDAq2Ackg8HIPagDyy/0qzitom0y+1KZJLlVeRbHbGXdjhGcDHIyMkHp+NekfDH4dJPfJdGGONbZ5LW4kEbRCWPP3Qo+XcrKR75DHk4rXv/ABz8NvA1xfzXWujVLt2O+1tgswRj94AKAoyR/ETjnGOa4m68d+PPiXawaH8PPD7+G9CuW8n+0JsplQCSA+MDgHhcn3oAn+Ouu3XxG8a2Xgbwsn2my0x2vNTnU5QFRg8j+6Cw92bHavUfAWjQXXiV9QS2txp2hRNpWlyoozICQXfPtwmfUP61xfgLwo2iWp8LeEZQ2oFri31zWgvMa+YACOo8wqpCpn5Qcn39y0fTbXSNLtdP0+IQ2ltGI4kHZRQBcooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorj/FB1K88aaHpFhrd9pNtPp97dytZxQO8jxSWqoCZo5AABM/QDt6UATf8K48D/wDQm+G//BXB/wDE1LaeAfB1ndQ3Vn4T8PwXMDrJFLFp0KPG6nIZWC5BBAIIrg/D+tal4g13VNN0jWvH9wmmag+m3d55OipDFIrYZsNGHKjrwpOO2eK7PwZc6jHJ4ss9R1O41Q6ZqIggnuo4kk2Gzt5treUiKfmlfnGcUAddRXkfgz4mX1z4btNa8QM9x9rtoGisbHw7d2rNPMyKkcdxNIYpeXwMEAj5sgA1vp8TLSQm3j0HXH1RZriJ9OUW/moIFjaRy3neXtHmoPv5JOAKAO9orhNF+Jml6xrGladZ2N8JdRtIL2NppLaLbHLGJF+RpQ74BAby1cA8ZpPHnxT8PeCdVTT9XaVrjyFupAksKeXEWKhsSSKznKt8sYdsDpyMgHeUVwEvxNthqwsLXw7r948l9Np0EsK2wjnniUs6qWmBA2qzbmAGAec8ViN8VVi1ybUvseqXHhg6Da6k6xwwhrMtPcJJJLucMcBFBVS/3SQOpIB61RXGD4hWH2iT/iW6oLGLUf7LlvykQgjnMgjGf3m4qWK/MFI+YZwcgUZvirpSwT3Fvpes3VpbQPeXM8MUW2C1WR4xO2ZASjeVIyhQW2rnaBigD0GiuKs/iJp9zrq6d/ZuqRRSXs+nR30ixCCSeJGdkGJC/wB1GIYqBxjIPFcxffGa3uYzD4e0ue51GG/sbee3M9pPmKefyzteK4KB+CoDMMMykjbkgA9corz7TPixoF94ti8O7LiDUJJ2tCJJrclJ1Qs0bIspkGMFd23YWGAx4z6DQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNdFkRkdQyMMFSMginUUAcFrPgS7gu7rUPBusS6VdzoI5LScefZSqM4BjPKfeONhGPSuR8ReG7q7gW28U/D211QR2Rto7rTJI5gHwMOQ/lyDp2z+Ne10UAfKviL4f/DkpfMNF17SruOGIQRSQTwq8nO/BKsOmD1qWH4VfDOWTdZ69eww/bVj+a+ERWAoCThlB+8etfUtRvBFIcvEjH3UGgD5WuPhf8MA1kL7xFe5lkn3F71XKIpYJ0XjPB96zbT4UfDw2MV2uvX0rLaebIgnQAzblGwYXd0z0r66NvAWBMMZI7lRSiCIEERICOnyigDwPS/CHgywnlbwR4Mm1l1eFoJ3ibYCrZcGWc45wOgNdzaeEPEGtEt4j1JNN0552uP7L0sndlhja1wcNjBIIQL1616OBgcUUAU9J0yy0ewistMtora1iGFjjGB9fc+55NXKKKACiivMNG03R59B1TXfFGt6vaRrq2oxyXEniK8tII0W/mijXCzKiAAIoAA7UAen0V5V9r+GH/Q/f+Xvdf/JNaGiaf4F167e10PxXfalcohkaKz8YXkzqgIBYhbgnGSBn3FAHotFcr/wgekf8/niT/wAKPUf/AI/R/wAIHpH/AD+eJP8Awo9R/wDj9AHVUVyv/CB6R/z+eJP/AAo9R/8Aj9H/AAgekf8AP54k/wDCj1H/AOP0AdVRXK/8IHpH/P54k/8ACj1H/wCP0f8ACB6R/wA/niT/AMKPUf8A4/QB1VFcr/wgekf8/niT/wAKPUf/AI/R/wAIHpH/AD+eJP8Awo9R/wDj9AHVUVyv/CB6R/z+eJP/AAo9R/8Aj9H/AAgekf8AP54k/wDCj1H/AOP0AdVRXK/8IHpH/P54k/8ACj1H/wCP0fDIyf8ACLyRy3FzceRqepW6PczvPJ5cd9OiAu5LNhVUZJJwKAOqooooAKKKKACiiigAooooAKKKKACiiigAooooAK5XUv8Akqfh7/sC6n/6PsK6qsrXfDmh+IPI/t7RtN1PyN3lfbbVJvL3Y3bdwOM4GcdcCgDzfVvhvqeq+NNI1VNO8M6IbDVm1CbVNLLrd30e4kRSJ5aj5sjeS785IHOK7Dwns/t3x95pAj/tiPcScAD+zrPPNP8A+FceB/8AoTfDf/grg/8Aia07PQtP0TR7uz8OabZ6akgdxFZQpApkK43YUAZ4UZ9h6UAcwnw+0Cfwn9k8Ozymynt4vsbXGpXl7axorI8bxJ9oG3G1SrRspHGDjg48nwkb/hH0s4dXi/tI3VxdSX8kd0X/AHyqrqhW6WTBCLkSSSBscg1n2nhfxudJhubm61kaxa2ejLAg1Y7GlTaLwuok2OSN2S+Q3UZNb/xe0rxXqcmkf8IzNdixQTi8is5THMzkL5TAi5t8hcPx5mMkZVuwBuaT4C0bT4tEVvt1y+kQQQ2wmvpjEpijEav5G/yg2B1C5yc9aseJtA0K6n/tjV5Z7KWCIRPeQajNY/uw2QrvG6blDEkBsgEnHWuEi8M+MfN+3y3+tS38FxpIh3X/AJUbxKIheF4FlaLJHmEg7uR8hOclJ/Dvjv7Fr1sL6/ZbCB7XRpE1AiS88ybzPNkbcPmjjCxAuc8Oe+SAeiw+F9HhvLe6js9s9veTahG3muds8qMkj4zg5V2GDwM8AcVkS/DXwrKYN+nz+XDbpaCJb64WOSFHaRUkQPtkAZ2OHB61zmpeHPE7Wl9dmbW7iZ9bkZrS31UxPJppkJCQnzFRG+6cllYKGUMoOKyv+EV8aXunXIubnXbcxaXfHT4V1llljuDMTapM6SDzHCYBZiy9izdaAPQ9f8IWmo+FNb0SwZbFdWaR55SpmIeRsyOAW4Y84wcKcHHGKZqXgDw1qUdpHd6c3l21qlkkcVxLCjwIcrFIqMBIgPRXBHJ45NcT/wAIh4qv9Qa71G912N5Nbh8xINZkijFh9kQSYRJAq5m39AH7rjqcbV/DXxHax06CK81gxQx3cSm3uhLcRt9qkMMrsbyASfuPKxvaTody5JoA9YuPCOgNHm4sUMcd1Nf/ADyvtEsqOkjnnGCsjjB4GeAOKx9O+Hfg6fTllsYJ7m1ube3WG4GqXM2IY28yDyZDISiqTuUoR7cVzt14U8VXF5NcyXmrNLPrEkci/wBpukP9nvbMpIiEm1f3hBGBvU8jjmun+EOk3WheAdK0zULDULG8tYY4ZkvLwXO51jRWaIiRwsRIO1Btx/dWgDS03wfpGmakt9YjUYpt29lGp3JikbbtLvEZNjsR1ZlJJ5JJ5roaKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArxHxr/yQjXv+xkuP/T61e3V4/rOj6jr3wZ1zT9GtWvL9/EF5IkCuiFxHrUkjYLkL91WPJHSgzrJypyS7M8u8NaN/a8Orvt3fYrKS6/13l424/2G3f7vy5/vCuh+Av8AyVMf9gW6/wDR9rUOh+HPiDo0eopa+DblxfWr2kvmXdocI3Uri4HPHvXQ/Bnwf4m0fx82pa3oc+nWS6ZPbiSW4gfdI8sDAARyMekbckY4oPlsswNaliKU5Qate/3Ox3fiTxZfaB4svVu2tn0Cy0OfWJo4rZjdHyiAVVzIE5zkZUdMZ7jA8VfEW+u7e30/Q9K13T9Tlv7SCUbLMzrDMrurR75GiywiYDd05yBxnuNY8G6JrGo3V9qNvczT3VlJp0w+2TqjW7jDpsDhRnPUDOcHOQDUj+EtEfUl1BrLN2rwSCTzX4aFXWI43Y4Ej/XPOcCg+tOMs/jT4Vee5tTNdyNaxTMJd0Ej3BiIVgI45C6MxPG9EB7cVozeN9YHjHw9pR8KanbW+ow3Mkq3D2plTy2gAkBW4KhB5rbhyx42g81sDwH4fCXsX2W6NpeLIk1mb+4NsRIcttg3+WhyScqoIPIwaWLwRoscuny41N57CVpbaaXVbuSRN2zcu9pCxjPlpmMkocdOtAGFoPxP0670axmuYb2S9ubeymiRLVYjdfaWKKYkMj4wwO4FztAzkjmp/B3xT8O+LfEDaRpTyGcxySxO0sDCVUYKx2pIzp1BAkVCRyOhrZtPBHhy0m0GWDS41l0KFoNOcu7GBGXaRkn5uBwWyRzjrU+ieFdL0O7kn0tb2EOGH2c38726bm3HZAzmNOf7qjGTjqaAOa8TfEqHTr3X9K0/TbqfVdMtJbj95LbojFYfMBEbzLM6dBuVCM5GeDivdfFex0ey0V/Eml3lhPqEUT7WubLKl2C7hELgyMuSD8qtgHnkEDqL/wAG6JqOqtqGowXV3MQ4Ec99PJCm+MxsUhLmNCUZhlVB+Y+prLb4X+FHVVe0v3Xy44mDardkSpGxaNZMy/vApJ2hs7e2KAK0vxR0iGZ3uNP1WHSwbsJqbpF5Ev2ZXaXaBJ5hA2MAdgBI4q94A+IOj+OJL+PSRIk1kI3kR5oJflkDbSGhkdf4WyCQwxyBkVk23wwtf+Eum1W9uLeXTSboppscU4jP2gFZN4ed4+QzZ8uOPcTk+ldhoGgWWgxyx6e9+Y5No23WoT3QULnAQSu2wc9Fx29BQBrVyvw0/wCRcvP+w1q3/pxuK6quV+Gn/IuXn/Ya1b/043FAHVUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFecaX4mtPB/w21bXNRhuZ7a21vUlaO2VTIxk1WaNcBmUdXHUjivR68M8f/wDJv3iT/sYbn/0+NTSuxpXdi5/w0N4e/wCgB4l/792v/wAfro/AHxY0fxvr8mkafpur2dyls93uvEhCMiuikApIxzmReo9a8c+GXh6xjh0LxHeNczzvrsFjBDbyKqxNkNvkJUkj/ZGPrzXUfDX/AJOU8Uf9el//AOlNvW06cUnY6KlKEU7dD3+ivH/G2p6TF8R9ZtvEPifUNHSLSLOWwittUlt2aZpbgMY4VcCZztjG0q2eBjms+T4ha1oWlzS680FjrJt9LjlNxEZIxPLDI8gZZLiGKLlDzuQZ4O44rA5j3Civn69+NOtL4Sj1My+H9Mul0qS+RL2J5BqEyTyxGKALMMY8oMfmcjzB1AyetvfHXiO01ieQW+m3WmJrkujR2cUEguZNtu0qsJN5XJK7duznPUUAeqUV4hb/ABU1mTR7i5i1HwrdstrbXMk8f7iKyeRyHt5PNnVXlABIUyRE4OQvFZl5481Wa41fU21+xFrP4Se8tbKWCa1+1yRm73eRtuSVcbFLOjMSmzBGA1AH0FRXnXhPxjdat4tn0u71XQ9P+zyeTHpEqOb+5QQhxMrtKPlOS3EbfKpy2ckUvFvjXVbPx3L4dtb3SYY54glukcS3V15jRM2XRblJIxkAgiJlxyWGeAD1Kivm4/GDVPDvw90GSLW9H1nU00qO4uI5LcbiVRA0Ukr3ikzqd2/ajtlgSg79fdfE/VY/FSWUTaQ5bVJrEaIInN+0SW8kqz7/ADMAOyKAPLIw45JyKAPYq5X4af8AIuXn/Ya1b/043Fcx8H/H+reMry7j1OPTBEltHOPsssIkhkJIaJ40uZn44+ZhGcggqDXT/DT/AJFy8/7DWrf+nG4oA6qiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAry5PC7eM/hXrOhJeixe41zUHFwYfNCGPVpZPu7lznZjqOteo1yreAtE864kik1u38+aS4eO21y+hj8yRy7kIkwVcszHAAGSaAPM9M+CPiXSo3TTPiG9kkhDOtvp8sYYjoTtuRkiui+G3wrvvCXjG58Q6l4kGrzz2ktsymyaJiXkjcuzmVyT+79O/Wuq/4QPSP+fzxJ/4Ueo//H6P+ED0j/n88Sf+FHqP/wAfqnOT3ZbqSejZ1VFcr/wgekf8/niT/wAKPUf/AI/R/wAIHpH/AD+eJP8Awo9R/wDj9SQaHiHwxpfiFov7XS7miQYMC3s0cMgznEkSOEkGR0cGtquV/wCED0j/AJ/PEn/hR6j/APH6P+ED0j/n88Sf+FHqP/x+gDqqK5X/AIQPSP8An88Sf+FHqP8A8fo/4QPSP+fzxJ/4Ueo//H6AOqorlf8AhA9I/wCfzxJ/4Ueo/wDx+j/hA9I/5/PEn/hR6j/8foA6qsRvC+lv4gj1qZLua/iYvF517PJFCxXYWSFnMaHaSMqoPJ9TVD/hA9I/5/PEn/hR6j/8fo/4QPSP+fzxJ/4Ueo//AB+gDqq5X4af8i5ef9hrVv8A043FH/CB6R/z+eJP/Cj1H/4/W1oOj2Wg6Ymn6YkqWyPJJ+9meZy8jtI7M7ksxLMxJJPWgDQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <em>",
"     Capillaria hepatica",
"    </em>",
"    has a direct life cycle that requires only one host. Adult worms invade the liver of the host (usually rodents, but may also be pigs, carnivores and primates, including humans), and lay hundreds of eggs in the surrounding parenchyma",
"    <strong>",
"     (1)",
"    </strong>",
"    . The eggs are not passed in the feces of the host, and remain in the liver until the animal dies and decomposes",
"    <strong>",
"     (2)",
"    </strong>",
"    , or is eaten by a predator or scavenger",
"    <strong>",
"     (3)",
"    </strong>",
"    . Eggs ingested by such an animal are unembryonated, are not infectious, and are passed in the feces, providing an efficient mechanism to release eggs into the environment",
"    <strong>",
"     (4)",
"    </strong>",
"    . Cannibalism has been reported as an important role in transmission among rodent populations. Eggs embryonate in the environment",
"    <strong>",
"     (5)",
"    </strong>",
"    , where they require air and damp soil to become infective. Under optimal conditions, this takes about 30 days. The cycle continues when embryonated eggs are eaten by a suitable mammalian host",
"    <strong>",
"     (6)",
"    </strong>",
"    . Infective eggs hatch in the intestine, releasing larvae. The larvae migrate via the portal vein to the liver. Larvae take about four weeks to mature into adults and mate. Humans are usually infected after ingesting embryonated eggs in fecal-contaminated food, water, or soil",
"    <strong>",
"     (7)",
"    </strong>",
"    . Occasionally in humans, larvae will migrate to the lungs, kidneys, or other organs. The presence of",
"    <em>",
"     C. hepatica",
"    </em>",
"    eggs in human stool during routine ova-and-parasite (O&amp;P) examinations indicates spurious passage of ingested eggs, and not a true infection. Diagnosis in humans is usually achieved by finding adults and eggs in biopsy or autopsy specimens.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Capillariasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/capillariasis.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/capillariasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_59_38838=[""].join("\n");
var outline_f37_59_38838=null;
var title_f37_59_38839="Evaluation of stillbirth";
var content_f37_59_38839=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of stillbirth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/59/38839/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/59/38839/contributors\">",
"     Drucilla J Roberts, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/59/38839/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/59/38839/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/59/38839/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/59/38839/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/59/38839/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postmortem examination is a useful and necessary tool for helping to determine the cause of stillbirth. Despite a comprehensive examination, however, some parents will still be left without a definitive reason for their baby's demise.",
"   </p>",
"   <p>",
"    Procedures for evaluation of the stillborn infant will be reviewed here. The incidence, etiology, prevention, and management of antepartum fetal death and counseling parents after stillbirth are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31306?source=see_link\">",
"     \"Incidence, etiology, and prevention of stillbirth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38999?source=see_link\">",
"     \"Counseling parents after stillbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MATERNAL LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal laboratory evaluation of women who have had a stillbirth is controversial. Many lists have been proposed, but the most cost-effective approach has not been determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/1-10\">",
"     1-10",
"    </a>",
"    ]. Our approach is guided by clinical, sonographic, and histopathologic findings.",
"   </p>",
"   <p>",
"    We order or review recent tests results for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetomaternal hemorrhage (eg, Kleihauer-Betke test, flow cytometry) in all women who have an unexplained stillbirth since detection of a large fetomaternal hemorrhage may explain the cause of an otherwise unexplained fetal demise. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/45/3800?source=see_link\">",
"       \"Diagnosis and management of massive fetomaternal hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urine toxicology",
"     </li>",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Serological testing for syphilis in women with a history of sexually transmitted infections and those who live in areas of high prevalence, or if this test has not been performed earlier in pregnancy",
"     </li>",
"     <li>",
"      A fasting glucose concentration or glycated hemoglobin level, which can be useful for excluding poor glycemic control as a cause of stillbirth in women who have not been evaluated for gestational diabetes and in those known to have diabetes mellitus",
"     </li>",
"     <li>",
"      Blood antibody screen to exclude red blood cell alloimmunization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thyroid function tests, lupus anticoagulant and anticardiolipin antibody titers, liver function tests, fibrinogen concentration, and thrombophilia evaluation are obtained in selected patients (those in whom there is a clinical suspicion of a specific underlying disorder) or to further evaluate unexplained stillbirths (stillborns with no gross or microscopic abnormalities).",
"   </p>",
"   <p>",
"    Routine serologic testing for infection is unlikely to be useful because many women have positive serologies from prior infections, which are unrelated to the stillbirth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/3\">",
"     3",
"    </a>",
"    ]. Culture of the fetus or placenta also may be misleading because of contamination during delivery, although culture of the area between the amnion and chorion may be more reliable. Cytomegalovirus titer (IgM, acute and convalescent IgG), toxoplasmosis titer (IgM, acute and convalescent IgG), parvovirus B19 titer (IgM), and a Listeria culture are obtained if indicated by maternal clinical, prenatal sonographic, or histopathologic findings. (See individual topic reviews on these infections). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4089?source=see_link\">",
"     \"Placental infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF THE AUTOPSY AND PLACENTAL EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical value",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of fetal death can often be determined through gross and histopathologic examination of the fetus and placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/10-16\">",
"     10-16",
"    </a>",
"    ]. Determining the cause of death is important because sooner or later parents will want to know \"Why did this happen?\" and \"Will it happen again?\" Answers to these questions are often impossible without information gained from pathologic examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/17-21\">",
"     17-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings at perinatal autopsy have been reported to change the clinical diagnosis of the cause of fetal death or yield additional findings in 22 to 76 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/21\">",
"     21",
"    </a>",
"    ]. This new information often influences management of future pregnancies. As an example, a study including 1477 stillbirths reported that autopsy findings identified the cause of death in 46 percent of cases and yielded new information in 51 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/19\">",
"     19",
"    </a>",
"    ]. This new information changed the estimated recurrence risk in 40 percent of cases, and changed recommendations for preconceptional care in 9 percent, prenatal diagnostic procedures in 21 percent, prenatal management in 7 percent, and neonatal management in 3 percent.",
"   </p>",
"   <p>",
"    Examples of histological findings of diagnostic importance are shown in the micrographs (",
"    <a class=\"graphic graphic_picture graphicRef63883 graphicRef53795 graphicRef56722 graphicRef50209 graphicRef66038 graphicRef77699 \" href=\"mobipreview.htm?43/48/44810\">",
"     picture 1A-F",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Role of the pathologist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compassionate parental counseling is important to obtain informed consent before the pathologic examination and when communicating the findings afterwards.",
"   </p>",
"   <p>",
"    Ideally, the autopsy should be performed by an experienced perinatal pathologist. If a perinatal pathologist is not available at the hospital where the stillbirth occurred, specimens may be sent for evaluation at a medical center with appropriate personnel and facilities. The fetus can be transferred to another institution intact or after evisceration. If questions persist or if the pathologist wishes, an experienced perinatal pathologist can be consulted and sent all of the slides and other materials (eg, photographs, radiographs) developed for the case.",
"   </p>",
"   <p>",
"    Good documentation and careful dissection is essential. Photographs of any malformations or suspected malformations (especially if an anomaly was diagnosed by imaging and not verified at autopsy), results of laboratory and imaging studies, unusual findings, and pertinent negative findings are extremely important.",
"   </p>",
"   <p>",
"    Completion of the autopsy needs to be timely, as the family and clinician's concerns and grieving period grow with delays. Autopsy reports should be completed promptly so that a family meeting with the clinicians can be timely. We believe that including the pathologist in these meetings is very helpful for explaining the autopsy report and answering questions (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Autopsy report'",
"    </a>",
"    below). The pathologist is often thought of as an impartial specialist since she was not involved in the patient's antepartum or intrapartum management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Components of the perinatal autopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Autopsy Committee of the College of American Pathologists, with representatives of other interested organizations, prepared a guideline to assist pathologists in reporting perinatal autopsies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/1\">",
"     1",
"    </a>",
"    ]. The judgment of the pathologist performing a specific case should guide the evaluation since there is no high quality evidence establishing the optimum combination of tests that should be performed routinely on all stillbirths. The following examinations are commonly performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review of the complete medical record to obtain the clinical history, with attention to medical, obstetrical (past and present), and genetic conditions potentially associated with stillbirth. Informational gaps may be provided by the patient or her clinician. We also review all previous obstetrical and gynecological specimens sent for examination by a pathologist. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31306?source=see_link&amp;anchor=H5#H5\">",
"       \"Incidence, etiology, and prevention of stillbirth\", section on 'Etiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31306?source=see_link&amp;anchor=H18#H18\">",
"       \"Incidence, etiology, and prevention of stillbirth\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Birth weight and external measurements (eg, foot length, head and chest circumference, crown-to-foot length).",
"     </li>",
"     <li>",
"      Gross external examination of the stillborn, with detailed description and photographs of abnormalities, dysmorphic features, and pertinent negative findings. Detailed photographs of the entire fetus from several views (anterior, posterior and lateral) and a facial photograph provide good documentation for future reference. Photographs of normal findings and pertinent negative findings can also be useful (as an example, a directed photograph of the fingers with nails can exclude many syndromes if the nail formation is normal). The facial photograph may be given to the parents, if requested.",
"     </li>",
"     <li>",
"      Gross and microscopic examination of the placenta and cord. Obtaining the placenta is critical, as often the placental findings are the most informative in determining the etiology of the stillbirth. The placenta is the best tissue for obtaining special studies (eg, karyotype) when autolysis is present. Umibilical cord or chorionic plate is the best tissue to send for karyotype as maternal contamination is avoided. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40840?source=see_link\">",
"       \"Gross examination of the placenta\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluation of the true complete cord length and number of vessels is essential. A short cord can be a sign of neuromuscular compromise, a long cord can be a sign of heart failure or that a cord accident may have played a pivotal role in the demise, while a single umbilical artery can be associated with genitourinary anomalies (eg, renal agenesis, horseshoe kidney). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27370?source=see_link\">",
"       \"Histopathology of placental disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacterial cultures performed on the placenta are an especially useful tool if autopsy permission is declined. The placenta, although contaminated by the birthing procedures and handling after delivery, can be cultured by peeling off the amnion from the chorion and swabbing this newly exposed chorionic surface. We have often found pathogens responsible for the fetal death (eg, Group B Streptococcus) using these techniques and have not had any contamination. Cultures of the placenta are sent for aerobic and anaerobic microbiologic studies. We do not feel viral or",
"      <span class=\"nowrap\">",
"       mycoplasma/ureaplasma",
"      </span>",
"      specialized cultures of the placenta are necessary or cost effective.",
"     </li>",
"     <li>",
"      We perform metabolic studies on all stillbirths. Analysis of blood spots is feasible even on markedly autolyzed specimens. A Guthrie card for this purpose is usually available in the newborn nursery. It should be labeled that the specimen is from a stillbirth and the source is autolyzed fluids.",
"     </li>",
"     <li>",
"      Gross and microscopic examination of major organs, including the weight of each organ.",
"     </li>",
"     <li>",
"      We typically open the thorax and then take a small portion of fetal lung using sterile utensils (a suture removal kit works well) and place it in a sterile container for further testing, if indicated, based on the clinical information and the autopsy findings (as an example, hydrops fetalis increases suspicion for a viral infection, preterm rupture of membranes increases suspicion for a bacterial infection).",
"     </li>",
"     <li>",
"      There is no consensus as to when cytogenetic, biochemical, and molecular genetic studies and viral cultures of the fetus are indicated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/2\">",
"       2",
"      </a>",
"      ]. One study evaluating a protocol for postmortem examination of stillbirths concluded that gross examination, photography, radiography, and bacterial cultures should be performed in all cases, while karyotyping and microscopy could be reserved for stillborns that are abnormal on gross examination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/22\">",
"       22",
"      </a>",
"      ]. This approach was less costly than performing these studies routinely, but still provided adequate information for genetic counseling since the prevalence of karyotype abnormalities is low (&lt;2 percent) in the absence of dysmorphic features, growth abnormalities, structural anomalies, or hydrops after careful postmortem examination. However, this protocol might fail to detect some chromosomal abnormalities and some nongenetic disorders, such as viral infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27370?source=see_link\">",
"       \"Histopathology of placental disorders\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4089?source=see_link\">",
"       \"Placental infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23562?source=see_link\">",
"       \"Congenital cytogenetic abnormalities\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We follow a decision tree to decide if we will obtain tissue for karyotype or tissues for other special studies (",
"      <a class=\"graphic graphic_table graphicRef70214 graphicRef63874 \" href=\"mobipreview.htm?38/35/39484\">",
"       table 1A-B",
"      </a>",
"      ). In our opinion, fetal lung tissue should be taken, using sterile techniques, for microbiologic studies in all cases and for virology if indicated or requested. In general, anaerobic and aerobic studies are necessary if a bacterial process is suspected. Viral cultures are rarely indicated, as the histopathology of the placental and fetal organs is diagnostic in most cases (eg, CMV, parvovirus, herpes simplex virus). Coxsackie virus can be passed across the placenta and should be suspected if myocarditis is found on histopathology; molecular studies can confirm this infection.",
"     </li>",
"     <li>",
"      X-rays may reveal unrecognized skeletal malformations, or can be obtained to further evaluate suspected skeletal abnormalities. Plain whole body anteroposterior and lateral radiographs are taken with the infant's head \"straight\" (use cellophane tape to hold the head straight, nose in line with umbilicus, arms and legs in anatomic position) and the extremities extended (the legs are placed as if jogging, with one leg flexed above the other and with extended arms slightly separated). Magnetic resonance imaging and computed tomography may be useful and acceptable to parents who refuse autopsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. Magnetic resonance imaging shows soft tissue well but not bone, whereas computed tomography shows bone well but is less good for imaging soft tissue. Ultrasound examination is less useful.",
"      <br/>",
"      <br/>",
"      Fetal radiographs should be examined carefully by the autopsy pathologist for specific findings:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Appropriate ossification of bones for gestational age",
"     </li>",
"     <li>",
"      Documentation and timing of fractures (which should be sampled histologically)",
"     </li>",
"     <li>",
"      Presence of ectopic",
"      <span class=\"nowrap\">",
"       mineralization/ossification",
"      </span>",
"      of nonbony tissues (eg, heart, arteries, bowel lumen), which can be associated with a variety of in-utero disorders (eg, TORCH infections, bowel abnormalities, hypoxic-ischemic encephalopathy, metabolic diseases).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tissue may be frozen (at 4&ordm; Celsius) for future examination and laboratory studies (",
"      <a class=\"graphic graphic_table graphicRef52278 \" href=\"mobipreview.htm?21/58/22443\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Specimen collection and processing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Genetic analysis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19422868\">",
"    <span class=\"h4\">",
"     Karyotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amniocentesis or chorionic villus sampling performed upon diagnosis of fetal demise appears to yield a higher rate of viable cells for successful culture and G-banded karyotyping than studies performed on the stillborn after delivery (success rate: 80 to 100 percent from amniotic fluid obtained before delivery versus 10 to 30 percent from skin or umbilical cord blood after delivery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytogenetic studies may be performed on the stillborn's blood, tissue, or body fluids (eg, bile, urine, vitreous humor), as long as the cells are viable. Blood can be collected from the umbilical cord; at least 3 mL should be placed in a heparinized tube. Skin samples are obtained by washing the skin with alcohol or sterile saline, drying the area with sterile gauze, and removing one square centimeter of tissue with underlying dermis. A specimen of adequate size and depth is important for successful culture. Fascia samples are usually taken from the Achilles tendon or thigh, using sterile technique. Fresh tissue samples should be placed in sterile medium (eg, Hanks",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/62/30690?source=see_link\">",
"     balanced salt solution",
"    </a>",
"    ) from the cytogenetics laboratory, or sterile saline solution, and kept at room temperature (do not use fixatives such as formaldehyde). DNA can be extracted from a blood sample on a Guthrie card.",
"   </p>",
"   <p>",
"    In cases of moderate or marked autolysis (retention of a stillbirth), the umbilical cord or chorionic plate vessel can be sampled for karyotype analysis. We suggest that in these cases, two separate samples be obtained and sent for cytogenetics: one from fetal skin and the other from umbilical cord. If culture fails and, therefore, karyotype analysis cannot be performed, directed fluorescence in situ hybridization (FISH) studies (eg, for Trisomy 13, 18, or 21) can be done on the paraffin embedded blocks of fetal or placental tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A limitation of using placental tissue for karyotype is the potential for confounding from confined placental mosaicism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28169?source=see_link&amp;anchor=H19#H19\">",
"     \"Chorionic villus sampling: Risks, complications, and techniques\", section on 'Confined placental mosaicism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19422875\">",
"    <span class=\"h4\">",
"     Microarray",
"    </span>",
"    &nbsp;&mdash;&nbsp;Array comparative genomic hybridization (aCGH) does not require dividing cells, and therefore can be useful in fetal demise with culture failure. In addition, aCGH is more likely than karyotype analysis to provide a genetic diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7208?source=see_link&amp;anchor=H12423093#H12423093\">",
"     \"Use of array comparative genomic hybridization (aCGH) in obstetrics\", section on 'Fetal demise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The advantages of microarray testing for genetic abnormalities in stillborns were illustrated in a study of 532 stillbirths in which both karyotype and microarray testing were attempted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/29\">",
"     29",
"    </a>",
"    ]. Compared to traditional karyotype, microarray analysis was significantly more likely to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Yield a result (87.4 versus 70.5 percent)",
"     </li>",
"     <li>",
"      Detect genomic abnormalities, ie, aneuploidy plus pathogenic variants (8.3 versus 5.8 percent)",
"     </li>",
"     <li>",
"      Detect genomic abnormalities in both subgroups of patients studied: antepartum fetal demise (8.8 versus 6.5 percent), stillborn with structural anomalies (29.9 versus 19.4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Importantly, of the 157 stillbirths for which karyotype failed to provide a result, microarray yielded a definitive result in 125 cases (79.6 percent) and this result was abnormal in 9 cases (5.7 percent; aneuploidy 7 cases, pathogenic variant 2 cases). Conversely, microarray identified aneuploidy or a pathogenic variant in 44 stillbirths of which 18 had a normal or failed karyotype.",
"   </p>",
"   <p>",
"    The utility and clinical importance of microarray technology in the routine evaluation of stillbirth as part of the autopsy protocol needs further validation. At the Massachusetts General Hospital, we will consider instituting this test as part of our autopsy protocol as further validation studies are published. Until then, we consider its use when anatomic findings or family history suggest a genetic cause of the loss. While microarray has many benefits, issues to consider are cost",
"    <span class=\"nowrap\">",
"     (karyotype/FISH",
"    </span>",
"    is less costly than array) and that both parents should have blood samples drawn when arrays are ordered. The rate of variants of unknown significance can be further decreased by comparison to the parental studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Microbiologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microbiologic studies can be performed on fetal blood taken from the heart or umbilical cord; however, fetal culture is more easily obtained from the fetal lung at autopsy. After the chest wall is opened and before any evaluation of the contents is performed or organs handled, using a sterile suture removal kit, lift up the right lower lobe of the lung and snip off a small portion (5 mm3 is sufficient) and place it in a sterile jar or in sterile medium for transport to the microbiology lab.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sections from the fetal and placental tissues should be processed for histological examination in all cases, even when severely autolyzed or structurally normal. Important pathologic findings that have clinical relevance beyond that of identifying a cause of death can still be diagnosed in severely autolyzed tissues (eg, viral infections and tumors are still easily identified in autolyzed specimens).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other special studies may be indicated and can be performed at evisceration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1324420603\">",
"    <span class=\"h2\">",
"     Estimating time of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, fetal death is not witnessed on ultrasound examination or by fetal heart monitoring, so the exact time of death is not known. Examination of the stillborn fetus and placenta can help in estimating the time of death, but the reliability of postmortem changes in estimating time of death has not been systematically evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following gross findings appear to be good predictors of the time of fetal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brown or red discoloration of the umbilical cord or desquamation &ge;1 cm suggests the fetus has been dead at least six hours",
"     </li>",
"     <li>",
"      Desquamation of the face, back, abdomen suggests the fetus has been dead at least 12 hours",
"     </li>",
"     <li>",
"      Desquamation &ge;5 percent of the body or &ge;2 body zones suggests the fetus has been dead at least 18 hours (body zones = scalp, face, neck, chest, back, arms, hand, leg, foot, scrotum)",
"     </li>",
"     <li>",
"      Skin color that is brown or tan suggests the fetus has been dead at least 24 hours",
"     </li>",
"     <li>",
"      Mummification (ie, reduced soft tissue volume, leathery skin, deeply brown-stained tissues) suggests the fetus has been dead at least two weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When this system was used to assign time death in 26 cases with known time of fetal demise, 18 fetuses (69 percent) were correctly assigned to one of six intrauterine retention intervals (0 to 6, 6 to 12, 12 to 18, 18 to 24 hours, 24 hours to two weeks, and more than two weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/31\">",
"     31",
"    </a>",
"    ]. The presence of a single gross change from the above list was not reliable; however, when two or more postmortem changes were present, 22 fetuses (85 percent) were correctly classified.",
"   </p>",
"   <p>",
"    A number of histological changes in the placenta (eg, villous intravascular karyorrhexis, stem villous vessels luminal abnormalities) and fetal organs (eg, loss of nuclear basophilia) have also been correlated with time of fetal death (",
"    <a class=\"graphic graphic_table graphicRef66529 \" href=\"mobipreview.htm?19/28/19917\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/30,32,33\">",
"     30,32,33",
"    </a>",
"    ]. The development of fetal organ changes is affected by factors such as presence of hydrops and a death to autopsy interval exceeding 24 hours, which hasten postmortem changes, and the gestational age (gestational age less than 25 weeks slows the development of postmortem changes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     AUTOPSY PROTOCOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal autopsies should be performed with the care and respect that all autopsies are given. Also, it is not uncommon for a family to decide to view the body after the postmortem examination has been done; therefore; careful dissection to avoid any disfigurement is important. In our experience, even the smallest, youngest (in gestational age), and most autolyzed cases can receive a thorough post-mortem examination and be returned in a condition suitable for viewing.",
"   </p>",
"   <p>",
"    Performance of the fetal autopsy is nearly identical to that of the adult or pediatric autopsy, but the focus on the dissection is modified. Since one major goal is to detect",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    verify congenital malformations, it is important that the dissection be careful with attention to detail, despite the fetus' size and level of autolysis (",
"    <a class=\"graphic graphic_table graphicRef57160 \" href=\"mobipreview.htm?3/33/3613\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We obtain the following measurements:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Body weight",
"     </li>",
"     <li>",
"      Crown-to-rump length (crown to ischial tuberosities, \"sitting height\")",
"     </li>",
"     <li>",
"      Crown-to-heel length (crown to heel of extended leg)",
"     </li>",
"     <li>",
"      Foot length",
"     </li>",
"     <li>",
"      Hand length",
"     </li>",
"     <li>",
"      Head circumference (ie, occipitofrontal circumference - above ears, as if wearing glasses)",
"     </li>",
"     <li>",
"      Chest circumference (around nipples)",
"     </li>",
"     <li>",
"      Abdominal circumference (at umbilical insertion)",
"     </li>",
"     <li>",
"      Inner canthal distance",
"     </li>",
"     <li>",
"      Outer canthal distance",
"     </li>",
"     <li>",
"      Any other potentially anomalous measurement (eg, finger, lip, ear)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We compare weight, crown-to-rump length, foot length, and heart weight to the range of values for gestational age in published tables and use a combination of these parameters to make a best estimate gestational age. We then compare this estimate with the clinical estimate of gestational age using menstrual data, ultrasound examination,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physical examination.",
"   </p>",
"   <p>",
"    Body weight, placental weight (trimmed of cord and membranes), and organ weights are very important, as are the body measurements as outlined in the protocol. A good 0 to 500 g (in at least 1 gram increments) tabletop scale, and hanging 100 to 5000 g scale (in 10 gram increments), is essential. Paired organs are weighed together. Many good standards for weights and measurements are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38839/abstract/34-38\">",
"     34-38",
"    </a>",
"    ] and should be posted at the bench where the autopsy is performed for quick consultation. If a weight significantly deviates from the norm, additional tests or sampling may be indicated. Brain weight is often facilitated by weighing a vessel of fixative, then allowing the brain to \"slip\" into the fixative while dissecting, then reweighing the vessel (with brain and fixative) and subtracting out the first weight. We do not open the GI tract (you need to preserve the contents), nor do we inflate the lungs (retain the in utero lung contents).",
"   </p>",
"   <p>",
"    Dissection of the fetal heart can be difficult, especially in autolyzed cases. Fixing the heart-lung block can be very helpful. The dissection of the fetal heart starts with a good in situ examination looking at situs, pulmonary venous return, persistence of the left superior vena cava, and caliber of the aortic arch and the brachiocephalic vein. Any anomalies in these structures should warrant careful dissection, and consideration of consultation with a cardiac surgeon or a pathologist with expertise; such consultation should be performed before continuing the dissection. Removing the heart and great vessels from the lungs and dissection along lines of flow (being careful to cut away from the septa, see below), observation of normal fetal structures (patent and competent foramen ovale, patent ductus arteriosis), and documentation of all valves should be completed before the great vessels are removed and the heart weighed. If possible, photographic documentation of findings and pertinent negatives should always be performed.",
"   </p>",
"   <p>",
"    We always obtain tissue for microscopy and sample all tissues; many samples can often be placed in a single cassette.",
"   </p>",
"   <p>",
"    The entire autopsy generally takes about 10 to 20 cassettes, including the placenta. A detailed procedure is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef57160 \" href=\"mobipreview.htm?3/33/3613\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     AUTOPSY REPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following template for autopsy reports is simple and provides the key information for the clinician and family:",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     (Male/Female)",
"    </span>",
"    fetus of estimated gestational age ____ weeks based on autopsy measurements of _____grams, _____cm crown-to-rump length, _____ cm foot length. The fetus is",
"    <span class=\"nowrap\">",
"     appropriate/small/large",
"    </span>",
"    for clinical estimation of gestational age of ____ weeks based on (1st trimester sonogram, LMP, other).",
"   </p>",
"   <p>",
"    Pertinent maternal data:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Best determination of anatomic cause of death:",
"     </li>",
"     <li>",
"      Cause of death:",
"     </li>",
"     <li>",
"      Congenital anomalies: no or yes (list)",
"     </li>",
"     <li>",
"      Other pertinent fetal findings:",
"     </li>",
"     <li>",
"      Placenta: full surgical pathology report",
"     </li>",
"     <li>",
"      Microbiology results:",
"     </li>",
"     <li>",
"      Radiographic findings:",
"     </li>",
"     <li>",
"      Pertinent negative findings:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We follow this information with a comment stating whether or not an anatomic cause of death was determined by the autopsy. If no anatomic cause of death was identified, we state this and then provide a description and interpretation of all findings.",
"   </p>",
"   <p>",
"    Families usually read these reports; therefore, they should be carefully worded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perinatal autopsy may provide information about the cause of fetal death that is different from that derived from other clinical examinations. This information often changes the estimated risk of stillbirth recurrence and frequently influences recommendations for management of future pregnancies. For these reasons, we suggest perinatal autopsy of stillborn infants (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical value'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perinatal autopsy can include review of clinical records and patient interview, gross and microscopic examination of the infant and placenta, photographs and x-rays, bacterial and viral cultures, and chromosome analysis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Components of the perinatal autopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Amniocentesis or chorionic villus sampling performed upon diagnosis of fetal demise may yield a higher rate of viable cells for successful culture and karyotyping than studies on the stillborn's blood, tissue, or body fluids performed after delivery. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Specimen collection and processing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal laboratory evaluation of women who have had a stillbirth is controversial. We suggest that the evaluation be guided by clinical, sonographic, and histopathologic findings. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Maternal laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/1\">",
"      Bove KE. Practice guidelines for autopsy pathology: the perinatal and pediatric autopsy. Autopsy Committee of the College of American Pathologists. Arch Pathol Lab Med 1997; 121:368.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Genetic evaluation of stillbirths and neonatal deaths. ACOG Committee Opinion No 257. American College of Obstetricians and Gynecologists, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/3\">",
"      Incerpi MH, Miller DA, Samadi R, et al. Stillbirth evaluation: what tests are needed? Am J Obstet Gynecol 1998; 178:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/4\">",
"      Fr&oslash;en JF, Vege A, Ormerod E, Stray-Pedersen B. [Finding the cause of death in intrauterine death--which examination should be done?]. Tidsskr Nor Laegeforen 2001; 121:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/5\">",
"      Martinek IE, Vial Y, Hohlfeld P. [Management of in utero foetal death: Which assessment to undertake?]. J Gynecol Obstet Biol Reprod (Paris) 2006; 35:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/6\">",
"      Eller AG, Branch DW, Byrne JL. Stillbirth at term. Obstet Gynecol 2006; 108:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/7\">",
"      Silver RM, Varner MW, Reddy U, et al. Work-up of stillbirth: a review of the evidence. Am J Obstet Gynecol 2007; 196:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/8\">",
"      Committee on Genetics. ACOG Committee Opinion No. 383: Evaluation of stillbirths and neonatal deaths. Obstet Gynecol 2007; 110:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/9\">",
"      ACOG Practice Bulletin No. 102: management of stillbirth. Obstet Gynecol 2009; 113:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/10\">",
"      Korteweg FJ, Erwich JJ, Timmer A, et al. Evaluation of 1025 fetal deaths: proposed diagnostic workup. Am J Obstet Gynecol 2012; 206:53.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/11\">",
"      Kliman HJ. The placenta revealed. Am J Pathol 1993; 143:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/12\">",
"      Redline RW. Placental pathology: a neglected link between basic disease mechanisms and untoward pregnancy outcome. Curr Opin Obstet Gynecol 1995; 7:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/13\">",
"      Redline RW, Patterson P. Villitis of unknown etiology is associated with major infiltration of fetal tissue by maternal inflammatory cells. Am J Pathol 1993; 143:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/14\">",
"      Kovalovszki L, Vill&aacute;nyi E, Benk&oacute; G. Placental villous edema: a possible cause of antenatal hypoxia. Acta Paediatr Hung 1990; 30:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/15\">",
"      Redline RW, Wilson-Costello D, Borawski E, et al. The relationship between placental and other perinatal risk factors for neurologic impairment in very low birth weight children. Pediatr Res 2000; 47:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/16\">",
"      Redline RW, Wilson-Costello D, Borawski E, et al. Placental lesions associated with neurologic impairment and cerebral palsy in very low-birth-weight infants. Arch Pathol Lab Med 1998; 122:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/17\">",
"      Saller DN Jr, Lesser KB, Harrel U, et al. The clinical utility of the perinatal autopsy. JAMA 1995; 273:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/18\">",
"      Faye-Petersen OM, Guinn DA, Wenstrom KD. Value of perinatal autopsy. Obstet Gynecol 1999; 94:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/19\">",
"      Michalski ST, Porter J, Pauli RM. Costs and consequences of comprehensive stillbirth assessment. Am J Obstet Gynecol 2002; 186:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/20\">",
"      Sankar VH, Phadke SR. Clinical utility of fetal autopsy and comparison with prenatal ultrasound findings. J Perinatol 2006; 26:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/21\">",
"      Gordijn SJ, Erwich JJ, Khong TY. Value of the perinatal autopsy: critique. Pediatr Dev Pathol 2002; 5:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/22\">",
"      Mueller RF, Sybert VP, Johnson J, et al. Evaluation of a protocol for post-mortem examination of stillbirths. N Engl J Med 1983; 309:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/23\">",
"      Naeye RL. The investigation of perinatal deaths. N Engl J Med 1983; 309:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/24\">",
"      Woodward PJ, Sohaey R, Harris DP, et al. Postmortem fetal MR imaging: comparison with findings at autopsy. AJR Am J Roentgenol 1997; 168:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/25\">",
"      Thayyil S, Chitty LS, Robertson NJ, et al. Minimally invasive fetal postmortem examination using magnetic resonance imaging and computerised tomography: current evidence and practical issues. Prenat Diagn 2010; 30:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/26\">",
"      Khare M, Howarth E, Sadler J, et al. A comparison of prenatal versus postnatal karyotyping for the investigation of intrauterine fetal death after the first trimester of pregnancy. Prenat Diagn 2005; 25:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/27\">",
"      Korteweg FJ, Bouman K, Erwich JJ, et al. Cytogenetic analysis after evaluation of 750 fetal deaths: proposal for diagnostic workup. Obstet Gynecol 2008; 111:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/28\">",
"      Wolfe KQ, Herrington CS. Interphase cytogenetics and pathology: a tool for diagnosis and research. J Pathol 1997; 181:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/29\">",
"      Reddy UM, Page GP, Saade GR, et al. Karyotype versus microarray testing for genetic abnormalities after stillbirth. N Engl J Med 2012; 367:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/30\">",
"      Marchetti D, Belviso M, Marino M, Gaudio R. Evaluation of the placenta in a stillborn fetus to estimate the time of death. Am J Forensic Med Pathol 2007; 28:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/31\">",
"      Genest DR, Singer DB. Estimating the time of death in stillborn fetuses: III. External fetal examination; a study of 86 stillborns. Obstet Gynecol 1992; 80:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/32\">",
"      Genest DR, Williams MA, Greene MF. Estimating the time of death in stillborn fetuses: I. Histologic evaluation of fetal organs; an autopsy study of 150 stillborns. Obstet Gynecol 1992; 80:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/33\">",
"      Genest DR. Estimating the time of death in stillborn fetuses: II. Histologic evaluation of the placenta; a study of 71 stillborns. Obstet Gynecol 1992; 80:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/34\">",
"      De Paepe ME, Friedman RM, Gundogan F, Pinar H. Postmortem lung weight/body weight standards for term and preterm infants. Pediatr Pulmonol 2005; 40:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/35\">",
"      Guihard-Costa AM, M&eacute;nez F, Delezoide AL. Organ weights in human fetuses after formalin fixation: standards by gestational age and body weight. Pediatr Dev Pathol 2002; 5:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/36\">",
"      Maroun LL, Graem N. Autopsy standards of body parameters and fresh organ weights in nonmacerated and macerated human fetuses. Pediatr Dev Pathol 2005; 8:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38839/abstract/37\">",
"      Shepard TH, Shi M, Fellingham GW, et al. Organ weight standards for human fetuses. Pediatr Pathol 1988; 8:513.",
"     </a>",
"    </li>",
"    <li>",
"     Wigglesworth, JS, Singer, DB. Textbook of fetal and perinatal pathology: Blackwell Science, 2nd ed, Wigglesworth, JS, Singer, DB (Eds), Backwell Publishers 1998.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5402 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-2110654F66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_59_38839=[""].join("\n");
var outline_f37_59_38839=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MATERNAL LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF THE AUTOPSY AND PLACENTAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical value",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Role of the pathologist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Components of the perinatal autopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Specimen collection and processing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Genetic analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19422868\">",
"      Karyotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19422875\">",
"      Microarray",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Microbiologic studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1324420603\">",
"      Estimating time of death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      AUTOPSY PROTOCOL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      AUTOPSY REPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5402\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5402|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/13/26837\" title=\"picture 1A\">",
"      Intraluminal cal meconium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/11/8376\" title=\"picture 1B\">",
"      Rhabdomyoma fetal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/51/15162\" title=\"picture 1C\">",
"      Congenital myocardial infar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/14/41190\" title=\"picture 1D\">",
"      Congenital CMV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/17/4375\" title=\"picture 1E\">",
"      Congenital HSV 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/51/1842\" title=\"picture 1F\">",
"      Congential HSV 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5402|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/63/7164\" title=\"table 1A\">",
"      Decision tree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/50/6955\" title=\"table 1B\">",
"      Indic for karyotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/58/22443\" title=\"table 2\">",
"      Stillbirth evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/28/19917\" title=\"table 3\">",
"      Findings associated with time since fetal death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/33/3613\" title=\"table 4\">",
"      Perinatal autopsy procedure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28169?source=related_link\">",
"      Chorionic villus sampling: Risks, complications, and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38999?source=related_link\">",
"      Counseling parents after stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/45/3800?source=related_link\">",
"      Diagnosis and management of massive fetomaternal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40840?source=related_link\">",
"      Gross examination of the placenta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27370?source=related_link\">",
"      Histopathology of placental disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31306?source=related_link\">",
"      Incidence, etiology, and prevention of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4089?source=related_link\">",
"      Placental infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7208?source=related_link\">",
"      Use of array comparative genomic hybridization (aCGH) in obstetrics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_59_38840="Pulmonary rehabilitation in COPD";
var content_f37_59_38840=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary rehabilitation in COPD",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/59/38840/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/59/38840/contributors\">",
"     Bartolome R Celli, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/59/38840/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/59/38840/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/59/38840/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/59/38840/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/59/38840/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary rehabilitation is a broad therapeutic concept. It is defined by the American Thoracic Society and the European Respiratory Society as an evidence-based, multidisciplinary, and comprehensive intervention for patients with chronic respiratory diseases who are symptomatic and often have decreased daily life activities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/1\">",
"     1",
"    </a>",
"    ]. Integrated into the individualized treatment of the patient, pulmonary rehabilitation is designed to reduce symptoms, optimize functional status, increase participation, and reduce health care costs by stabilizing or reversing systemic manifestations of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of pulmonary rehabilitation on quality of life and health care utilization will be reviewed here, focusing on the primary goals of rehabilitation &mdash; lower and upper extremity exercise conditioning, breathing retraining, education, and psychosocial support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/2\">",
"     2",
"    </a>",
"    ]. Other important therapeutic modalities that are stressed in many rehabilitation programs, including smoking cessation, oxygen therapy, bronchodilators, antibiotics, nutritional support, and respiratory muscle training and resting, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/39/43639?source=see_link\">",
"     \"Nutritional support in advanced lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28549?source=see_link\">",
"     \"Respiratory muscle training and resting in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic obstructive pulmonary disease (COPD) often decrease their physical activity because exercise can worsen dyspnea. The progressive deconditioning associated with inactivity initiates a vicious cycle, with dyspnea becoming problematic at ever lower physical demands. Pulmonary rehabilitation aims to break the cycle. Benefits of pulmonary rehabilitation include decreased dyspnea, improved health-related quality of life, fewer days of hospitalization, and decreased health-care utilization (",
"    <a class=\"graphic graphic_table graphicRef64591 \" href=\"mobipreview.htm?39/8/40075\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mortality and exercise tolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of rehabilitation on mortality is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/3,6-9\">",
"     3,6-9",
"    </a>",
"    ]. In a prospective observational study of 1218 patients, pulmonary rehabilitation did not confer a mortality benefit, but was associated with improved exercise capacity, dyspnea, and quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, another observational study that included patients with a wider range of airflow obstruction detected improved survival among patients whose exercise capacity and dyspnea improved after rehabilitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/7\">",
"     7",
"    </a>",
"    ]. A meta-analysis demonstrated decreased hospital readmission and mortality among patients who received rehabilitation after an exacerbation of COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A three-year prospective case control study of 80 patients with moderate to severe COPD showed improvements in body mass index (BMI), lung function, and health status with pulmonary rehabilitation compared with usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/8\">",
"     8",
"    </a>",
"    ]. Taken together, these studies emphasize the need for prospective randomized trials that are large enough to determine whether pulmonary rehabilitation impacts survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of medical interventions is increasingly being judged by their impact on a patient's quality of life, a criterion that requires data on a range of patient symptoms, activities, social interactions, and psychological state. Several studies have demonstrated improved quality of life following both inpatient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/7,9-11\">",
"     7,9-11",
"    </a>",
"    ] and outpatient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/12-15\">",
"     12-15",
"    </a>",
"    ] programs.",
"   </p>",
"   <p>",
"    A Cochrane meta-analysis of 23 randomized controlled trials concluded that pulmonary rehabilitation was more effective than standard community-based care with respect to quality of life and functional exercise capacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Health care utilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several uncontrolled studies suggest that pulmonary rehabilitation decreases total hospital stay and recurrent hospitalization rates in patients with COPD. The average decrease was 23 days per year per patient for the studies analyzed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The longest study thus far reported included 64 patients followed for four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/19\">",
"     19",
"    </a>",
"    ]. For the 44 patients alive at the end of the study, hospitalization had decreased from a cumulative level of 529 days (12 days patient per year) in the year prior to therapy to an average of 145, 270, 278, and 207 days (an average of five days per patient per year) for the four years of follow-up.",
"   </p>",
"   <p>",
"    The benefits have been less clear in controlled studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. One report found a decrease in hospitalization over six months in a group of treated patients when compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/20\">",
"     20",
"    </a>",
"    ]. In contrast, a subsequent large study found only a modest (-2.4 days per patient per year) and not statistically significant decrease in hospitalization rate in the in patients participating in a comprehensive rehabilitation program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/21\">",
"     21",
"    </a>",
"    ]. A subsequent study randomly assigned 99 patients to a 6-week program of pulmonary rehabilitation, while 101 patients received usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/22\">",
"     22",
"    </a>",
"    ]. After one year, there were no differences in the number of patients hospitalized, although the length of stay was significantly shorter among hospitalized patients who had been randomized to rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effect of comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with COPD are likely to have additional comorbid diseases, such as hypertension, diabetes, heart failure, and coronary heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Among 2962 patients with COPD enrolled in a pulmonary rehabilitation program, the presence of comorbidities, particularly metabolic diseases and heart disease, reduced the likelihood of an improved outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/24\">",
"     24",
"    </a>",
"    ]. However, a prospective study in 316 patients with moderate to severe COPD, performed by the same investigators, found that only functional disability at baseline and coexisting osteoporosis resulted in a poorer outcome from pulmonary rehabilitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/25\">",
"     25",
"    </a>",
"    ]. While the numbers are small, the presence of CAD in 11 percent did not adversely affect the likelihood of achieving improved exercise tolerance and quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Durability of benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be some loss of the benefits of pulmonary rehabilitation with time; however, the role of periodic retraining of patients to sustain these gains has yet to be defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/10,11,13\">",
"     10,11,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An observational study evaluated 48 patients who participated in five successive hospital based rehabilitation programs over a 7 year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/26\">",
"     26",
"    </a>",
"    ]. The patients showed improvement in exercise capacity, health status, dyspnea, and the BODE index (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?22/50/23329?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) at the end of each program, although the degree of improvement decreased with successive programs. Exercise tolerance, dyspnea, and health-related quality of life did not worsen over the 7 years despite progressive worsening in forced expiratory volume in one second.",
"   </p>",
"   <p>",
"    Maintenance with a simplified program, including self-monitoring, helped to maintain improvements in exercise tolerance and health status in an observational study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/27\">",
"     27",
"    </a>",
"    ], while repeat programs reproduced the initial gains in another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     COMPONENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary rehabilitation consists of conditioning, breathing retraining, education, and psychological support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Conditioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditioning can be performed using lower extremity or upper extremity exercise. Lower extremity training has been better studied and is the more widely used approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Lower extremity exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased exercise endurance following lower extremity exercise has been demonstrated in multiple controlled and uncontrolled trials performed in both hospital and home settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/12,29-39\">",
"     12,29-39",
"    </a>",
"    ]. One report, for example, randomized 33 patients to a conventional regimen or an exercise program consisting of a daily 12 minute walk and stair-climbing exercises [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/31\">",
"     31",
"    </a>",
"    ]. There was a 24 percent increase in walking distance in the exercise group.",
"   </p>",
"   <p>",
"    A larger trial randomized 89 stable patients with COPD to an eight-week in hospital rehabilitation program (including leg and upper extremity exercise) or conventional community care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/37\">",
"     37",
"    </a>",
"    ]. Rehabilitation led to significant and sustained improvements in walking distance, dyspnea score, and quality of life. Similar benefits have been demonstrated in the home setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/36,40,41\">",
"     36,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall benefit of rehabilitation in COPD was confirmed in two meta-analyses that assessed the effect on exercise capacity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the health-related quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/30,42\">",
"     30,42",
"    </a>",
"    ]. Respiratory rehabilitation was defined as exercise training (for at least four weeks) with or without education and psychological support. Both functional capacity and dyspnea were significantly improved to an extent that was clinically important.",
"   </p>",
"   <p>",
"    Mild weight training may provide additional benefit. One report, for example, evaluated 14 patients with COPD enrolled in a home program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/35\">",
"     35",
"    </a>",
"    ]. The patients were randomized to daily walking while carrying a light backpack (controls) or the same regimen with additional weight lifting (wrist and arms curls, partial leg squats, calf raises, and supine dumbbell press) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/35\">",
"     35",
"    </a>",
"    ]. After training, weight lifters had reduced their minute ventilation and increased their ergometry endurance by 16 percent, when compared with controls.",
"   </p>",
"   <p>",
"    The mechanism by which exercise improves endurance remains unclear. The benefits generally occur without change in lung and respiratory muscle function, making a mechanical explanation unlikely. Two hypotheses have been put forward: desensitization to dyspnea; or a true training effect.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study supporting the role of desensitization to dyspnea, patients were randomized to upper or lower extremity exercise [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/43\">",
"       43",
"      </a>",
"      ]. Muscle biopsies of the trained limbs were obtained before and after training. In spite of a significant increase in exercise endurance, there were no changes in the oxidative enzyme content of the trained muscle. However, the study may not have provided the patients with a large enough load to promote adequate conditioning.",
"     </li>",
"     <li>",
"      In contrast, support for a true training effect has been demonstrated by the finding that aerobic exercise leads to skeletal muscle adaptation, as evidenced by increased activity of skeletal muscle oxidative enzymes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/44\">",
"       44",
"      </a>",
"      ]. One report, for example, showed reductions in exercise-induced lactic acidosis and ventilation after training [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/45\">",
"       45",
"      </a>",
"      ]. The improvement was proportional to the intensity of the training, with a 12 percent lower rise in lactic acidosis in patients trained at a low work rate versus a 32 percent lower rise in patients trained at a high work rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the absence of significant lactic acidosis during exercise does not preclude achieving a training effect. In a study of 25 patients with COPD who underwent a six week cycle ergometry exercise program, rehabilitation resulted in a mean increase of 36 percent in peak work rate and 77 percent in endurance on a constant work rate test despite the absence of significant metabolic acidosis during baseline testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/46\">",
"     46",
"    </a>",
"    ]. A physiologic training effect was demonstrated by a lower heart rate response during constant work rate testing and evidence of faster kinetics of oxygen consumption and carbon dioxide production, ie, the steady-state values were achieved sooner during exercise.",
"   </p>",
"   <p>",
"    Even patients with the most severe COPD and poor exercise performance can undergo exercise training. One study evaluated 50 patients with COPD who had a range of FEV1 from 0.38 to 3.24 L [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/47\">",
"     47",
"    </a>",
"    ]. An inverse relationship was observed between the baseline 12 minute walk distance and the improvement following exercise training.",
"   </p>",
"   <p>",
"    While the weight of evidence supports a role for lower extremity exercise in improving the functional status of patients with COPD, the optimal duration of the activity, frequency of the exercise sessions, and intensity of the task remain poorly defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. However, studies demonstrating physiologic improvement following exercise programs tended to have the most intense exercise prescriptions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Upper extremity exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of our knowledge about exercise conditioning is derived from programs emphasizing leg training. This is unfortunate, because the performance of many everyday tasks requires the hands plus the concerted action of other muscle groups that are used in upper torso and arm positioning. Some of these muscle groups serve a dual function (respiratory and postural), and arm exercise decreases their capacity to participate in ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/50\">",
"     50",
"    </a>",
"    ]. Arm training results in improved performance, which is mostly task specific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. Although some studies suggest a possible effect of arm training on respiratory muscle function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/50,52\">",
"     50,52",
"    </a>",
"    ], others found no change in ventilatory muscle performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/43,51,53,54\">",
"     43,51,53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study comparing different types of upper extremity exercise, unsupported arm training (against gravity) decreased oxygen uptake more than arm cranking training at the same workload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/55\">",
"     55",
"    </a>",
"    ]. Thus, unsupported arm exercise may be a more effective way of training patients in activities that resemble those of daily living [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/56\">",
"     56",
"    </a>",
"    ]. In a meta-analysis, unsupported upper extremity exercise decreased dyspnea and arm fatigue during activities of daily living, but did not result in a clinically important difference in the Borg scale (",
"    <a class=\"graphic graphic_table graphicRef63981 \" href=\"mobipreview.htm?15/10/15532\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/57\">",
"     57",
"    </a>",
"    ]. Like lower extremity exercise, the optimal duration of the activity, frequency of the exercise sessions, and intensity of the task remain poorly defined for upper extremity exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Continuous versus interval exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of training used in pulmonary rehabilitation programs has traditionally been continuous, high intensity exercise. As an example, a patient who can achieve a maximal workload of 100 watts may target exercise at a workload of 70 watts continuously for the entire 20 minute session. Many patients, however, cannot exercise continuously. Interval exercise training may be an acceptable alternative to continuous training in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/58-62\">",
"     58-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was best illustrated by a trial that randomly assigned 98 patients with severe COPD to receive interval or continuous exercise training for three weeks, followed by exercise at home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/58\">",
"     58",
"    </a>",
"    ]. At the end of the three weeks, the groups had similar improvement in quality of life and six-minute walking distance. However, adherence to the assigned protocol was higher in the interval training group (48 versus 24 percent).",
"   </p>",
"   <p>",
"    In addition, a randomized trial of 42 patients with moderately severe COPD found that interval load exercise had a similar effect on BODE improvement compared to constant load exercise (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?22/50/23329?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Breathing retraining",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are other less conventional forms of training that may offer new avenues of therapy. Patients with lung disease have a rapid shallow breathing pattern that may be deleterious to ventilation and gas exchange. Interventions designed to change the breathing pattern could prove beneficial, although conflicting results have been obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retraining with breathing techniques that decrease breathing frequency, such as yoga and pursed lip breathing, have in some studies led to increases in tidal volume and oxygen saturation, and a reduction in dyspnea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/64\">",
"       64",
"      </a>",
"      ]. In a meta-analysis that included sixteen studies with a total of 1233 participants, three months of yoga with timed breathing techniques was associated with a significant improvement in six-minute walk distance, but there was no consistent improvement in dyspnea or health-related quality of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, an evaluation of the effect of diaphragmatic breathing in patients with COPD showed increases in the work of breathing and dyspnea with diaphragmatic compared to natural breathing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ventilatory muscle training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts to increase the strength",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endurance of the ventilatory muscles have had mixed results. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 25 studies that assessed the efficacy of inspiratory muscle training in patients with stable COPD found significant increases in inspiratory muscle strength, exercise capacity, and one measure of quality of life and a significant decrease in dyspnea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of 17 randomized studies of ventilatory muscle training (VMT) revealed nonsignificant changes in muscle strength in 11 studies and in respiratory muscle endurance in the 9 studies in which that outcome was assessed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/68\">",
"       68",
"      </a>",
"      ]. However, in 5 studies in which there were improvements in strength or endurance of the breathing muscles, gains in functional capacity were noted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with upper and lower extremity exercise training, the optimal duration, frequency, and intensity of VMT remain to be defined. Furthermore, an effective response may be dependent upon controlling the pattern of breathing during the inspiratory maneuver to insure that an adequate training stimulus has been achieved, ie, 30 percent of maximal inspiratory pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/69\">",
"     69",
"    </a>",
"    ]. While VMT is not recommended as a routine element in pulmonary rehabilitation programs, it may be considered in selected patients with COPD and ventilatory muscle weakness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should receive education to improve compliance in matters such as medication, oxygen therapy, smoking cessation, nutrition, exercise, and health preservation. Several studies show that patients instructed about the nature of their disease and the implications of therapy can better understand, recognize, and treat the symptoms of their disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/70\">",
"     70",
"    </a>",
"    ]. However, there is little evidence that education can be considered a substitute for exercise training (",
"    <a class=\"graphic graphic_table graphicRef67040 \" href=\"mobipreview.htm?27/5/27739\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 76 patients with COPD were randomized to three treatment groups that included behavior modification, cognitive modification, and behavior-cognitive modification [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/71\">",
"       71",
"      </a>",
"      ]. They were compared to two control groups. After three months, the treatment groups increased their exercise endurance and an index of quality of life, compared to controls. Unfortunately, some patients in the treatment groups were encouraged to perform walking and breathing exercises, thereby confounding the results.",
"     </li>",
"     <li>",
"      Four studies in which education alone was used as a control intervention, and the results compared to treatment with exercise, found that education alone was of little benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/12,21,34,72\">",
"       12,21,34,72",
"      </a>",
"      ]. In one report, for example, 119 patients with COPD were randomized to a comprehensive rehabilitation program or to education alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/21\">",
"       21",
"      </a>",
"      ]. The comprehensive program was associated with increases in exercise tolerance and endurance (+10.3 versus +1.3 min with education) and in a dyspnea score (-7.0 versus +0.6 with education).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Psychological support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe COPD is a risk factor for the development of depression, which may contribute to symptoms such as anxiety and fatigue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/73\">",
"     73",
"    </a>",
"    ]. This can result in decreased participation in social activities, often including sexual activity.",
"   </p>",
"   <p>",
"    These problems are likely to improve as patients become involved in a pulmonary rehabilitation program, and protracted psychologic counseling is usually not necessary. It has been shown, for example, that 15 to 20 rehabilitation sessions that include education, exercise breathing techniques, and relaxation techniques are more effective in reducing anxiety than a similar number of psychotherapy sessions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, it may be necessary to administer short courses of antidepressant medications. Issues about sexuality should be raised and discussed and, when necessary, sexual counseling should be initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF EXERCISE CAPACITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise capacity is typically assessed before and after participation in a pulmonary rehabilitation program. One of several clinical tests may be used, such as the six-minute walk test, the shuttle walk test, or cardiopulmonary exercise testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a six-minute walk test, the patient walks as far as possible during a period of six minutes; the total distance walked (in meters), oxygen saturation during the walk, and dyspnea are monitored [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/77\">",
"       77",
"      </a>",
"      ]. In a systematic analysis of 4 trials that measured six-minute walk distance before and after pulmonary rehabilitation, the mean improvement in the six-minute walk test was 106.64 meters (95% CI 84-129) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/4\">",
"       4",
"      </a>",
"      ]. An increase of 35 meters or more is considered significant.",
"     </li>",
"     <li>",
"      For a shuttle walk test, the patient walks back and forth between two cones using either a progressive increase in speed or a constant speed at 85 percent of a previous maximal speed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/75,78\">",
"       75,78",
"      </a>",
"      ]. In an analysis of two trials that measured shuttle walk distance before and after pulmonary rehabilitation, the mean improvement in the shuttle walk test was 81 meters (95% CI 48-115) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiopulmonary exercise testing is the most comprehensive of the three tests and uses either a cycle ergometer or a treadmill to measure physiologic outcomes such as oxygen uptake, carbon dioxide output, tidal volume, minute ventilation, electrocardiographic tracings, and pulse oximetry [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/75,79\">",
"       75,79",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25144?source=see_link\">",
"       \"Exercise physiology\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PRACTICAL ASPECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of a pulmonary rehabilitation program is uncertain. In one randomized, controlled trial, there was little difference between a four and seven week program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/80\">",
"     80",
"    </a>",
"    ]. It is generally believed, however, that longer programs confer more durable benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/42,81\">",
"     42,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Attendance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular attendance during a rehabilitation program is desirable, but not always possible. Factors found to decrease attendance include: current smoking, greater breathlessness, higher frequency of hospital admissions, longer duration of the program (eg, 6 versus 18 weeks), and longer journey time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38840/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/13/1236?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/52/14148?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence indicates that certain components of pulmonary rehabilitation benefit patients with symptomatic COPD. It is not yet clear if these benefits translate into less health care use.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aerobic lower extremity training is of benefit in several areas of importance to patients with COPD, including exercise endurance, perception of dyspnea, and quality of life (",
"      <a class=\"graphic graphic_figure graphicRef67751 \" href=\"mobipreview.htm?13/51/14142\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef60099 \" href=\"mobipreview.htm?18/7/18558\">",
"       figure 2",
"      </a>",
"      ). Therefore, aerobic leg training should be part of all programs of pulmonary rehabilitation.",
"     </li>",
"     <li>",
"      The effectiveness and role of upper extremity exercise training and breathing retraining require further study. Evidence from several small studies suggests that arm training is beneficial to patients who complain of symptoms when performing upper extremity exercise.",
"     </li>",
"     <li>",
"      Education and psychological support improve patients' awareness and understanding of their disease, but are of limited value when used alone.",
"     </li>",
"     <li>",
"      Pulmonary rehabilitation, when coupled with smoking cessation, optimization of blood gases, and medication, is part of the optimal treatment program for patients with symptomatic airflow obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/1\">",
"      Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006; 173:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/2\">",
"      Troosters T, Casaburi R, Gosselink R, Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/3\">",
"      Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007; 131:4S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/4\">",
"      Puhan M, Scharplatz M, Troosters T, et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009; :CD005305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/5\">",
"      Bianchi R, Gigliotti F, Romagnoli I, et al. Impact of a rehabilitation program on dyspnea intensity and quality in patients with chronic obstructive pulmonary disease. Respiration 2011; 81:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/6\">",
"      Ries AL, Make BJ, Lee SM, et al. The effects of pulmonary rehabilitation in the national emphysema treatment trial. Chest 2005; 128:3799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/7\">",
"      Cote CG, Celli BR. Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 2005; 26:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/8\">",
"      Stav D, Raz M, Shpirer I. Three years of pulmonary rehabilitation: inhibit the decline in airflow obstruction, improves exercise endurance time, and body-mass index, in chronic obstructive pulmonary disease. BMC Pulm Med 2009; 9:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/9\">",
"      Puhan MA, Scharplatz M, Troosters T, Steurer J. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality -- a systematic review. Respir Res 2005; 6:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/10\">",
"      Guyatt GH, Berman LB, Townsend M. Long-term outcome after respiratory rehabilitation. CMAJ 1987; 137:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/11\">",
"      Ketelaars CA, Abu-Saad HH, Schl&ouml;sser MA, et al. Long-term outcome of pulmonary rehabilitation in patients with COPD. Chest 1997; 112:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/12\">",
"      Man WD, Polkey MI, Donaldson N, et al. Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. BMJ 2004; 329:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/13\">",
"      Vale F, Reardon JZ, ZuWallack RL. The long-term benefits of outpatient pulmonary rehabilitation on exercise endurance and quality of life. Chest 1993; 103:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/14\">",
"      Wijkstra PJ, TenVergert EM, van der Mark TW, et al. Relation of lung function, maximal inspiratory pressure, dyspnoea, and quality of life with exercise capacity in patients with chronic obstructive pulmonary disease. Thorax 1994; 49:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/15\">",
"      Finnerty JP, Keeping I, Bullough I, Jones J. The effectiveness of outpatient pulmonary rehabilitation in chronic lung disease: a randomized controlled trial. Chest 2001; 119:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/16\">",
"      Lacasse Y, Brosseau L, Milne S, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; :CD003793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/17\">",
"      Petty TL, Nett LM, Finigan MM, et al. A comprehensive care program for chronic airway obstruction. Methods and preliminary evaluation of symptomatic and functional improvement. Ann Intern Med 1969; 70:1109.",
"     </a>",
"    </li>",
"    <li>",
"     Hodgkin JE, Celli BR, Connors GL. Pulmonary rehabilitation. In: Guidelines To Success, 3rd ed, Williams and Wilkins, Philadelphia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/19\">",
"      Hudson LD, Tyler ML, Petty TL. Hospitalization needs during an outpatient rehabilitation program for severe chronic airway obstruction. Chest 1976; 70:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/20\">",
"      Jensen PS. Risk, protective factors, and supportive interventions in chronic airway obstruction. Arch Gen Psychiatry 1983; 40:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/21\">",
"      Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995; 122:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/22\">",
"      Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000; 355:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/23\">",
"      Seymour JM, Moore L, Jolley CJ, et al. Outpatient pulmonary rehabilitation following acute exacerbations of COPD. Thorax 2010; 65:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/24\">",
"      Crisafulli E, Costi S, Luppi F, et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008; 63:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/25\">",
"      Crisafulli E, Gorgone P, Vagaggini B, et al. Efficacy of standard rehabilitation in COPD outpatients with comorbidities. Eur Respir J 2010; 36:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/26\">",
"      Foglio K, Bianchi L, Bruletti G, et al. Seven-year time course of lung function, symptoms, health-related quality of life, and exercise tolerance in COPD patients undergoing pulmonary rehabilitation programs. Respir Med 2007; 101:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/27\">",
"      Ringbaek T, Br&oslash;ndum E, Martinez G, et al. Rehabilitation in COPD: the long-term effect of a supervised 7-week program succeeded by a self-monitored walking program. Chron Respir Dis 2008; 5:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/28\">",
"      Hill K, Bansal V, Brooks D, Goldstein RS. Repeat pulmonary rehabilitation programs confer similar increases in functional exercise capacity to initial programs. J Cardiopulm Rehabil Prev 2008; 28:410.",
"     </a>",
"    </li>",
"    <li>",
"     Casaburi R. Exercise Training in Chronic Obstructive Lung Disease. In: Principles and Practice of Pulmonary Rehabilitation, Casaburi R, Petty TL (Eds), Saunders, Philadelphia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/30\">",
"      Lacasse Y, Wong E, Guyatt GH, et al. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet 1996; 348:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/31\">",
"      Sinclair DJ, Ingram CG. Controlled trial of supervised exercise training in chronic bronchitis. Br Med J 1980; 280:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/32\">",
"      Cockcroft AE, Saunders MJ, Berry G. Randomised controlled trial of rehabilitation in chronic respiratory disability. Thorax 1981; 36:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/33\">",
"      O'Donnell DE, Webb KA, McGuire MA. Older patients with COPD: benefits of exercise training. Geriatrics 1993; 48:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/34\">",
"      Toshima MT, Kaplan RM, Ries AL. Experimental evaluation of rehabilitation in chronic obstructive pulmonary disease: short-term effects on exercise endurance and health status. Health Psychol 1990; 9:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/35\">",
"      O'Hara, WJ, Lasachuk, BP, Matheson, P, et al. Weight training and backpacking in chronic obstructive pulmonary disease. Respir Care 1984; 29:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/36\">",
"      Wijkstra PJ, Van Altena R, Kraan J, et al. Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home. Eur Respir J 1994; 7:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/37\">",
"      Goldstein RS, Gort EH, Stubbing D, et al. Randomised controlled trial of respiratory rehabilitation. Lancet 1994; 344:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/38\">",
"      G&uuml;ell R, Casan P, Belda J, et al. Long-term effects of outpatient rehabilitation of COPD: A randomized trial. Chest 2000; 117:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/39\">",
"      O'Shea SD, Taylor NF, Paratz JD. Progressive resistance exercise improves muscle strength and may improve elements of performance of daily activities for people with COPD: a systematic review. Chest 2009; 136:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/40\">",
"      G&uuml;ell MR, de Lucas P, G&aacute;ldiz JB, et al. [Home vs hospital-based pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: a Spanish multicenter trial]. Arch Bronconeumol 2008; 44:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/41\">",
"      Maltais F, Bourbeau J, Shapiro S, et al. Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2008; 149:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/42\">",
"      Salman GF, Mosier MC, Beasley BW, Calkins DR. Rehabilitation for patients with chronic obstructive pulmonary disease: meta-analysis of randomized controlled trials. J Gen Intern Med 2003; 18:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/43\">",
"      Belman MJ, Kendregan BA. Exercise training fails to increase skeletal muscle enzymes in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1981; 123:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/44\">",
"      Maltais F, LeBlanc P, Simard C, et al. Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/45\">",
"      Casaburi R, Patessio A, Ioli F, et al. Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. Am Rev Respir Dis 1991; 143:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/46\">",
"      Casaburi R, Porszasz J, Burns MR, et al. Physiologic benefits of exercise training in rehabilitation of patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 155:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/47\">",
"      Zu Wallack, RL, Patel, K, Reardon, JZ, et al. Predictors of improvement in the 12-minute walking distance following a six-week outpatient pulmonary rehabilitation program. Chest 1991; 99:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/48\">",
"      Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based guidelines. ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel. American College of Chest Physicians. American Association of Cardiovascular and Pulmonary Rehabilitation. Chest 1997; 112:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/49\">",
"      O'Shea SD, Taylor NF, Paratz J. Peripheral muscle strength training in COPD: a systematic review. Chest 2004; 126:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/50\">",
"      Celli BR. The clinical use of upper extremity exercise. Clin Chest Med 1994; 15:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/51\">",
"      Ries AL, Ellis B, Hawkins RW. Upper extremity exercise training in chronic obstructive pulmonary disease. Chest 1988; 93:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/52\">",
"      Keens TG, Krastins IR, Wannamaker EM, et al. Ventilatory muscle endurance training in normal subjects and patients with cystic fibrosis. Am Rev Respir Dis 1977; 116:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/53\">",
"      Janaudis-Ferreira T, Hill K, Goldstein RS, et al. Resistance arm training in patients with COPD: A Randomized Controlled Trial. Chest 2011; 139:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/54\">",
"      Lake FR, Henderson K, Briffa T, et al. Upper-limb and lower-limb exercise training in patients with chronic airflow obstruction. Chest 1990; 97:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/55\">",
"      Martinez FJ, Vogel PD, Dupont DN, et al. Supported arm exercise vs unsupported arm exercise in the rehabilitation of patients with severe chronic airflow obstruction. Chest 1993; 103:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/56\">",
"      Costi S, Crisafulli E, Antoni FD, et al. Effects of unsupported upper extremity exercise training in patients with COPD: a randomized clinical trial. Chest 2009; 136:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/57\">",
"      Pan L, Guo YZ, Yan JH, et al. Does upper extremity exercise improve dyspnea in patients with COPD? A meta-analysis. Respir Med 2012; 106:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/58\">",
"      Puhan MA, B&uuml;sching G, Sch&uuml;nemann HJ, et al. Interval versus continuous high-intensity exercise in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2006; 145:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/59\">",
"      Coppoolse R, Schols AM, Baarends EM, et al. Interval versus continuous training in patients with severe COPD: a randomized clinical trial. Eur Respir J 1999; 14:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/60\">",
"      Vogiatzis I, Nanas S, Roussos C. Interval training as an alternative modality to continuous exercise in patients with COPD. Eur Respir J 2002; 20:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/61\">",
"      Beauchamp MK, Nonoyama M, Goldstein RS, et al. Interval versus continuous training in individuals with chronic obstructive pulmonary disease--a systematic review. Thorax 2010; 65:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/62\">",
"      Zainuldin R, Mackey MG, Alison JA. Optimal intensity and type of leg exercise training for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; :CD008008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/63\">",
"      Nasis IG, Vogiatzis I, Stratakos G, et al. Effects of interval-load versus constant-load training on the BODE index in COPD patients. Respir Med 2009; 103:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/64\">",
"      Tandon MK. Adjunct treatment with yoga in chronic severe airways obstruction. Thorax 1978; 33:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/65\">",
"      Holland AE, Hill CJ, Jones AY, McDonald CF. Breathing exercises for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 10:CD008250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/66\">",
"      Gosselink RA, Wagenaar RC, Rijswijk H, et al. Diaphragmatic breathing reduces efficiency of breathing in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/67\">",
"      Geddes EL, O'Brien K, Reid WD, et al. Inspiratory muscle training in adults with chronic obstructive pulmonary disease: an update of a systematic review. Respir Med 2008; 102:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/68\">",
"      Smith K, Cook D, Guyatt GH, et al. Respiratory muscle training in chronic airflow limitation: a meta-analysis. Am Rev Respir Dis 1992; 145:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/69\">",
"      Belman MJ, Botnick WC, Nathan SD, Chon KH. Ventilatory load characteristics during ventilatory muscle training. Am J Respir Crit Care Med 1994; 149:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/70\">",
"      Make B. Collaborative self-management strategies for patients with respiratory disease. Respir Care 1994; 39:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/71\">",
"      Atkins CJ, Kaplan RM, Timms RM, et al. Behavioral exercise programs in the management of chronic obstructive pulmonary disease. J Consult Clin Psychol 1984; 52:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/72\">",
"      Wedzicha JA, Bestall JC, Garrod R, et al. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J 1998; 12:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/73\">",
"      van Manen JG, Bindels PJ, Dekker FW, et al. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 2002; 57:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/74\">",
"      Lustig FM, Haas A, Castillo R. Clinical and rehabilitation regime in patients with chronic obstructive pulmonary diseases. Arch Phys Med Rehabil 1972; 53:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/75\">",
"      Clini EM, Crisafulli E. Exercise capacity as a pulmonary rehabilitation outcome. Respiration 2009; 77:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/76\">",
"      Dolmage TE, Evans RA, Hill K, et al. The effect of pulmonary rehabilitation on critical walk speed in patients with COPD: a comparison with self-paced walks. Chest 2012; 141:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/77\">",
"      ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/78\">",
"      Singh SJ, Morgan MD, Scott S, et al. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992; 47:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/79\">",
"      Hsia D, Casaburi R, Pradhan A, et al. Physiological responses to linear treadmill and cycle ergometer exercise in COPD. Eur Respir J 2009; 34:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/80\">",
"      Sewell L, Singh SJ, Williams JE, et al. How long should outpatient pulmonary rehabilitation be? A randomised controlled trial of 4 weeks versus 7 weeks. Thorax 2006; 61:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/81\">",
"      du Moulin M, Taube K, Wegscheider K, et al. Home-based exercise training as maintenance after outpatient pulmonary rehabilitation. Respiration 2009; 77:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38840/abstract/82\">",
"      Sabit R, Griffiths TL, Watkins AJ, et al. Predictors of poor attendance at an outpatient pulmonary rehabilitation programme. Respir Med 2008; 102:819.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1463 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-C266496ECC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_59_38840=[""].join("\n");
var outline_f37_59_38840=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mortality and exercise tolerance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Health care utilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effect of comorbidities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Durability of benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      COMPONENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Conditioning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Lower extremity exercise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Upper extremity exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Continuous versus interval exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Breathing retraining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ventilatory muscle training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Psychological support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MEASUREMENT OF EXERCISE CAPACITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PRACTICAL ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Attendance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1463\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1463|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/51/14142\" title=\"figure 1\">",
"      Effect on exercise capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/7/18558\" title=\"figure 2\">",
"      Effect on dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1463|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/8/40075\" title=\"table 1\">",
"      Benefits pulmonary rehab COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/10/15532\" title=\"table 2\">",
"      Borg scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/5/27739\" title=\"table 3\">",
"      Education in pulmonary rehab",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?22/50/23329?source=related_link\" title=\"calculator 1\">",
"      Calculator: BODE Index for COPD survival prediction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/35/25144?source=related_link\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/39/43639?source=related_link\">",
"      Nutritional support in advanced lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/52/14148?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/13/1236?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28549?source=related_link\">",
"      Respiratory muscle training and resting in COPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_59_38841="Patient selection for antiviral therapy for chronic hepatitis C virus infection";
var content_f37_59_38841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patient selection for antiviral therapy for chronic hepatitis C virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/59/38841/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/59/38841/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/59/38841/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/59/38841/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/59/38841/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/59/38841/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/59/38841/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H9641703\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to treat a patient with chronic hepatitis C virus (HCV) infection is based upon several factors, including the natural history and stage of the disease, the efficacy of therapy, and potential side effects. In general, patients being considered for treatment should have histologic and virologic evidence of chronic HCV infection. When identifying patients who are candidates for treatment, factors that are associated with a favorable response (eg, HCV genotype 2) should be weighed against factors associated with a lower likelihood of response (eg, older age). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review patient selection for antiviral therapy with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . Patients with HCV genotype 1 may also be candidates for treatment with a protease inhibitor (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    ). The treatment of acute HCV, as well as detailed information on the use of peginterferon, ribavirin, and protease inhibitors for the treatment of chronic HCV are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18554?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18026?source=see_link\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9643543\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2009 guidelines from the American Association for the Study of Liver Diseases (AASLD) are commonly used in making decisions about which patients to treat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/1\">",
"     1",
"    </a>",
"    ]. The guidelines can be accessed at",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     www.aasld.org/practiceguidelines/Pages/default.aspx",
"    </a>",
"    . It should be noted that these guidelines were issued prior to the availability of protease inhibitors for the treatment of HCV.",
"   </p>",
"   <p>",
"    In 2012, UK consensus guidelines were released regarding the treatment of genotype 1 patients with protease inhibitor based-triple therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/2\">",
"     2",
"    </a>",
"    ]. The discussion that follows is consistent with both the AASLD and UK consensus guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641710\">",
"    <span class=\"h1\">",
"     PATIENTS FOR WHOM THERAPY IS WIDELY ACCEPTED",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy is generally accepted for patients with all of the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least 18 years of age",
"     </li>",
"     <li>",
"      HCV RNA detectable in the serum",
"     </li>",
"     <li>",
"      Liver biopsy with chronic hepatitis and significant fibrosis (bridging fibrosis or higher)",
"     </li>",
"     <li>",
"      Compensated liver disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Total serum bilirubin &lt;1.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (25.7",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      INR &lt;1.5",
"     </li>",
"     <li>",
"      Albumin &gt;3.4",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (34",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"     </li>",
"     <li>",
"      Platelet count &gt;75,000",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      (75,000 x",
"      <span class=\"nowrap\">",
"       10(6)/L)",
"      </span>",
"     </li>",
"     <li>",
"      No evidence of hepatic encephalopathy or ascites",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acceptable hematological and biochemical indices",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hemoglobin &gt;13",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      for men and &gt;12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      for women",
"     </li>",
"     <li>",
"      Neutrophil count &gt;1500",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      (1500 x",
"      <span class=\"nowrap\">",
"       10(6)/L)",
"      </span>",
"     </li>",
"     <li>",
"      Creatinine &lt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (133",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Willing to be treated and to conform to treatment requirements",
"     </li>",
"     <li>",
"      No contraindications to treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the 2012 UK consensus guidelines recommend treatment with peginterferon,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , and a protease inhibitor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    ) for most patients with genotype 1, including patients who are treatment na&iuml;ve or who have failed prior therapy with peginterferon and ribavirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/2\">",
"     2",
"    </a>",
"    ]. The guidelines note that because of drug interactions, treatment of patients with HIV needs to be considered on a case-by-case basis. In addition, the guidelines do not currently recommend treatment in patients with decompensated liver disease, hepatitis B co-infection, or active cancer, or in patients who have undergone organ transplantation due to limited data. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18026?source=see_link\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641717\">",
"    <span class=\"h1\">",
"     PATIENTS WHO MAY BE CANDIDATES FOR THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy can be considered in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who failed prior treatment (nonresponders and relapsers) with standard interferon (with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      ) or peginterferon monotherapy. As noted above, the 2012 UK consensus guidelines recommend protease inhibitor-based triple therapy for patients with genotype 1, regardless of prior treatment response. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148834010#H148834010\">",
"       \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Treatment regimens'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link&amp;anchor=H12154514#H12154514\">",
"       \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\", section on 'Relapsers and nonresponders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Current users of illicit drugs or alcohol who are willing to participate in a substance abuse program (such as a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      program) or alcohol support program. (See",
"      <a class=\"local\" href=\"#H9641822\">",
"       'Active illicit drug use'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H9641829\">",
"       'Ongoing alcohol use'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Liver biopsy without fibrosis or with only mild fibrosis. (See",
"      <a class=\"local\" href=\"#H9641773\">",
"       'Persistently normal serum ALT'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H9641780\">",
"       'Mild liver disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Acute hepatitis C. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18554?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Coinfection with HIV. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11848?source=see_link\">",
"       \"Evaluation of the HIV-infected patient with chronic hepatitis C virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link&amp;anchor=H12154772#H12154772\">",
"       \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\", section on 'Coinfection with HIV'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Less than 18 years of age. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/2/6186?source=see_link&amp;anchor=H18#H18\">",
"       \"Hepatitis C virus infection in children\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic kidney disease either requiring or not requiring hemodialysis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37353?source=see_link\">",
"       \"Renal disease associated with hepatitis C virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31114?source=see_link\">",
"       \"Hepatitis C virus infection in patients on maintenance dialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decompensated cirrhosis. (See",
"      <a class=\"local\" href=\"#H9641801\">",
"       'Decompensated cirrhosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Recipient of a liver transplant. (See",
"      <a class=\"local\" href=\"#H9641808\">",
"       'Recurrence after liver transplantation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients with genotype 1 being considered for protease inhibitor based-triple therapy, caution should be exercised in patients with significant neutropenia, thrombocytopenia, or anemia, or who are taking medications that may interact with protease inhibitors (",
"      <a class=\"graphic graphic_table graphicRef78070 \" href=\"mobipreview.htm?11/30/11744\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef66181 \" href=\"mobipreview.htm?7/31/7664\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641724\">",
"    <span class=\"h1\">",
"     PATIENTS IN WHOM THERAPY IS CONTRAINDICATED",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral therapy with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for chronic HCV infection is contraindicated in patients who have one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major, uncontrolled depressive illness",
"     </li>",
"     <li>",
"      A kidney, heart, or lung transplant",
"     </li>",
"     <li>",
"      Autoimmune hepatitis or other conditions known to be exacerbated by interferon or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"     </li>",
"     <li>",
"      Untreated thyroid disease",
"     </li>",
"     <li>",
"      Severe concurrent disease such as severe hypertension, heart failure, significant coronary artery disease, poorly controlled diabetes, obstructive pulmonary disease",
"     </li>",
"     <li>",
"      Known hypersensitivity to drugs used to treat HCV",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therapy is also contraindicated in patients who are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Less than two years of age",
"     </li>",
"     <li>",
"      Pregnant, contemplating pregnancy (including men), or unwilling to assure contraception;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      is pregnancy category X due to significant",
"      <strong>",
"       teratogenic and embryocidal effects",
"      </strong>",
"      , and interferon is pregnancy category C (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28184?source=see_link&amp;anchor=H12#H12\">",
"       \"Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection\", section on 'Adverse effects of ribavirin'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641731\">",
"    <span class=\"h1\">",
"     INFLUENCE OF SIDE EFFECTS AND DRUG INTERACTION ON PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon monotherapy and combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    (for patients with genotype 1) are associated with several adverse effects. In some patients, treatment is contraindicated due to the risk of side effects, whereas in others, treatment should be undertaken with extreme caution. Conditions that may be complicated or worsened by side effects of treatment include significant anemia or leukopenia, pregnancy, severe depression or other psychiatric conditions, cardiac disease, poorly controlled diabetes, seizure disorders, and autoimmune or potentially immune-mediated diseases. In addition, treatment efficacy may be reduced with advancing age (particularly in those older than 60 years) because of an increased frequency of side effects requiring dose reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link&amp;anchor=H32984748#H32984748\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'Dose reduction and adherence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148836436#H148836436\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Side effects of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug interactions are also an important consideration in patients with genotype 1 who are being considered for treatment with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    and should be taken into account prior to starting therapy (",
"    <a class=\"graphic graphic_table graphicRef78070 \" href=\"mobipreview.htm?11/30/11744\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66181 \" href=\"mobipreview.htm?7/31/7664\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148834094#H148834094\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Drug interactions with protease inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18026?source=see_link&amp;anchor=H819606#H819606\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\", section on 'Potential drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641738\">",
"    <span class=\"h1\">",
"     PATIENT EVALUATION PRIOR TO TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641745\">",
"    <span class=\"h2\">",
"     Liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients undergo liver biopsy prior to treatment of chronic hepatitis C virus (HCV) infection, although the utility of a routine biopsy continues to be debated. A liver biopsy has many practical advantages in the care of patients with HCV in whom treatment is being considered, especially patients with genotype 1 infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39398?source=see_link\">",
"     \"Histologic scoring systems for chronic liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Advantages of a pretreatment liver biopsy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver histology is useful for predicting the stage and prognosis of the disease. Once identified, patients with cirrhosis should undergo periodic screening for hepatocellular carcinoma and esophageal varices. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/6/28778?source=see_link\">",
"       \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17337?source=see_link&amp;anchor=H21#H21\">",
"       \"Overview of the complications, prognosis, and management of cirrhosis\", section on 'Variceal bleeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A liver biopsy can establish the presence of concomitant diseases (such as hemochromatosis, alcoholic hepatitis, nonalcoholic",
"      <span class=\"nowrap\">",
"       steatohepatitis/nonalcoholic",
"      </span>",
"      fatty liver disease, and hepatic sarcoidosis) and the degree to which these conditions contribute to the patient's liver disease.",
"     </li>",
"     <li>",
"      Once treatment has started, baseline liver histology can assist in decisions regarding medication adjustments in patients who experience adverse effects (eg, the threshold to discontinue therapy may be relatively high in patients who have advanced histologic features).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the past, a liver biopsy was recommended in all patients with chronic hepatitis C prior to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/5\">",
"     5",
"    </a>",
"    ]. However, current guidelines recognize that a liver biopsy may not be necessary in all patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/1\">",
"     1",
"    </a>",
"    ]. In particular, a biopsy may not be required prior to treatment of patients with genotype 2 or 3 (in whom the virologic response rate is as high as 80 percent), provided that other causes of liver disease have been excluded.",
"   </p>",
"   <p>",
"    We generally perform a liver biopsy prior to treatment in patients with genotypes 1 and 4. For patients with genotypes 2 and 3 we do not routinely perform a pretreatment liver biopsy, but we do perform a liver biopsy in those who do not respond to therapy. Following treatment, we do not perform a repeat liver biopsy in patients who have had a sustained virologic response. By contrast, a repeat liver biopsy may be performed in two years (some authorities use longer intervals) to evaluate disease progression in patients who do not respond to treatment or who decline treatment. There is little information on the appropriate interval for subsequent evaluations.",
"   </p>",
"   <p>",
"    Noninvasive measures of hepatic fibrosis may be an alternative to liver biopsy in selected patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30650?source=see_link\">",
"     \"Noninvasive assessment of hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641752\">",
"    <span class=\"h2\">",
"     Evaluation for conditions that might affect therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to initiating antiviral therapy, a thorough evaluation for other types of liver disease should be obtained, and other medical conditions should be investigated since they may have a bearing on the treatment plan. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interferon is contraindicated in patients with active major depression because such patients are at risk for committing suicide during treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/62/24551?source=see_link\">",
"       \"Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Recognition and risk factors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/40/1674?source=see_link\">",
"       \"Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Treatment and prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with underlying autoimmune disorders may be at increased risk from therapy with interferon. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/41/36505?source=see_link\">",
"       \"Principles of interferon therapy in liver disease and the induction of autoimmunity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       Ribavirin",
"      </a>",
"      is contraindicated in patients who are pregnant, contemplating pregnancy (including men), or are unwilling to assure contraception (ribavirin is pregnancy category X due to significant",
"      <strong>",
"       teratogenic and embryocidal",
"      </strong>",
"      &nbsp;",
"      <strong>",
"       effects",
"      </strong>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28184?source=see_link&amp;anchor=H12#H12\">",
"       \"Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection\", section on 'Adverse effects of ribavirin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other liver diseases can interact adversely with chronic hepatitis C. As an example, alcohol abuse reduces the responsiveness to interferon, accelerates disease progression, and increases the risk of hepatocellular carcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. As a result, patients with chronic hepatitis C should be counseled not to drink alcohol. In addition, steatosis is associated with lower treatment response rates. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link&amp;anchor=H16092975#H16092975\">",
"       \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'Other predictors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Certain underlying diseases can modify the treatment plan. Patients with concurrent hereditary hemochromatosis or porphyria cutanea tarda, for example, should first be treated with phlebotomy to reduce iron accumulation.",
"     </li>",
"     <li>",
"      Patients with concurrent human immunodeficiency virus (HIV) infection have an accelerated rate of progression of HCV. The responsiveness to interferon is determined in part by the immune status and is lower overall than in patients infected with HCV alone. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11848?source=see_link\">",
"       \"Evaluation of the HIV-infected patient with chronic hepatitis C virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18026?source=see_link\">",
"       \"Treatment of hepatitis C virus infection in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients being treated for HCV with peginterferon and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      who have insulin resistance have lower sustained virologic response rates. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link&amp;anchor=H14409014#H14409014\">",
"       \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'Insulin resistance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple drug interactions exist with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      and need to be taken into account prior to starting one of these agents. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148834094#H148834094\">",
"       \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Drug interactions with protease inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641759\">",
"    <span class=\"h1\">",
"     SPECIAL SITUATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the decision to offer therapy to a treatment-na&iuml;ve patient with a detectable viral load, significant chronic hepatitis and fibrosis on liver biopsy, and without any contraindications to treatment is usually straight-forward, the decision is more complicated in patients who do not meet these criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641766\">",
"    <span class=\"h2\">",
"     Relapsers and nonresponders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to retreat patients who fail to respond to treatment or who relapse after treatment should take into account the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The previous type of response",
"     </li>",
"     <li>",
"      The previous therapy and the difference in the potency of the new therapy",
"     </li>",
"     <li>",
"      The severity of the underlying liver disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39398?source=see_link\">",
"       \"Histologic scoring systems for chronic liver disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Viral genotype and other predictive factors of response (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link\">",
"       \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tolerance and compliance with previous therapy",
"     </li>",
"     <li>",
"      HCV genotype since protease inhibitor based-triple therapy is an option in patients with genotype 1",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, IL28B genotype (CC, CT, or TT) may be a factor to take into consideration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In one study of patients who had failed prior therapy for HCV genotype 1, IL28B genotype CC was associated with an increased chance of attaining an SVR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link&amp;anchor=H16092947#H16092947\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'IL28B polymorphisms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641773\">",
"    <span class=\"h2\">",
"     Persistently normal serum ALT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 30 percent of patients with chronic hepatitis C virus (HCV) infection have a persistently normal serum alanine aminotransferase (ALT) level. The optimal management of such patients remains controversial. As a group, they may have a better prognosis than those who have elevated serum ALT levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15847?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases\", section on 'Course and management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A role for treatment is supported by the observation that some of these patients have substantial inflammation on liver biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, the response to combination therapy with peginterferon plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in patients with normal serum aminotransferases is similar to the response in those with elevated aminotransferase levels.",
"   </p>",
"   <p>",
"    It is reasonable to withhold treatment in patients with persistently normal serum ALT levels who have characteristics associated with slower rates of progression of hepatic fibrosis, such as HCV acquisition before the age of 35 years, female sex, alcohol abstinence, and no or minimal fibrosis on liver biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/13\">",
"     13",
"    </a>",
"    ]. By contrast, we offer treatment to patients who do not fit this profile and whose initial biopsies show moderate activity or some degree of fibrosis because the risk of disease progression is increased in such patients. We usually treat these patients using combination therapy with peginterferon plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (plus a protease inhibitor for patients with genotype 1). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148834010#H148834010\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Treatment regimens'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641780\">",
"    <span class=\"h2\">",
"     Mild liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have a persistent elevation in serum ALT levels but do not have fibrosis and have minimal necroinflammatory changes are likely to have slow disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/14\">",
"     14",
"    </a>",
"    ]. Such patients can be monitored periodically. However, the decision to treat should be individualized. We treat these patients in the same way as patients with a persistently normal ALT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641787\">",
"    <span class=\"h2\">",
"     Extrahepatic manifestations of HCV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon alfa has been used with reasonable success for the treatment of some extrahepatic manifestations of HCV infection, such as essential mixed cryoglobulinemia and glomerulonephritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/52/36682?source=see_link\">",
"     \"Treatment of the mixed cryoglobulinemia syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15498?source=see_link\">",
"     \"Extrahepatic manifestations of hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641794\">",
"    <span class=\"h2\">",
"     Advanced hepatic fibrosis and compensated cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of treatment in patients with advanced hepatic fibrosis or compensated cirrhosis has been derived mostly from subgroup analyses of large clinical trials. The analyses have suggested that the response rate is lower in these patients than in those without cirrhosis. The use of growth factors (such as erythropoietin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    , and granulocyte macrophage colony-stimulating factor) may be helpful during treatment by limiting the need for reductions in the dose of antiviral therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2010 meta-analysis of 26 studies examined the association between achieving a sustained virologic response (SVR, defined as a negative HCV RNA six months after the completion of therapy) and adverse outcomes in patients with advanced fibrosis or cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients with advanced fibrosis or cirrhosis who underwent treatment but did not attain an SVR had a liver-related mortality rate of 2.7 percent per year. Patients with chronic HCV and advanced fibrosis who did achieve an SVR had a much lower risk of liver-related mortality (relative risk [RR] 0.19; 95% confidence interval 0.10-0.37). Patients who attained an SVR were also significantly less likely to develop hepatocellular carcinoma (RR 0.32) or hepatic decompensation (RR 0.13).",
"   </p>",
"   <p>",
"    In a study of patients with advanced hepatitis C (Ishak fibrosis score of at least 3), 140 patients who attained an SVR were compared with 309 patients who had no response to therapy and 77 patients who experienced viral breakthrough or relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients were followed for a median of 86, 85, and 79 months, respectively. Compared with patients who had no response to treatment, the patients who attained an SVR had significantly lower morbidity rates (21 versus 2 percent) and lower mortality rates (27 versus 3 percent). There were no significant differences in the morbidity and mortality rates when the patients who had attained an SVR were compared with the patients who experienced viral breakthrough or relapse.",
"   </p>",
"   <p>",
"    Based upon the improved prognosis in patients with advanced fibrosis or compensated cirrhosis who receive treatment with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , we suggest that these patients receive treatment if they are otherwise candidates. Patients with genotype 1 should also receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    , provided there are no contraindications. However, telaprevir and boceprevir should be used cautiously in patients with cirrhosis. There appear to be some patients with apparently compensated cirrhosis who are at risk of decompensation when treated with a protease inhibitor in combination with peginterferon and ribavirin, although the risk factors for decompensation among these patients are not clear. Hepatic decompensation in patients with cirrhosis was not seen in the pivotal clinical trials of protease inhibitors combined with peginterferon and ribavirin, but it has been observed in clinical practice and registry-type studies. Preliminary results from a study that included 455 patients with hepatitis C and cirrhosis who were treated with either telaprevir or boceprevir found that serious adverse events occurred in 38 to 49 percent of patients, with 4 percent of patients developing hepatic decompensation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/17\">",
"     17",
"    </a>",
"    ]. It has been speculated that patient selection was more rigorous in the clinical trials, accounting for the lack of hepatic decompensation in those trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15785?source=see_link\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641801\">",
"    <span class=\"h2\">",
"     Decompensated cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary treatment for patients with decompensated cirrhosis is liver transplantation. However, experienced hepatologists may consider antiviral therapy in patients with mild degrees of decompensation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. Decompensated cirrhosis refers to a history of or the presence of, ascites, hepatic encephalopathy or jaundice (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 3",
"    </a>",
"    ). In addition, marked abnormalities in serum albumin, bilirubin, and prothrombin times are features of decompensation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/5/16474?source=see_link\">",
"     \"Liver transplantation for hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17337?source=see_link\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few reports have described treatment of patients with decompensated cirrhosis with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/19\">",
"     19",
"    </a>",
"    ]. Treatment has been associated with substantial side effects and dropouts, but some patients have achieved an SVR, which has been associated with improved survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. At present, such treatment should only be attempted at centers with experience and systems to care for such patients, preferably in the context of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641808\">",
"    <span class=\"h2\">",
"     Recurrence after liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence of HCV occurs in more than 95 percent of patients after liver transplantation. Disease progression in this setting is more rapid, and complications are more frequent than in immunocompetent patients with HCV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/14\">",
"     14",
"    </a>",
"    ]. Disease progression correlates with HCV RNA levels at the time of transplantation, the age of the organ donor, and the degree of immunosuppression in the post-transplant period.",
"   </p>",
"   <p>",
"    There are few high-quality studies to guide treatment of HCV after liver transplantation. Antiviral therapy is generally initiated only if there is significant histologic liver injury. However, the therapeutic options are limited in this population, and rigorous clinical trials are difficult to conduct. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/5/16474?source=see_link&amp;anchor=H15#H15\">",
"     \"Liver transplantation for hepatitis C virus infection\", section on 'Treatment of recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641815\">",
"    <span class=\"h2\">",
"     Kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The renal diseases associated with HCV and issues related to HCV infection in patients on maintenance dialysis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641822\">",
"    <span class=\"h2\">",
"     Active illicit drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether treatment with interferon-based regimens should be offered to patients who are actively using illicit drugs is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Treatment of such patients should be individualized. The 2009 guideline issued by the AASLD recommends that treatment should",
"    <strong>",
"     not",
"    </strong>",
"    &nbsp;",
"    <strong>",
"     be withheld",
"    </strong>",
"    from those who currently use illicit drugs or those who are in a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance program, provided that they wish to be treated and are willing and able to maintain close monitoring and practice contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important adjunct to treatment is continued support from drug abuse and psychiatric counseling services. HCV therapy can be successful even when patients have not been abstinent from continued drug use or are receiving pharmacologic treatments for drug dependency (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    or subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/21,23-25\">",
"     21,23-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641829\">",
"    <span class=\"h2\">",
"     Ongoing alcohol use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol is an important cofactor in HCV disease progression, and the amount of alcohol that is safe during treatment is unknown. While a history of alcohol abuse is not an absolute contraindication to treatment, continued alcohol use decreases the response to therapy, and patients should be encouraged to abstain from alcohol. In patients who continue to drink alcohol, treatment should be performed along with efforts to treat the alcohol abuse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9496?source=see_link\">",
"     \"Hepatitis C and alcohol\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study demonstrated that patients with ongoing alcohol use or less than six months of sobriety prior to treatment can be successfully treated using a multi-disciplinary approach that included addiction care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/26\">",
"     26",
"    </a>",
"    ]. An SVR was achieved in 35 of 73 patients (48 percent), which was similar to the rate seen in matched controls who did not drink (49 percent SVR rate). Factors associated with an increased SVR rate included a low viral load and length of abstinence during treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H236106227\">",
"    <span class=\"h2\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have examined the treatment of older adults (&ge;60 to 65 years of age) with HCV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. As is the case with younger patients, HCV genotype and changes in viral load during therapy are important predictors of treatment response in older patients. However, older patients often have comorbid illnesses and may be less tolerant of the side effects of treatment, such as anemia than younger patients. In addition, older adults are more likely to be taking medications that could lead to drug interactions (",
"    <a class=\"graphic graphic_table graphicRef78070 \" href=\"mobipreview.htm?11/30/11744\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66181 \" href=\"mobipreview.htm?7/31/7664\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=see_link&amp;anchor=H15544702#H15544702\">",
"     \"Overview of the management of chronic hepatitis C virus infection\", section on 'Side effects of treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148834094#H148834094\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Drug interactions with protease inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In deciding which older patients with HCV to treat, we first determine if the patient has any contraindications to treatment. If no contraindications are present, we then look for evidence of significant hepatic fibrosis (bridging fibrosis or cirrhosis), either with a liver biopsy or noninvasive testing. Noninvasive testing may be particularly attractive in patients who do not appear to have significant fibrosis based upon their physical examination and blood tests (eg, no stigmata of chronic liver disease, normal hepatic synthetic function). However, in patients with signs suggestive significant fibrosis, we prefer to obtain a liver biopsy. (See",
"    <a class=\"local\" href=\"#H9641724\">",
"     'Patients in whom therapy is contraindicated'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30650?source=see_link\">",
"     \"Noninvasive assessment of hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients without significant fibrosis, regardless of genotype, we prefer to manage the patient expectantly.",
"   </p>",
"   <p>",
"    In patients with significant fibrosis, our approach depends upon the patient's HCV genotype. In patients HCV genotype 1 or 4, we obtain an IL28B genotype to determine if the patient is likely to respond to therapy. Our preference is to withhold antiviral therapy if the patient does not have a favorable genotype (CC at the rs12979860 polymorphic site). However, in an otherwise healthy patient with HCV genotype 1 or 4 and a favorable IL28B genotype, treatment is reasonable with close monitoring for side effects. Similarly, treatment is reasonable in otherwise healthy patients with significant fibrosis who have HCV genotype 2 or 3 (regardless IL28B genotype) since treatment response rates are high in this population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link&amp;anchor=H16092947#H16092947\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'IL28B polymorphisms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641836\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of children with hepatitis C virus infection is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/2/6186?source=see_link&amp;anchor=H18#H18\">",
"     \"Hepatitis C virus infection in children\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9641843\">",
"    <span class=\"h1\">",
"     PROPORTION OF PATIENTS WHO RECEIVE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proportion of patients with chronic HCV infection who are treated has not been accurately determined, but the reported rate has ranged from 12 to 28 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of 327 patients referred to a liver clinic in a metropolitan area, 83 (28 percent) were ultimately treated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/30\">",
"       30",
"      </a>",
"      ]. The most common reasons for a lack of treatment were failure to adhere to evaluation procedures (37 percent), medical or psychiatric contraindications (34 percent), patient preferences (11 percent), absence of HCV RNA (10 percent), and normal liver enzymes (5 percent).",
"     </li>",
"     <li>",
"      Among 134,934 HCV-infected United States veterans, only 12 percent were treated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/31\">",
"       31",
"      </a>",
"      ]. Furthermore, of those on treatment who were followed for more than one year, only 23 percent completed a full 48-week course of treatment. Noncompletion was significantly associated with baseline anemia and depression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other risk factors for nontreatment include relatively inexperienced providers, older age, single patients, hepatic dysfunction, genotype 1, African American race with genotype 1, and anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38841/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/39/32370?source=see_link\">",
"       \"Patient information: Hepatitis C (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/4/17478?source=see_link\">",
"       \"Patient information: Hepatitis C (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9643002\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decision to treat a patient with chronic HCV infection is based upon several factors, including the natural history of the disease, the stage of fibrosis, and the efficacy and adverse effects related to therapy. In general, patients being considered for treatment should have histologic and virologic evidence of chronic HCV infection. (See",
"      <a class=\"local\" href=\"#H9641703\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of the management of chronic hepatitis C virus infection\", section on 'Guidelines'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H9641745\">",
"       'Liver biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is generally indicated in treatment-na&iuml;ve patients with a detectable viral load, significant chronic hepatitis and fibrosis on liver biopsy, and without any contraindications to treatment. (See",
"      <a class=\"local\" href=\"#H9641710\">",
"       'Patients for whom therapy is widely accepted'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment decisions in other populations can be more difficult. (See",
"      <a class=\"local\" href=\"#H9641759\">",
"       'Special situations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The decision to retreat patients who fail to respond to treatment or who relapse after treatment should take into account multiple factors, including the previous type of therapy, the severity of the underlying liver disease, and factors that predict a response to treatment, such as viral genotype. (See",
"      <a class=\"local\" href=\"#H9641766\">",
"       'Relapsers and nonresponders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest monitoring without specific treatment for women with a persistently normal ALT or mild liver disease who acquired the disease under the age of 35 years, do not drink alcohol, and have no or minimal fibrosis on liver biopsy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9641773\">",
"       'Persistently normal serum ALT'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9641780\">",
"       'Mild liver disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment with peginterferon plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for patients with a persistently normal ALT or mild liver disease who do not fit the above profile and whose initial biopsies show moderate activity or some degree of fibrosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients with genotype 1 should also receive a protease inhibitor (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9641773\">",
"       'Persistently normal serum ALT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link\">",
"       \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link\">",
"       \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest treatment with peginterferon and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for patients with advanced fibrosis or compensated cirrhosis who are otherwise candidates for antiviral therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). As above, patients with genotype 1 should also receive a protease inhibitor. While the response rate to treatment in these patients is lower than the response rate in patients without cirrhosis, achievement of a sustained virologic response in such patients is associated with decreased rates of mortality, hepatocellular carcinoma, and hepatic decompensation. (See",
"      <a class=\"local\" href=\"#H9641794\">",
"       'Advanced hepatic fibrosis and compensated cirrhosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with active substance abuse should receive ongoing support from",
"      <span class=\"nowrap\">",
"       drug/alcohol",
"      </span>",
"      abuse and psychiatric counseling services during antiviral treatment. (See",
"      <a class=\"local\" href=\"#H9641822\">",
"       'Active illicit drug use'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9641829\">",
"       'Ongoing alcohol use'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/1\">",
"      Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/2\">",
"      Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012; 35:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/3\">",
"      Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/4\">",
"      Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997; 26:57S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/5\">",
"      The National Institutes of Health Consensus Development Conference. Management of hepatitis C. Hepatology 1997; 26 Suppl 1:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/6\">",
"      Okazaki T, Yoshihara H, Suzuki K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994; 29:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/7\">",
"      Nalpas B, Driss F, Pol S, et al. Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease. J Hepatol 1991; 12:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/8\">",
"      Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002; 36:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/9\">",
"      Chevaliez S, Soulier,A, Hezode C, et, al. The IL28B genotype is a major determinant in the induction of a virological response by high-dose peginterferon and ribavirin in null-resonders to standard-of-care therapy. Hepatology 2010; 52:383A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/10\">",
"      O'Brien TR, Everhart JE, Chung RT, et, al. An IL28B genotype-based model for personalized prediction of response to pegylated-interferon-alfa and ribavirin in the treatment of chronic hepatitis C. Hepatology 2010; 52:382A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/11\">",
"      Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/12\">",
"      Puoti C, Magrini A, Stati T, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/13\">",
"      Missale G, Cariani E, Lamonaca V, et al. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients. Hepatology 1997; 26:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/14\">",
"      National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997; 26:2S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/15\">",
"      Singal AG, Volk ML, Jensen D, et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/16\">",
"      Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/17\">",
"      Hezode C, Dorival C, Zoulim T. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non-responders. First results of the French Early Access Program (ANRS CO20-CUPIC). J Hepatol 2012; 56:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/18\">",
"      Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/19\">",
"      Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/20\">",
"      Iacobellis A, Perri F, Valvano MR, et al. Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol 2011; 9:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/21\">",
"      Jeffrey GP, MacQuillan G, Chua F, et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology 2007; 45:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/22\">",
"      Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/23\">",
"      Mauss S, Berger F, Goelz J, et al. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/24\">",
"      Bonkovsky HL, Tice AD, Yapp RG, et al. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol 2008; 103:2757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/25\">",
"      Dimova RB, Zeremski M, Jacobson IM, et al. Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis. Clin Infect Dis 2013; 56:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/26\">",
"      Le Lan C, Guillygomarc'h A, Danielou H, et al. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. J Hepatol 2012; 56:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/27\">",
"      Giannini EG, Basso M, Savarino V, Picciotto A. Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. Dig Dis Sci 2010; 55:3193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/28\">",
"      Tsui JI, Currie S, Shen H, et al. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. Dig Dis Sci 2008; 53:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/29\">",
"      Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol 2007; 102:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/30\">",
"      Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/31\">",
"      Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int 2010; 30:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38841/abstract/32\">",
"      Kanwal F, Hoang T, Spiegel BM, et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 2007; 46:1741.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15832 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7CC26F0507-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_59_38841=[""].join("\n");
var outline_f37_59_38841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9643002\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9641703\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9643543\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9641710\">",
"      PATIENTS FOR WHOM THERAPY IS WIDELY ACCEPTED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9641717\">",
"      PATIENTS WHO MAY BE CANDIDATES FOR THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9641724\">",
"      PATIENTS IN WHOM THERAPY IS CONTRAINDICATED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9641731\">",
"      INFLUENCE OF SIDE EFFECTS AND DRUG INTERACTION ON PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9641738\">",
"      PATIENT EVALUATION PRIOR TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9641745\">",
"      Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9641752\">",
"      Evaluation for conditions that might affect therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9641759\">",
"      SPECIAL SITUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9641766\">",
"      Relapsers and nonresponders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9641773\">",
"      Persistently normal serum ALT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9641780\">",
"      Mild liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9641787\">",
"      Extrahepatic manifestations of HCV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9641794\">",
"      Advanced hepatic fibrosis and compensated cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9641801\">",
"      Decompensated cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9641808\">",
"      Recurrence after liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9641815\">",
"      Kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9641822\">",
"      Active illicit drug use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9641829\">",
"      Ongoing alcohol use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H236106227\">",
"      Older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9641836\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9641843\">",
"      PROPORTION OF PATIENTS WHO RECEIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9643002\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/15832\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/15832|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/30/11744\" title=\"table 1\">",
"      Telaprevir drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/31/7664\" title=\"table 2\">",
"      Boceprevir drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/21/8540\" title=\"table 3\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15847?source=related_link\">",
"      Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18554?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11848?source=related_link\">",
"      Evaluation of the HIV-infected patient with chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9496?source=related_link\">",
"      Hepatitis C and alcohol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/2/6186?source=related_link\">",
"      Hepatitis C virus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31114?source=related_link\">",
"      Hepatitis C virus infection in patients on maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39398?source=related_link\">",
"      Histologic scoring systems for chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/5/16474?source=related_link\">",
"      Liver transplantation for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28184?source=related_link\">",
"      Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/62/24551?source=related_link\">",
"      Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Recognition and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/40/1674?source=related_link\">",
"      Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30650?source=related_link\">",
"      Noninvasive assessment of hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=related_link\">",
"      Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/6/28778?source=related_link\">",
"      Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/41/36505?source=related_link\">",
"      Principles of interferon therapy in liver disease and the induction of autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15785?source=related_link\">",
"      Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18026?source=related_link\">",
"      Treatment of hepatitis C virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/52/36682?source=related_link\">",
"      Treatment of the mixed cryoglobulinemia syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_59_38842="Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation";
var content_f37_59_38842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/59/38842/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/59/38842/contributors\">",
"     Bonnie L Bermas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/59/38842/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/59/38842/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/59/38842/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/59/38842/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/59/38842/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/59/38842/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/59/38842/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory disorders such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD) often occur in women of childbearing age. When considering treatment options, a major tenet of treating women during pregnancy is to minimize or avoid medications that may increase maternal or fetal risk. However, the relative benefits and risks to the mother and fetus of using a particular medication to maintain disease control or to treat active disease during pregnancy depend upon the specific clinical context and may be influenced by the stage of the pregnancy and by other factors.",
"   </p>",
"   <p>",
"    For practical purposes, we divide the antiinflammatory and immunosuppressive medications used to treat inflammatory disorders into four categories, recognizing that there are differences in risks between medications in any category and that some drugs may fall into more than one category depending upon various factors. These categories are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minimal fetal or maternal risk",
"     </li>",
"     <li>",
"      Selective use allowed during pregnancy",
"     </li>",
"     <li>",
"      Moderate to high risk of fetal harm",
"     </li>",
"     <li>",
"      Unknown risk",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is limited information regarding the toxicities and teratogenetic potential of many antiinflammatory and immunosuppressive medications in pregnant women because of the ethical issues involved in testing such drugs in the setting of pregnancy. The following discussion presents the risks of these medications in pregnancy and lactation according to a similar format for each drug:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Animal use data",
"     </li>",
"     <li>",
"      Data from use in human pregnancy",
"     </li>",
"     <li>",
"      Specific statement regarding lactation",
"     </li>",
"     <li>",
"      Overall recommendations regarding use in pregnancy and lactation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Information related to the toxicity and teratogenicity of immunosuppressive medications in pregnant women must be interpreted in light of the background risk of adverse pregnancy outcomes in all women. Major birth defects are defined as events of medical, surgical, or cosmetic significance. It is estimated that the prevalence of major birth defects is 2 to 4 percent among live-born infants. This prevalence does not vary among ethnic groups (",
"    <a class=\"graphic graphic_table graphicRef79937 \" href=\"mobipreview.htm?35/15/36092\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7386?source=see_link\">",
"     \"Genetic and environmental causes of birth defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The uses of antiinflammatory and immunosuppressive medications in pregnancy and during lactation will be reviewed here. Approaches to the therapy of individual conditions are presented separately in the appropriate topic reviews. Additional information regarding each medication is provided in the drug information topic for each agent. Strategies for the preservation of fertility in patients undergoing cytotoxic therapy, as well as the cryopreservation of sperm, oocytes, and embryos, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=see_link\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MINIMAL FETAL OR MATERNAL RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following medications are viewed as relatively safe in pregnancy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       Hydroxychloroquine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonsteroidal antiinflammatory drugs (NSAIDs) and low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    present very low fetal or maternal risk when their use is limited to the time from a positive pregnancy test up to the beginning of the third trimester. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'NSAIDs and aspirin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hydroxychloroquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    (HCQ) is an antimalarial agent. Specific details regarding the use and monitoring of this medication are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=see_link\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HCQ is stored in tissues, particularly the liver, and has a half-life of approximately eight weeks. Thus, unless pregnancy is planned, fetal exposure cannot be avoided by discontinuing the medication at the time the pregnancy is discovered.",
"   </p>",
"   <p>",
"    HCQ crosses the placenta. However, there does not appear to be fetal toxicity with HCQ doses used for the treatment of connective tissue disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/1\">",
"     1",
"    </a>",
"    ]. In a retrospective series of 257 pregnancies from the Johns Hopkins Lupus Cohort, the pregnancies were divided into three groups: mothers with no HCQ exposure during pregnancy (n = 163), those in whom HCQ was used continuously (n = 56), and those in whom HCQ was stopped during the first trimester or within three months of conception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/2\">",
"     2",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were no differences in the three groups in terms of miscarriages, stillbirths, pregnancy losses, and congenital abnormalities.",
"     </li>",
"     <li>",
"      SLE flares were more common, and the mean",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      doses were higher among the women who stopped taking HCQ during pregnancy. However, serious complications of SLE were not more common in that group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The apparent safety of HCQ in pregnancy was corroborated by the results of two other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 36 pregnancies in women with SLE exposed to HCQ during pregnancy, the percentage of women with successful pregnancies was not different than that of 53 control women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 133 pregnancies during which the mother was exposed to HCQ, 88 percent of the pregnancies were successful, compared with 84 percent in a comparison group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/4\">",
"       4",
"      </a>",
"      ]. During a mean of 108 months&rsquo; follow-up of the children resulting from these pregnancies, there was no difference in the rate of growth, and there was no evidence of visual or developmental abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash; HCQ is found in human breast milk. Breastfed infants may be exposed to 2 percent of the maternal dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/5\">",
"       5",
"      </a>",
"      ]. The American Academy of Pediatrics (AAP) considers use of HCQ compatible with breastfeeding.",
"     </li>",
"     <li>",
"      Recommendation &mdash; We suggest continuing HCQ during pregnancy and lactation in patients with SLE to help prevent disease flares.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sulfasalazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    (SSZ) possesses both antiinflammatory properties mediated by its 5-aminosalicylic acid moiety and antibacterial characteristics associated with its sulfapyridine moiety. Specific details regarding the use and monitoring of this medication are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20344?source=see_link\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/27/2490?source=see_link\">",
"     \"Sulfasalazine in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SSZ has been used since its development in the 1940s as an agent for the treatment of IBD and RA. Most of the information regarding the use of this medication during pregnancy is gleaned from its effects upon patients with IBD.",
"   </p>",
"   <p>",
"    SSZ and its metabolite sulfapyridine cross the placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/6\">",
"     6",
"    </a>",
"    ]. However, neither SSZ nor sulfapyridine causes significant displacement of bilirubin from albumin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, SSZ use by pregnant women does not appear to increase the risk of kernicterus.",
"   </p>",
"   <p>",
"    Birth defects have been recorded in several case reports of patients treated with SSZ. Reported congenital anomalies include reports of cleft lip and palate, hydrocephalus, macrocephaly, ventricular septal defect, and a coarctation of the aorta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. A large, multicenter, case-control study reported teratogenic effects of dihydrofolate reductase inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    and five other agents) taken during the first trimester, including cardiovascular defects (relative risk [RR] 3.4, 95% CI 1.8-6.4) and oral clefts (RR 2.6, 95% CI 1.1-6.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/10\">",
"     10",
"    </a>",
"    ]. Maternal use of multivitamins with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    (0.4 mg daily) reduced the risk.",
"   </p>",
"   <p>",
"    However, case series of patients have shown no increased incidence of adverse pregnancy outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study reported 247 IBD patients who had a total of 240 births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/11\">",
"     11",
"    </a>",
"    ]. There was no increased risk of fetal anomalies in patients treated with SSZ alone or with the combination of glucocorticoids and SSZ. In addition, none of the 107 mothers who received SSZ during pregnancy had babies with jaundice.",
"   </p>",
"   <p>",
"    Use of SSZ:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash; The amount of SSZ found in the breast milk and in the serum of nursing babies is low [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Sulfapyridine concentrations in the serum of nursing babies is 40 percent that of the level of the metabolite in mothers. Diarrhea in a nursing child whose mother was taking SSZ has been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/15\">",
"       15",
"      </a>",
"      ]. The consensus on the use of SSZ in lactating mothers is that the practice is safe. The AAP recommends the use of SSZ during lactation with caution.",
"     </li>",
"     <li>",
"      Recommendation &mdash; SSZ does not appear to increase the risk of adverse fetal outcome, if the mother is taking a multivitamin with at least 0.4 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      , or to have adverse affects during lactation. For women with active inflammatory disease who require treatment during pregnancy, SSZ therapy is a viable option with relatively low risk. Concomitant folate supplementation is recommended, and the dose of SSZ should not exceed 2",
"      <span class=\"nowrap\">",
"       grams/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/16\">",
"       16",
"      </a>",
"      ]. If SSZ use is not considered essential to the health of the mother during pregnancy, the drug should be discontinued for one full menstrual cycle before attempts at conception.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SELECTIVE USE ALLOWED DURING PREGNANCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     NSAIDs and aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative safety and the nature of the risks during pregnancy and lactation of nonsteroidal antiinflammatory drugs (NSAIDs), including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other salicylates, are generally dependent upon the timing of use during pregnancy, the dose, and the specific class of medication. These drugs are widely used for their analgesic, antiinflammatory, and antiplatelet properties. Specific details regarding the use and monitoring of these medications are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5703?source=see_link\">",
"     \"NSAIDs: Therapeutic use and variability of response in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/47/2807?source=see_link\">",
"     \"Aspirin: Mechanism of action, major toxicities, and use in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    has been used for years in patients requiring NSAID therapy during pregnancy. Although some case-control studies have reported associations between human congenital malformations and aspirin use early in gestation, no consistent adverse outcome attributable to drug use has been observed. Salicylates readily cross the placenta, but a 2002 meta-analysis did not find evidence of an overall increase in risk of congenital defects associated with first trimester use of aspirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/17\">",
"     17",
"    </a>",
"    ]. A population-based study involving 110,783 pregnancies, including 5267 in which mothers were exposed to NSAIDs during the first trimester, found no significant increase in risk of major congenital malformations in general, although a possible increased risk of musculoskeletal malformations was suggested among the 114 patients who received cyclooxygenase (COX)-2 selective inhibitors (coxibs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data are supported by a prospective study of 88 pregnant women, which compared the outcome in 45 who were treated with NSAIDs for a mean of 15.3 weeks during pregnancy with the outcomes in 43 patients who did not receive drug therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/19\">",
"     19",
"    </a>",
"    ]. There were no differences in pregnancy outcome, duration of labor, complications at delivery, or neonatal health between the two groups.",
"   </p>",
"   <p>",
"    Low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    has been used to prevent preeclampsia, providing further evidence of its relative safety. Although the efficacy of low-dose aspirin for this indication is controversial, individual patient data from over 32,000 women and their babies showed that low-dose aspirin had no significant effect on the risk of bleeding events either in the women or in their babies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/20\">",
"     20",
"    </a>",
"    ]. Low doses of aspirin have also been used during pregnancy in selected patients with the antiphospholipid syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41609?source=see_link\">",
"     \"Prevention of preeclampsia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/0/44041?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, third trimester use of these agents may pose greater risk. The inhibition of prostaglandin synthesis by NSAIDs or by high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy in the third trimester has the potential for causing premature closure of the ductus arteriosus;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    appear to have much stronger ductal effects than aspirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. High-dose aspirin near delivery may increase the risk of fetal or neonatal bleeding or bruising, although data are inconsistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/21,23-25\">",
"     21,23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports and some small series have shown transient infertility in some women treated with NSAIDs, which appears to be mediated by inhibition of the rupture of the luteinized follicle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several observational studies have suggested that NSAID use may increase the risk of spontaneous abortion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]; other studies have not detected any increased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/32\">",
"     32",
"    </a>",
"    ]. A large, nested, case-control study using data from a Canadian registry suggested that exposure to (non-salicylate) nonselective and COX-2 selective NSAIDs in the first 20 weeks of pregnancy may be associated with an increased risk of miscarriage (odds ratio 2.4, 95% CI 2.1-2.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/29\">",
"     29",
"    </a>",
"    ]. These findings should be interpreted with significant caution. The control group was not matched for maternal age, which is an important risk factor for spontaneous abortion, and smoking status and use of over the counter NSAIDs were not known. In addition, the studies are limited by lack of adjustment for the disorder for which NSAIDs were taken, and the effects of other comorbidities and medications, as well as dosing regimens, were not fully analyzed. Further study is needed to determine whether NSAIDs actually increase the risk of spontaneous abortion and whether short-term use (eg, &lt;24 to 48 hours) is harmful.",
"   </p>",
"   <p>",
"    Use of NSAIDs and salicylates:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash; NSAIDs are excreted in breast milk in very small amounts. It is generally agreed that salicylates in normally recommended doses are not harmful to nursing infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/24\">",
"       24",
"      </a>",
"      ]. Many of these drugs appear compatible with breastfeeding but should be used with caution. (See drug information for each medication.)",
"     </li>",
"     <li>",
"      Recommendation &mdash; We advise that women avoid NSAIDs during a planned conception cycle until either a confirmed pregnancy test or menstruation occurs, as these medications can impede implantation. Women should be counseled regarding the possibility that NSAID use may be associated with a small increased risk of spontaneous abortion before 20 weeks of gestation. This is particularly important for women with a prior history of spontaneous abortion. From week 30 of gestation onward, we suggest avoiding the use of these drugs altogether, because of the risk of premature closure of the ductus arteriosus, with the exception of low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      being given for obstetric-related indications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids (GCs) have a variety of side effects when given systemically or by inhalation. Specific details regarding the use and monitoring of these drugs, including the use of inhaled agents during pregnancy and prenatal use to promote fetal lung maturity in women at risk of premature birth, are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=see_link\">",
"     \"Pharmacologic use of glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=see_link\">",
"     \"Major side effects of inhaled glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29226?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of asthma during pregnancy\", section on 'Inhaled'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most commonly used short-acting GCs are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    . The most common long-acting agents are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    . Prednisone and prednisolone cross the placenta but appear in only small amounts in cord blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/33\">",
"     33",
"    </a>",
"    ]. In contrast, dexamethasone and betamethasone reach higher concentrations in the fetus because they are metabolized less efficiently by the placenta.",
"   </p>",
"   <p>",
"    The administration of GCs to pregnant rodents can result in cleft palates in the offspring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/34\">",
"     34",
"    </a>",
"    ]. Cases of cleft palate and fatal adrenal hypoplasia have been described in humans after in utero GC exposure. Orofacial clefts (cleft lip",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    palate) occur in approximately 1.7 in 1000 live births in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/35\">",
"     35",
"    </a>",
"    ]. The risk of cleft palate with glucocorticoid exposure is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case-control study of 1092 infants with orofacial clefts, neural tube defects, or limb reduction defects assessed maternal GC use in the time period between one month before and three months after conception [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/36\">",
"       36",
"      </a>",
"      ]. A significantly increased risk of cleft lip and palate was observed in infants of mothers exposed to GC during the time period selected, with odds ratios of 4.3 and 5.3, respectively.",
"     </li>",
"     <li>",
"      A systematic meta-analysis of studies of women who used GCs during pregnancy reported an overall odds ratio for bearing a child with cleft palate of 3.4 (95% CI 1.97-5.69) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    GC therapy during pregnancy may increase the risk of premature rupture of the membranes (PROM) and intrauterine growth restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/38,39\">",
"     38,39",
"    </a>",
"    ] and, in the mother, may increase the risk of pregnancy-induced hypertension, gestational diabetes, osteoporosis, and infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who received greater than 20 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    per day for more than three weeks in the six months prior to delivery should be assumed to have suppression of hypothalamic-pituitary-adrenal function and should be managed accordingly during labor and delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17384?source=see_link\">",
"     \"The surgical patient taking glucocorticoids\"",
"    </a>",
"    .) In contrast, significant suppression of this axis in the newborn is infrequent and typically transient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of glucocorticoids (GC):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash; GCs are excreted into the breast milk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/41\">",
"       41",
"      </a>",
"      ], but their use during lactation is deemed compatible by the American Academy of Pediatrics (AAP) if justified by the potential benefit to the health of the mother. We advise discarding breast milk for the first four hours following ingestion of a dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &ge;20 mg.",
"     </li>",
"     <li>",
"      Recommendations &mdash; We recommend using the lowest effective GC dose and, if possible, avoiding GCs altogether during the first trimester while the hard palate is forming. If GCs have been used for a prolonged period during pregnancy, stress dose GCs should be administered perioperatively. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17384?source=see_link\">",
"       \"The surgical patient taking glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Azathioprine and 6-MP",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    (AZA) is metabolized to 6-mercaptopurine (6-MP) in vivo. Thus, these two medications should theoretically have the same effects during pregnancy. Specific details regarding the use and monitoring of these medication are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7673?source=see_link\">",
"     \"Immunomodulator therapy in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/5/21592?source=see_link\">",
"     \"Azathioprine and 6-mercaptopurine in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radioactive labeling studies in humans have shown that 64 to 93 percent of AZA administered to mothers appears in fetal blood as inactive metabolites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/42\">",
"     42",
"    </a>",
"    ]. This is because the placenta metabolizes AZA to thiouric acid, which is inactive, rather than 6-mercaptopurine (6-MP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/42\">",
"     42",
"    </a>",
"    ]. After birth, AZA is metabolized to 6-MP.",
"   </p>",
"   <p>",
"    Data on the use of AZA in pregnant women come primarily from studies of patients who have undergone organ transplantation and of those who have Crohn&rsquo;s disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/16,43-45\">",
"     16,43-45",
"    </a>",
"    ]. Such studies have reached conflicting conclusions.",
"   </p>",
"   <p>",
"    Among transplant recipients, one report evaluated 146 renal allograft recipients who received AZA and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (90 percent), AZA alone (2 percent), or glucocorticoids alone (8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/46\">",
"     46",
"    </a>",
"    ]. Low birth weights, prematurity, jaundice, respiratory distress syndrome, and aspiration all occurred significantly more frequently among the offspring of mothers in the two AZA groups. In addition, there were isolated cases of immunoglobulin deficiency, chromosomal abnormalities, and malformations, but the frequency of these events was not higher than that expected in a healthy obstetrical population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Crohn&rsquo;s disease, a nationwide cohort study in Denmark included 900 children born to women with that disease between 1996 and 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/43\">",
"     43",
"    </a>",
"    ]. Twenty mothers in that study were exposed to AZA or 6-MP during pregnancy. The following findings were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women exposed to AZA or 6-MP alone or in combination with other Crohn&rsquo;s disease medications had higher risks of preterm births (25 percent) compared with patients who received the combination of glucocorticoids and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      (SSZ) (13 percent), SSZ alone (4 percent), or no medications for Crohn&rsquo;s disease during pregnancy (7 percent). Compared with the reference group of patients who received no medications, the relative risk of preterm birth was 4.2 in the AZA or 6-MP group (95% CI 1.4-12.5). It is possible that patients using these medications were sicker, which may have also affected the risk of preterm birth.",
"     </li>",
"     <li>",
"      Congenital abnormalities occurred in 15 percent of the AZA or 6-MP group, compared with 4, 6, and 6 percent in women treated with glucocorticoid and SSZ, with SSZ alone, and with no medications, respectively. Compared with the reference group of patients who received no medications, the AZA or 6-MP group had nearly three times the risk of congenital abnormalities (relative risk 2.9, 95% CI 0.9-8.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study was limited by the small number of patients treated with AZA or 6-MP and by the fact that the investigators were not able to adjust their analysis for disease severity. In addition, results were not separately analyzed for each individual drug but were combined.",
"   </p>",
"   <p>",
"    Other data on the use of AZA or 6-MP by women who are pregnant are more encouraging with regard to the risk of adverse birth outcomes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective cohort study of 155 IBD patients reported no statistical difference in fertility, birth defects, infections, and maternal malignancies among the group treated with 6-MP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study of 101 pregnancies in women with IBD on AZA also revealed no association with poor pregnancy outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Breast feeding during AZA treatment of the mother has been discouraged in the past, including a recommendation of the World Health Organization that was formulated in 1988 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Data on this point remain limited. One study of four women being treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    found no detectable 6-MP in their breast milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/49\">",
"     49",
"    </a>",
"    ]. The theoretical absolute infant dose was less than 0.09 percent of the mother&rsquo;s weight-adjusted dose. Another study, involving 10 nursing women who provided a total of 31 breast milk samples, reported the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-nine of the 31 samples contained no detectable 6-MP.",
"     </li>",
"     <li>",
"      Two samples from one woman contained low concentrations of 6-MP (1.2 and 7.6",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      compared with a plasma concentration of 50",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      that is normally considered therapeutic).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The AZA metabolites 6-MP and 6-thioguanine were not detectable in neonatal blood, and there were no clinical or hematologic signs of immunosuppression in any of the 10 neonates. Two smaller studies of women following renal transplantation reported similar findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of AZA and 6-MP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash; The manufacturers&rsquo; inserts for AZA and 6-MP say that they are excreted in breast milk and should not be used in women who are breastfeeding. Subsequent data have suggested that excretion in breast milk is very low in most women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. The potential benefits of breastfeeding must be weighed against the possible risks in patients treated with these drugs.",
"     </li>",
"     <li>",
"      Recommendations &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      , the medication more commonly used in rheumatologic disorders, may be safer than 6-MP, and there is a general consensus that AZA may be safer than many other immunosuppressive agents during pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/16\">",
"       16",
"      </a>",
"      ]. When the benefit of immunosuppression appears to outweigh the risks (eg, in renal transplant recipients, recently active lupus or inflammatory bowel disease), AZA or 6-MP is preferred over agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and other immunosuppressive medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     TNF inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies and case reports of women exposed to TNF inhibitors during pregnancy suggest that their pregnancy outcomes, including rates of preterm birth, of spontaneous abortion, and of congenital anomalies, are similar to those in women with rheumatoid arthritis (RA) or inflammatory bowel disease who have not received these medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/16,53-61\">",
"     16,53-61",
"    </a>",
"    ]. These data are limited by the small number of studies exploring this issue but are supported by animal studies that have not raised any significant concerns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Specific details regarding the use and monitoring of these medications are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of biologic agents in the rheumatic diseases\", section on 'TNF inhibition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A case report suggested a possible association between TNF inhibitor use and a collection of malformations that rarely occur together, referred to as the VACTERL association (Vertebral anomalies, Anal atresia, Cardiac defects, Tracheoesophageal fistula, Esophageal atresia, Renal anomalies, and Limb dysplasia), and prompted a search of reports to the FDA of congenital anomalies after exposure to TNF inhibitors through December 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. A total of 61 congenital anomalies thought to be related to TNF inhibitor exposure were identified in 41 children, including the index case [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/65\">",
"     65",
"    </a>",
"    ]. However, the concerns raised by this group remain controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/55,66,67\">",
"     55,66,67",
"    </a>",
"    ]. By one estimate, based upon chance alone, approximately 4600 congenital anomalies would have been expected among children born to an estimated 220,000 exposed patients since the TNF inhibitors have been available, in contrast to the very small number that have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/55\">",
"     55",
"    </a>",
"    ]. In addition, no increase in congenital anomalies belonging to the VACTERL association was found among infants exposed to TNF inhibitors in utero in a subsequent study from a European congenital anomaly database [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observations regarding safety during pregnancy have been made about the following TNF inhibitors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      (a soluble fusion protein)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      (a chimeric monoclonal antibody)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      (a humanized monoclonal antibody)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pregnancy outcome data in humans regarding the newer agents,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    , are not available, although animal studies suggest that risk is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of TNF inhibitors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash; There are insufficient data to address the safety of breastfeeding while using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      . The concentration of etanercept in breast milk has been measured in a single patient who was lactating (but not nursing her newborn) and was approximately 4 percent of the maternal serum concentration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/69\">",
"       69",
"      </a>",
"      ]. In contrast, in a patient who was receiving infliximab for the treatment of Crohn&rsquo;s disease, levels of the medication were undetectable in the patient&rsquo;s breast milk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/70\">",
"       70",
"      </a>",
"      ]. The high molecular weights and the very limited human data suggest that the three agents may be compatible with breastfeeding; the proteins are probably digested in the infant&rsquo;s gut. Until additional data are available, we suggest avoiding TNF inhibitor use during breastfeeding and discussing the lack of sufficient data to document the level of risk with the patient.",
"     </li>",
"     <li>",
"      Recommendation &mdash; We suggest the discontinuation of TNF inhibitors prior to conception, whenever possible, given the limitations of the available data and the uncertainties regarding the risk of congenital malformations. A decision regarding the continuation or discontinuation of TNF inhibitor therapy can occur at the time of a confirmed pregnancy test in individuals who require these medications to control disease that has been extremely active. In patients with continued flares during pregnancy, the decision to resume therapy depends upon patient preference, which should be based upon an understanding of the balance of benefits and risks, including the uncertain potential for congenital anomalies such as the VACTERL association.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More data are required to better assess the safety of these medications in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin (IVIG, sometimes abbreviated by industry and regulatory agencies as &ldquo;IGIV&rdquo;) is a modulator of inflammatory processes hypothesized to operate through anti-idiotype mechanisms. Specific details regarding the use and monitoring of this medication are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immune globulin given by the subcutaneous route has been used safely in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31896?source=see_link\">",
"     \"Subcutaneous and intramuscular immune globulin therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is little information regarding the teratogenicity of IVIG in animals. One report showed that IVIG was tolerated well in a mouse model of antiphospholipid syndrome in the setting of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, IVIG appears to cross the placenta after 30 to 32 weeks of gestation, even after modification that alters the Fc binding sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/72\">",
"     72",
"    </a>",
"    ]. There have been no reports of fetal malformations in humans. However, hemolytic disease of the newborn and (prior to 1994) transmission of hepatitis C have been reported in selected cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. IVIG crosses the placenta beginning in the second trimester, but the highest transport is in the third trimester.",
"   </p>",
"   <p>",
"    Use of IVIG:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash; It is not known if IVIG is excreted in breast milk.",
"     </li>",
"     <li>",
"      Recommendation &mdash; IVIG is a reasonable treatment for some autoimmune diseases during pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=see_link\">",
"       \"General principles in the use of immune globulin\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    A (CSA) is a calcineurin inhibitor. Specific details regarding the use and monitoring of this medication are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is little or no transplacental passage of CSA in rodents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/75\">",
"     75",
"    </a>",
"    ]. Studies in pregnant rats have generally no effect of CSA on organogenesis, although some renal proximal tubular cell damage can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. There are conflicting reports on the transfer of CSA across the human placenta; some reports have found little or no transfer, while others have found CSA levels in the placenta that were equivalent to those in maternal blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/78-80\">",
"     78-80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have reported the passage of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    to the fetus late in the third trimester, at birth, and with breastfeeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/81-90\">",
"     81-90",
"    </a>",
"    ]. The cord blood to maternal plasma ratios ranged from 0.35 to 0.63. In one case, cord blood and amniotic fluid levels eight hours after a 325 mg dose were 57 and 234",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Teratogenicity data in humans are derived primarily from organ transplant recipients. The risk of teratogenicity among the offspring of women treated with CSA appears to be low, but premature labor and infants who are small for gestational age have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/16,91\">",
"     16,91",
"    </a>",
"    ]. Such findings may be related to the underlying medical condition rather than to the drug and could also be related to both the medical condition and the drug. The following studies indicate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2001 meta-analysis of 15 studies of women who received CSA during pregnancy reported major malformations in 4.1 percent of offspring, a rate similar to that of the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second study compared the pregnancy outcomes of 115 renal transplant recipients (154 total pregnancies) treated with CSA with those of patients whose transplant immunosuppression regimen consisted only of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/46\">",
"       46",
"      </a>",
"      ]. The overall complication rate among newborns in the CSA group was slightly lower, and no congenital malformations were seen. However, CSA was associated with lower birth weights and a higher incidence of maternal diabetes, hypertension, and renal allograft rejection. These may be related to the patients&rsquo; medical conditions rather than to CSA itself.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of CSA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash; CSA is excreted in breast milk, and therapeutic levels have been reported in some breastfed infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/40,62,90,93,94\">",
"       40,62,90,93,94",
"      </a>",
"      ]. Thus, the use of CSA by lactating mothers is not recommended. The American Academy of Pediatrics has also expressed concern regarding the potential toxicity of this agent in nursing infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/95\">",
"       95",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recommendation &mdash; The long-term immunomodulatory effects of CSA on the offspring of women who receive this medication are not known. When the administration of CSA is necessary during pregnancy, the minimum dose should be used, and the maternal blood pressure and renal function should be monitored closely.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      should not be given to breastfeeding women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    is a calcineurin inhibitor. Specific details regarding the use and monitoring of this medication are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are relatively few data concerning the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    on pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/96\">",
"     96",
"    </a>",
"    ]. Among 100 pregnancies in 84 women treated with tacrolimus, 68 pregnancies progressed to live births. Sixty percent of these live births were premature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/97\">",
"     97",
"    </a>",
"    ]. There were four babies with malformations, but there was no consistent pattern of anatomic abnormality. Two other studies in which infants were exposed to tacrolimus in utero, including 27 and 19 pregnancies, respectively, showed no increased risk of fetal anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Two case reports found that the maximal dose infants received from nursing mothers was 0.02 to 0.5 percent of the mother&rsquo;s weight-adjusted dose, suggesting that this medication may be compatible with breastfeeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/100,101\">",
"     100,101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"      is generally not recommended during lactation, but very limited data suggest it may be compatible with breastfeeding given the very low levels of medication detected in exposed infants reported.",
"     </li>",
"     <li>",
"      Recommendation &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"      is a reasonable alternative to more aggressive immunosuppressive agents for patients requiring therapy during pregnancy. The long-term immunomodulatory effects of tacrolimus on the offspring of women who receive this medication are not known. When the administration of tacrolimus is necessary during pregnancy, the minimum dose should be used, and blood pressure and renal function should be monitored closely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MODERATE TO HIGH RISK OF FETAL HARM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some immunosuppressive medications with known potential for causing teratogenic effects must be used in pregnancy if the mother&rsquo;s health is directly threatened by an inflammatory illness. Such medications can be used with apparent safety, but are always employed with reluctance because of their possible adverse impact on the pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    (CYC) is an alkylating agent. Specific details regarding the use and monitoring of this medication are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The administration of CYC to pregnant animals produces congenital anomalies such as exophthalmos, cleft palate, skeletal abnormalities, fetal resorption, and growth retardation. The risk of teratogenicity with CYC exposure in humans is high, and the medication should be avoided in all circumstances except the development of disease complications that pose grave health threats to the mother.",
"   </p>",
"   <p>",
"    Most of the data in humans related to CYC exposure during pregnancy comes from isolated case reports. Normal offspring have been born to mothers who received CYC during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/102\">",
"     102",
"    </a>",
"    ]. The syndrome of &ldquo;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    embryopathy&rdquo; is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link&amp;anchor=H13#H13\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Teratogenicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The likelihood of embryotoxicity resulting from CYC administration during pregnancy varies according to the stage of pregnancy at which exposure to the drug occurs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of teratogenicity from CYC is highest when the medication is used during the first trimester [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Better outcomes are possible if exposure occurs during the second or third trimester. At least 36 women have been treated with CYC as part of chemotherapeutic regimens for breast cancer during the late second or third trimester without reported adverse pregnancy or neonatal events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/103,104\">",
"       103,104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Limited data suggest that the pregnancies of patients with SLE fare poorly when severe disease flares occur during pregnancy, regardless of when CYC is used [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of CYC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash; Because CYC is excreted in breast milk, it should be avoided during lactation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recommendation &mdash; We strongly recommend avoidance of CYC during pregnancy except in life-threatening medical conditions in which no alternative therapy is available. Breastfeeding is contraindicated for mothers receiving CYC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/62\">",
"       62",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17207?source=see_link\">",
"       \"Breast cancer during pregnancy and lactation: Epidemiology and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    (MTX) is a folate antagonist. Specific details regarding the use and monitoring of this medication are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=see_link\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Animal studies have shown that MTX is embryotoxic in early pregnancy and causes skeletal abnormalities and cleft palate later in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, MTX is teratogenic and is an abortifacient. MTX exposure during pregnancy can induce multiple congenital deformities such as cleft palate, hydrocephalus, anencephaly, meningoencephalocele, congenital stenosis of tubular long bones, abnormal facial features (low-set ears, micrognathia), and delayed ossification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/108,109\">",
"     108,109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the data on adverse events related to MTX use in pregnancy are from patients undergoing cancer therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/110-113\">",
"     110-113",
"    </a>",
"    ]. The rate of congenital malformations has been estimated to be 9 to 17 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/16,112\">",
"     16,112",
"    </a>",
"    ]. Among 63 pregnancies in which the fetus was exposed to MTX during the first trimester, 19 were terminated electively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/16\">",
"     16",
"    </a>",
"    ]. Among the remaining 44 pregnancies, the following outcomes were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Miscarriages &mdash; 11 (25 percent)",
"     </li>",
"     <li>",
"      Congenital anomalies &mdash; 4 (9 percent)",
"     </li>",
"     <li>",
"      Healthy infants &mdash; 29 (66 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In women with exposure very early during pregnancy, the risk of congenital anomalies may be lower than 9 percent.",
"   </p>",
"   <p>",
"    MTX is widely distributed in maternal tissues and can persist in the liver for up to four months after exposure. This medication should be discontinued one to three months prior to conception.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    supplementation should be continued during this time and throughout the pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=see_link&amp;anchor=H9#H9\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Dosing of MTX'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of MTX:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash; MTX is excreted into breast milk in low concentrations and can accumulate in neonatal tissues [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/114\">",
"       114",
"      </a>",
"      ]. Thus, the drug is contraindicated during lactation.",
"     </li>",
"     <li>",
"      Recommendation &mdash; We strongly recommend against using MTX during either pregnancy or lactation. We strongly advise contraceptive use in patients taking MTX. Women on MTX should discontinue this medication and should allow one to three full menstrual cycles to pass before attempting to conceive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF) is an inhibitor of purine biosynthesis. Specific details regarding the use and monitoring of this medication are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=see_link\">",
"     \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2006 review of data from the manufacturer identified 119 human pregnancies with maternal or fetal exposure to MMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/16\">",
"     16",
"    </a>",
"    ]. The outcomes, known for only 65 of the pregnancies, included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Healthy live births &mdash; 22 (34 percent)",
"     </li>",
"     <li>",
"      Elective terminations &mdash; 13 (20 percent)",
"     </li>",
"     <li>",
"      Miscarriages &mdash; 20 (31 percent)",
"     </li>",
"     <li>",
"      Congenital anomalies &mdash; 10 (15 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings have been noted in kidney transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/115\">",
"     115",
"    </a>",
"    ]. Problems reported with MMF include increases both in first trimester pregnancy loss and in congenital malformations, such as cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, and kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/116\">",
"     116",
"    </a>",
"    ]. A possibly characteristic phenotype including cleft lip and palate, microtia, and external auditory canals has been reported in six cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/117\">",
"     117",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11241?source=see_link&amp;anchor=H12#H12\">",
"     \"Pregnancy in women with underlying renal disease\", section on 'Mycophenolate mofetil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These risks are consistent with observations in animals in which MMF may cause problems with the development of ova [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of MMF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash; MMF is excreted into breast milk. This medication is contraindicated in lactating women.",
"     </li>",
"     <li>",
"      Recommendation &mdash; We recommend using MMF only in patients who employ reliable means of contraception and avoiding the use of this medication during lactation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Leflunomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available on the outcomes of pregnancies occurring in women taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    (LEF), an antimetabolite that inhibits dihydroorotate dehydrogenase, the enzyme which catalyzes the rate-limiting step in pyrimidine biosynthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/112,119-123\">",
"     112,119-123",
"    </a>",
"    ]. Although the half-life of LEF is only approximately 15 days, its major metabolite (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/45/8918?source=see_link\">",
"     teriflunomide",
"    </a>",
"    ) undergoes extensive enterohepatic circulation and remains detectable in serum for up to two years. Thus, discontinuation of LEF immediately before conception is insufficient for drug elimination. However, elimination of the drug and its metabolites can be accelerated through the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    (8 grams orally three times daily for 11 days) and can be confirmed by measurement of drug levels less than 0.02",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    on two tests performed two weeks apart. Additional cholestyramine treatment is indicated if plasma levels remain greater than 0.02",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     \"Leflunomide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific details regarding the use and monitoring of this medication are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=see_link\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concerns regarding its safety during pregnancy derive both from animal studies, which have demonstrated embryotoxicity and marked teratogenicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/119,124\">",
"     119,124",
"    </a>",
"    ], and from the persistence of drug metabolites for many months following discontinuation of therapy. Several case reports have also raised concerns, although good pregnancy outcomes have been observed as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/121-123\">",
"     121-123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest reported series of women exposed to LEF during conception and during the first few weeks of pregnancy compared 64 women with RA who became pregnant while taking LEF with 108 pregnant women with RA not on LEF and 78 healthy pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/123\">",
"     123",
"    </a>",
"    ]. LEF was discontinued in all exposed patients, with the last dose at a mean of 3.1 weeks post-conception (range 0 to 8.6 weeks). Most women (95 percent) were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    , resulting in undetectable levels at a mean of 10.7 weeks post-conception. There were no significant differences in the rate of major structural defects in the exposed patients compared with either control group (5.4, 4.2, and 4.2 percent, respectively). No specific pattern of major or minor anomalies was seen, nor was there an increase in rates of pregnancy loss.",
"   </p>",
"   <p>",
"    Despite this study, effective contraception is essential for women of childbearing potential for whom LEF is prescribed.",
"   </p>",
"   <p>",
"    Use of LEF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       Leflunomide",
"      </a>",
"      is contraindicated during lactation.",
"     </li>",
"     <li>",
"      Recommendation &mdash; We strongly recommend that women avoid LEF for up to two years before pregnancy and during pregnancy and lactation. An alternative to waiting is the enhanced elimination of the medication with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"       cholestyramine",
"      </a>",
"      , with follow up documentation of undetectable levels before attempting pregnancy. We advise women to wait at least three menstrual cycles before attempting conception after treatment with cholestyramine. We also recommend that women who conceive while on LEF should be treated using cholestyramine to rapidly eliminate the medication and its metabolites.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Third trimester use of NSAIDs and aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    should not be used during the third trimester because of the risk of premature closure of the ductus arteriosus. The exception is low-dose aspirin for obstetric indications. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'NSAIDs and aspirin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     UNKNOWN RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is generally insufficient evidence related to the risks associated with the use of certain biologic agents in pregnancy. It is occasionally necessary to continue administration of one of these medications during pregnancy, if the mother&rsquo;s health is highly dependent upon such treatment. In these situations, it is important that the mother has been counseled regarding the potential risks of the medication during pregnancy and that she participates actively in informed decision-making. These agents include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       Anakinra",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"       Abatacept",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       Tocilizumab",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Anakinra",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"     Anakinra",
"    </a>",
"    is a recombinant human interleukin (IL)-1 receptor antagonist (IL-1ra). Specific details regarding the use and monitoring of this medication are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of biologic agents in the rheumatic diseases\", section on 'IL-1 inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies on rats and rabbits using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    at doses up to 100-fold higher than those employed in humans did not indicate problems relating either to infertility or to fetal harm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/125\">",
"     125",
"    </a>",
"    ]. There have been no adequate studies of these issues in humans.",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash; There are insufficient data to address the issue of safety for breastfed infants.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       Anakinra",
"      </a>",
"      should be avoided during lactation until additional data are available. Anakinra (recombinant IL-1ra) is a non-glycosylated form of the human cytokine IL-1ra. The native form is present in breast milk and is thought to contribute to the known antiinflammatory properties of milk. Thus, there appears to be no risk to a nursing infant from administration of anakinra.",
"     </li>",
"     <li>",
"      Recommendation &mdash; We recommend avoiding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      during both pregnancy and lactation unless the mother&rsquo;s health is critically dependent upon this medication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is a chimeric monoclonal antibody that leads to peripheral B-cell depletion through targeting the CD20 antigen present on B lymphocytes, the precursors of plasma cells. Specific details regarding the use and monitoring of rituximab are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=see_link\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    has been detected in high concentrations in umbilical cord blood. Case reports in humans provide information about the use of rituximab in the setting of pregnancy. The range of data is summarized by the following points:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      caused complete but transient B-cell depletion in the child of a mother with Burkitt&rsquo;s lymphoma who received rituximab and CHOP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) chemotherapy during pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/126\">",
"       126",
"      </a>",
"      ]. The infant demonstrated B-cell count recovery, a normal immunophenotype, and normal responses to vaccinations.",
"     </li>",
"     <li>",
"      A patient under treatment for Hodgkin lymphoma inadvertently received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      during the first trimester of pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/127\">",
"       127",
"      </a>",
"      ]. The course of pregnancy remained normal, and a healthy, full-term baby was delivered.",
"     </li>",
"     <li>",
"      A patient with non-Hodgkin lymphoma was treated in the second trimester with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/128\">",
"       128",
"      </a>",
"      ]. A healthy baby was delivered at 35 weeks. Peripheral B-cell counts measured when the infant was four weeks old were normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash; There are insufficient data to address the issue of safety for breastfed infants.",
"     </li>",
"     <li>",
"      Recommendation &mdash; We recommend avoiding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      during both pregnancy and lactation unless the mother&rsquo;s health is critically dependent upon this medication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Abatacept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     Abatacept",
"    </a>",
"    (CTLA4-Ig) is an inhibitor of T-cell costimulation. Specific details regarding the use and monitoring of this medication are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9223?source=see_link&amp;anchor=H3#H3\">",
"     \"T cell targeted therapies for rheumatoid arthritis\", section on 'Costimulatory molecule inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     Abatacept",
"    </a>",
"    interferes with T-cell activation by binding to accessory molecules (CD80 and CD86) and by blocking interaction with CD28 (CTLA4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/129\">",
"     129",
"    </a>",
"    ]. Abatacept is not teratogenic in animals, but there are no adequate studies of its effects on human pregnancy to allow an assessment of its risk.",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash; There are insufficient data to address the issue of safety for breastfed infants.",
"     </li>",
"     <li>",
"      Recommendation &mdash; We recommend avoiding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"       abatacept",
"      </a>",
"      during both pregnancy and lactation unless the mother&rsquo;s health is highly dependent upon this medication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Tocilizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     Tocilizumab",
"    </a>",
"    is an interleukin (IL)-6 receptor inhibitor. Specific details regarding the use and monitoring of this medication are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35016?source=see_link&amp;anchor=H5#H5\">",
"     \"Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL\", section on 'Tocilizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon animal data,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    may cause fetal harm, but there are no adequate studies of its effects on human pregnancy to allow an assessment of its risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnancy outcomes have been reported for 31 pregnancies, which were associated with 13 elective abortions, with seven spontaneous abortions (five also exposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ), with one newborn infant death due to respiratory distress after fetomaternal hemorrhage due to placenta previa, and with 10 healthy newborns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/59/38842/abstract/131\">",
"     131",
"    </a>",
"    ]. No teratogenic effects were observed.",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation &mdash; There are insufficient data to address the issue of safety for breastfed infants.",
"     </li>",
"     <li>",
"      Recommendation &mdash; We recommend avoiding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      during both pregnancy and lactation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12098?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=see_link\">",
"       \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/20/5443?source=see_link\">",
"       \"Patient information: Inflammatory bowel disease and pregnancy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/42/36518?source=see_link\">",
"       \"Patient information: Systemic lupus erythematosus and pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All immunosuppressive agents have potential side effects, but their safety during pregnancy is variable. (See individual medication discussions above.)",
"   </p>",
"   <p>",
"    We suggest the following regimen for pregnant women with autoimmune disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In mild disease, immunosuppressive therapy should be avoided, if possible. A low-dose glucocorticoid (eg, 5 to 15 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      per day) is the first choice if treatment is necessary. Glucocorticoid use early during pregnancy increases the risk of cleft palate formation. Later in pregnancy, glucocorticoids increase the risk of gestational diabetes and pregnancy-induced hypertension. NSAIDs may be used from the time of the first missed menstrual cycle up until the beginning of the third trimester. Use during a conception cycle can potentially reduce implantation and, therefore, should be avoided. Use of NSAIDs after the second trimester carries the risk of premature closure of the ductus arteriosus.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       Hydroxychloroquine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      (with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      ) may be continued during pregnancy.",
"     </li>",
"     <li>",
"      In moderate to severe disease,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      , glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , and IVIG may be used. Although data are more limited, the decision to continue a TNF inhibitor during pregnancy should take into account patient preference, which should be based upon an understanding of the balance of benefits and risks, including the uncertain potential for congenital anomalies such as the VACTERL association. (See appropriate sections above.)",
"     </li>",
"     <li>",
"      In life-threatening disease, high-dose glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , and 6-mercaptopurine can be used.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      should be reserved for those cases in which there are no alternative therapies available.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       Leflunomide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil should be avoided in all circumstances, and counseling should be offered in the setting of inadvertent exposure.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/1\">",
"      Parke A, West B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 1996; 23:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/2\">",
"      Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006; 54:3640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/3\">",
"      Buchanan NM, Toubi E, Khamashta MA, et al. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996; 55:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/4\">",
"      Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003; 48:3207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/5\">",
"      Canadian rheumatology association. Canadian Consensus Conference on hydroxychloroquine. J Rheumatol 2000; 27:2919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/6\">",
"      J&auml;rnerot G, Into-Malmberg MB, Esbj&ouml;rner E. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. Scand J Gastroenterol 1981; 16:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/7\">",
"      J&auml;rnerot G, Andersen S, Esbj&ouml;rner E, et al. Albumin reserve for binding of bilirubin in maternal and cord serum under treatment with sulphasalazine. Scand J Gastroenterol 1981; 16:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/8\">",
"      Hoo JJ, Hadro TA, Von Behren P. Possible teratogenicity of sulfasalazine. N Engl J Med 1988; 318:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/9\">",
"      Craxi A, Pagliarello F. Possible embryotoxicity of sulfasalazine. Arch Intern Med 1980; 140:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/10\">",
"      Hern&aacute;ndez-D&iacute;az S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/11\">",
"      Mogadam M, Dobbins WO 3rd, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981; 80:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/12\">",
"      Levy N, Roisman I, Teodor I. Ulcerative colitis in pregnancy in Israel. Dis Colon Rectum 1981; 24:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/13\">",
"      Esbj&ouml;rner E, J&auml;rnerot G, Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand 1987; 76:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/14\">",
"      J&auml;rnerot G, Into-Malmberg MB. Sulphasalazine treatment during breast feeding. Scand J Gastroenterol 1979; 14:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/15\">",
"      Branski D, Kerem E, Gross-Kieselstein E, et al. Bloody diarrhea--a possible complication of sulfasalazine transferred through human breast milk. J Pediatr Gastroenterol Nutr 1986; 5:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/16\">",
"      &Oslash;stensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/17\">",
"      Kozer E, Nikfar S, Costei A, et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol 2002; 187:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/18\">",
"      Daniel S, Matok I, Gorodischer R, et al. Major malformations following exposure to nonsteroidal antiinflammatory drugs during the first trimester of pregnancy. J Rheumatol 2012; 39:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/19\">",
"      Ostensen M, Ostensen H. Safety of nonsteroidal antiinflammatory drugs in pregnant patients with rheumatic disease. J Rheumatol 1996; 23:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/20\">",
"      Askie LM, Duley L, Henderson-Smart DJ, et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/21\">",
"      Koren G, Florescu A, Costei AM, et al. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother 2006; 40:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/22\">",
"      Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 1976; 295:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/23\">",
"      Heymann MA. Non-narcotic analgesics. Use in pregnancy and fetal and perinatal effects. Drugs 1986; 32 Suppl 4:164.",
"     </a>",
"    </li>",
"    <li>",
"     Drug Facts and Comparisons. In: Facts and Comparison, 50th, Wolters Kluwer, St. Louis 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/25\">",
"      Ostensen M, Ramsey-Goldman R. Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Drug Saf 1998; 19:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/26\">",
"      Mendon&ccedil;a LL, Khamashta MA, Nelson-Piercy C, et al. Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology (Oxford) 2000; 39:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/27\">",
"      Uhler ML, Hsu JW, Fisher SG, Zinaman MJ. The effect of nonsteroidal anti-inflammatory drugs on ovulation: a prospective, randomized clinical trial. Fertil Steril 2001; 76:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/28\">",
"      Pall M, Frid&eacute;n BE, Br&auml;nnstr&ouml;m M. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. Hum Reprod 2001; 16:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/29\">",
"      Nakhai-Pour HR, Broy P, Sheehy O, B&eacute;rard A. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ 2011; 183:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/30\">",
"      Nielsen GL, S&oslash;rensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ 2001; 322:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/31\">",
"      Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 2003; 327:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/32\">",
"      Edwards DR, Aldridge T, Baird DD, et al. Periconceptional over-the-counter nonsteroidal anti-inflammatory drug exposure and risk for spontaneous abortion. Obstet Gynecol 2012; 120:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/33\">",
"      Beitins IZ, Bayard F, Ances IG, et al. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr 1972; 81:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/34\">",
"      PINSKY L, DIGEORGE AM. CLEFT PALATE IN THE MOUSE: A TERATOGENIC INDEX OF GLUCOCORTICOID POTENCY. Science 1965; 147:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/35\">",
"      Mossey PA, Little J, Munger RG, et al. Cleft lip and palate. Lancet 2009; 374:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/36\">",
"      Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 1999; 86:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/37\">",
"      Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/38\">",
"      Guller S, Kong L, Wozniak R, Lockwood CJ. Reduction of extracellular matrix protein expression in human amnion epithelial cells by glucocorticoids: a potential role in preterm rupture of the fetal membranes. J Clin Endocrinol Metab 1995; 80:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/39\">",
"      Lockwood CJ, Radunovic N, Nastic D, et al. Corticotropin-releasing hormone and related pituitary-adrenal axis hormones in fetal and maternal blood during the second half of pregnancy. J Perinat Med 1996; 24:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/40\">",
"      Petri M. Immunosuppressive drug use in pregnancy. Autoimmunity 2003; 36:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/41\">",
"      Ost L, Wettrell G, Bj&ouml;rkhem I, Rane A. Prednisolone excretion in human milk. J Pediatr 1985; 106:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/42\">",
"      Saarikoski S, Sepp&auml;l&auml; M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol 1973; 115:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/43\">",
"      N&oslash;rg&aring;rd B, Pedersen L, Christensen LA, S&oslash;rensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/44\">",
"      Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/45\">",
"      Moskovitz DN, Bodian C, Chapman ML, et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 2004; 99:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/46\">",
"      Armenti VT, Ahlswede KM, Ahlswede BA, et al. National transplantation Pregnancy Registry--outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 1994; 57:502.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Working Group on Drugs and Human Lactation. Drugs and Human Lactation. Elsevier; Amsterdam, 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/48\">",
"      EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. Nephrol Dial Transplant 2002; 17 Suppl 4:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/49\">",
"      Moretti ME, Verjee Z, Ito S, Koren G. Breast-feeding during maternal use of azathioprine. Ann Pharmacother 2006; 40:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/50\">",
"      Sau A, Clarke S, Bass J, et al. Azathioprine and breastfeeding: is it safe? BJOG 2007; 114:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/51\">",
"      Coulam CB, Moyer TP, Jiang NS, Zincke H. Breast-feeding after renal transplantation. Transplant Proc 1982; 14:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/52\">",
"      Grekas DM, Vasiliou SS, Lazarides AN. Immunosuppressive therapy and breast-feeding after renal transplantation. Nephron 1984; 37:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/53\">",
"      Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007; 46:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/54\">",
"      Vinet E, Pineau C, Gordon C, et al. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum 2009; 61:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/55\">",
"      Ali YM, Kuriya B, Orozco C, et al. Can tumor necrosis factor inhibitors be safely used in pregnancy? J Rheumatol 2010; 37:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/56\">",
"      Chambers C, Johnson DL, Jones KL, the OTIS Collaborative Research Group. Pregnancy outcome in women exposed to anti-TNF-alpha medications: The OTIS Rheumatoid Arthritis in Pregnancy Study. Arthritis Rheum 2004; 50:S479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/57\">",
"      Hyrich KL, Symmons DP, Watson KD, et al. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum 2006; 54:2701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/58\">",
"      Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/59\">",
"      Ventura SJ, Mosher WD, Curtin SC, et al. Trends in pregnancies and pregnancy rates by outcome: estimates for the United States, 1976-96. Vital Health Stat 21 2000; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/60\">",
"      Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig Dis Sci 2006; 51:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/61\">",
"      Strangfeld A. Pregnancy outcome after exposure to biologics: results from the German biologics register RABBIT. Arthritis Rheum 2007; 56:S311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/62\">",
"      Treacy G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody. Hum Exp Toxicol 2000; 19:226.",
"     </a>",
"    </li>",
"    <li>",
"     Reprotox Agent Detail - Adalimumab www.reprotox.org/Members/AgentDetail.aspx?a=4262 (Accessed on March 25, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/64\">",
"      Carter JD, Valeriano J, Vasey FB. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. J Rheumatol 2006; 33:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/65\">",
"      Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009; 36:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/66\">",
"      Koren G, Inoue M. Do tumor necrosis factor inhibitors cause malformations in humans? J Rheumatol 2009; 36:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/67\">",
"      Crijns HJ, Jentink J, Garne E, et al. The distribution of congenital anomalies within the VACTERL association among tumor necrosis factor antagonist-exposed pregnancies is similar to the general population. J Rheumatol 2011; 38:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/68\">",
"      Martin PL, Oneda S, Treacy G. Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am J Reprod Immunol 2007; 58:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/69\">",
"      Ostensen M, Eigenmann GO. Etanercept in breast milk. J Rheumatol 2004; 31:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/70\">",
"      Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol 2008; 14:3085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/71\">",
"      Bakimer R, Guilburd B, Zurgil N, Shoenfeld Y. The effect of intravenous gamma-globulin on the induction of experimental antiphospholipid syndrome. Clin Immunol Immunopathol 1993; 69:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/72\">",
"      H&ouml;ckel M, Kaufmann R. Placental transfer of class G immunoglobulins treated with beta-propiolactone (beta-PL) for intravenous application--a case report. J Perinat Med 1986; 14:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/73\">",
"      Potter M, Stockley R, Storry J, Slade R. ABO alloimmunisation after intravenous immunoglobulin infusion. Lancet 1988; 1:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/74\">",
"      Reznikoff-Etievant MF, de Lachaux Y, Marpeau L, Courouc&eacute; A. Intravenous immunoglobulins and hepatitis C transmission in healthy pregnant women. Lancet 1992; 340:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/75\">",
"      B&auml;ckman L, Brandt I, Appelkvist EL, Dallner G. Tissue and subcellular localizations of 3H-cyclosporine A in mice. Pharmacol Toxicol 1988; 62:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/76\">",
"      Schmid BP. Monitoring of organ formation in rat embryos after in vitro exposure to azathioprine, mercaptopurine, methotrexate or cyclosporin A. Toxicology 1984; 31:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/77\">",
"      Mason RJ, Thomson AW, Whiting PH, et al. Cyclosporine-induced fetotoxicity in the rat. Transplantation 1985; 39:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/78\">",
"      Nandakumaran M, Eldeen AS. Transfer of cyclosporine in the perfused human placenta. Dev Pharmacol Ther 1990; 15:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/79\">",
"      Venkataramanan R, Koneru B, Wang CC, et al. Cyclosporine and its metabolites in mother and baby. Transplantation 1988; 46:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/80\">",
"      Di Paolo S, Monno R, Stallone G, et al. Placental imbalance of vasoactive factors does not affect pregnancy outcome in patients treated with Cyclosporine A after transplantation. Am J Kidney Dis 2002; 39:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/81\">",
"      Lewis GJ, Lamont CA, Lee HA, Slapak M. Successful pregnancy in a renal transplant recipient taking cyclosporin A. Br Med J (Clin Res Ed) 1983; 286:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/82\">",
"      Flechner SM, Katz AR, Rogers AJ, et al. The presence of cyclosporine in body tissues and fluids during pregnancy. Am J Kidney Dis 1985; 5:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/83\">",
"      Burrows DA, O'Neil TJ, Sorrells TL. Successful twin pregnancy after renal transplant maintained on cyclosporine A immunosuppression. Obstet Gynecol 1988; 72:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/84\">",
"      L&ouml;wenstein BR, Vain NW, Perrone SV, et al. Successful pregnancy and vaginal delivery after heart transplantation. Am J Obstet Gynecol 1988; 158:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/85\">",
"      Ziegenhagen DJ, Crombach G, Dieckmann M, et al. [Pregnancy during cyclosporin medication following a kidney transplant]. Dtsch Med Wochenschr 1988; 113:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/86\">",
"      al-Khader AA, Absy M, al-Hasani MK, et al. Successful pregnancy in renal transplant recipients treated with cyclosporine. Transplantation 1988; 45:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/87\">",
"      Sims CJ, Porter KB, Knuppel RA. Successful pregnancy after a liver transplant. Am J Obstet Gynecol 1989; 161:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/88\">",
"      Kossoy LR, Herbert CM 3rd, Wentz AC. Management of heart transplant recipients: guidelines for the obstetrician-gynecologist. Am J Obstet Gynecol 1988; 159:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/89\">",
"      Munoz-Flores-Thiagarajan KD, Easterling T, Davis C, Bond EF. Breast-feeding by a cyclosporine-treated mother. Obstet Gynecol 2001; 97:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/90\">",
"      Moretti ME, Sgro M, Johnson DW, et al. Cyclosporine excretion into breast milk. Transplantation 2003; 75:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/91\">",
"      Cockburn I, Krupp P, Monka C. Present experience of Sandimmun in pregnancy. Transplant Proc 1989; 21:3730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/92\">",
"      Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001; 71:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/93\">",
"      Nyberg G, Haljam&auml;e U, Frisenette-Fich C, et al. Breast-feeding during treatment with cyclosporine. Transplantation 1998; 65:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/94\">",
"      Osadchy A, Koren G. Cyclosporine and lactation: when the mother is willing to breastfeed. Ther Drug Monit 2011; 33:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/95\">",
"      American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.",
"     </a>",
"    </li>",
"    <li>",
"     Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 9th, Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.1381.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/97\">",
"      Kainz A, Harabacz I, Cowlrick IS, et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 2000; 70:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/98\">",
"      Jain A, Venkataramanan R, Fung JJ, et al. Pregnancy after liver transplantation under tacrolimus. Transplantation 1997; 64:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/99\">",
"      Jain AB, Shapiro R, Scantlebury VP, et al. Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. Transplantation 2004; 77:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/100\">",
"      French AE, Soldin SJ, Soldin OP, Koren G. Milk transfer and neonatal safety of tacrolimus. Ann Pharmacother 2003; 37:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/101\">",
"      Gardiner SJ, Begg EJ. Breastfeeding during tacrolimus therapy. Obstet Gynecol 2006; 107:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/102\">",
"      Kart K&ouml;seoglu H, Y&uuml;cel AE, K&uuml;nefeci G, et al. Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy. Lupus 2001; 10:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/103\">",
"      Berry DL, Theriault RL, Holmes FA, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999; 17:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/104\">",
"      Ring AE, Smith IE, Jones A, et al. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol 2005; 23:4192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/105\">",
"      Clowse ME, Magder L, Petri M. Cyclophosphamide for lupus during pregnancy. Lupus 2005; 14:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/106\">",
"      Wiernik PH, Duncan JH. Cyclophosphamide in human milk. Lancet 1971; 1:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/107\">",
"      Skalko RG, Gold MP. Teratogenicity of methotrexate in mice. Teratology 1974; 9:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/108\">",
"      Buckley LM, Bullaboy CA, Leichtman L, Marquez M. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997; 40:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/109\">",
"      Milunsky A, Graef JW, Gaynor MF Jr. Methotrexate-induced congenital malformations. J Pediatr 1968; 72:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/110\">",
"      Kozlowski RD, Steinbrunner JV, MacKenzie AH, et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990; 88:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/111\">",
"      Ostensen M, Hartmann H, Salvesen K. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J Rheumatol 2000; 27:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/112\">",
"      Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003; 30:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/113\">",
"      Lewden B, Vial T, Elefant E, et al. Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol 2004; 31:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/114\">",
"      Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate into human milk. Am J Obstet Gynecol 1972; 112:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/115\">",
"      Sifontis NM, Coscia LA, Constantinescu S, et al. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006; 82:1698.",
"     </a>",
"    </li>",
"    <li>",
"     www.rocheusa.com/products/cellcept/pregnancy_notice.pdf (Accessed on September 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/117\">",
"      Perez-Aytes A, Ledo A, Boso V, et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A 2008; 146A:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/118\">",
"      Downs SM. Induction of meiotic maturation in vivo in the mouse by IMP dehydrogenase inhibitors: effects on the developmental capacity of ova. Mol Reprod Dev 1994; 38:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/119\">",
"      Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 2001; 63:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/120\">",
"      De Santis M, Straface G, Cavaliere A, et al. Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. Ann Rheum Dis 2005; 64:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/121\">",
"      Heine K, Poets CF. A pair of twins born after maternal exposure to leflunomide. J Perinatol 2008; 28:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/122\">",
"      Neville CE, McNally J. Maternal exposure to leflunomide associated with blindness and cerebral palsy. Rheumatology (Oxford) 2007; 46:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/123\">",
"      Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010; 62:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/124\">",
"      Fukushima R, Kanamori S, Hirashiba M, et al. Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Reprod Toxicol 2007; 24:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/125\">",
"      Physician's Desk Reference, Edition 58. Montvale, NJ, Thomson PDR, 2004; 31:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/126\">",
"      Friedrichs B, Tiemann M, Salwender H, et al. The effects of rituximab treatment during pregnancy on a neonate. Haematologica 2006; 91:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/127\">",
"      Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 2004; 72:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/128\">",
"      Herold M, Schnohr S, Bittrich H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol 2001; 19:3439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/129\">",
"      Abatacept (Orencia) for rheumatoid arthritis. Med Lett Drugs Ther 2006; 48:17.",
"     </a>",
"    </li>",
"    <li>",
"     Full prescribing information for Actemra (tocilizumab) www.gene.com/gene/products/information/actemra/pdf/pi.pdf (Accessed on June 09, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/59/38842/abstract/131\">",
"      Rubbert-Roth A, Goupile PM, Moosavi S, et al. First experiences with pregnancies in RA patients receiving tocilizumab therapy (abstract). Arthritis Rheum 2010; Suppl:384.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7998 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-9C98E7F444-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_59_38842=[""].join("\n");
var outline_f37_59_38842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MINIMAL FETAL OR MATERNAL RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hydroxychloroquine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sulfasalazine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SELECTIVE USE ALLOWED DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NSAIDs and aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Azathioprine and 6-MP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TNF inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MODERATE TO HIGH RISK OF FETAL HARM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Leflunomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Third trimester use of NSAIDs and aspirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      UNKNOWN RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Anakinra",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Abatacept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Tocilizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7998\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7998|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/15/36092\" title=\"table 1\">",
"      Frequency common birth defects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/47/2807?source=related_link\">",
"      Aspirin: Mechanism of action, major toxicities, and use in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/5/21592?source=related_link\">",
"      Azathioprine and 6-mercaptopurine in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17207?source=related_link\">",
"      Breast cancer during pregnancy and lactation: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7386?source=related_link\">",
"      Genetic and environmental causes of birth defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7673?source=related_link\">",
"      Immunomodulator therapy in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=related_link\">",
"      Leflunomide in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=related_link\">",
"      Leflunomide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29226?source=related_link\">",
"      Management of asthma during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/0/44041?source=related_link\">",
"      Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/20/5443?source=related_link\">",
"      Patient information: Inflammatory bowel disease and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12098?source=related_link\">",
"      Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/42/36518?source=related_link\">",
"      Patient information: Systemic lupus erythematosus and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11241?source=related_link\">",
"      Pregnancy in women with underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41609?source=related_link\">",
"      Prevention of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35016?source=related_link\">",
"      Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31896?source=related_link\">",
"      Subcutaneous and intramuscular immune globulin therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20344?source=related_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/27/2490?source=related_link\">",
"      Sulfasalazine in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9223?source=related_link\">",
"      T cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17384?source=related_link\">",
"      The surgical patient taking glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_59_38843="Haddon model firearm injuries";
var content_f37_59_38843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Haddon's injury control model for firearm injuries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Event stages",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        Epidemiological factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Human factor",
"       </td>",
"       <td class=\"subtitle2\">",
"        Agent or vehicle",
"       </td>",
"       <td class=\"subtitle2\">",
"        Physical environment",
"       </td>",
"       <td class=\"subtitle2\">",
"        Sociocultural/political environment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Pre-event",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Gun safety programs for children",
"        </p>",
"        <p>",
"         Family counseling",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Remove firearms from home",
"        </p>",
"        <p>",
"         Loaded chamber indicator",
"        </p>",
"        <p>",
"         Magazine disconnect device",
"        </p>",
"        <p>",
"         Trigger locks",
"        </p>",
"        <p>",
"         Personalized gun",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Lock boxes",
"        </p>",
"        <p>",
"         Store ammunition separately",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Regulation of handguns and assault weapons",
"        </p>",
"        <p>",
"         Regulation of firearms as a consumer product",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Event",
"       </td>",
"       <td>",
"        Bulletproof vest",
"       </td>",
"       <td>",
"        Safer bullet",
"       </td>",
"       <td>",
"        Safe firearm practice ranges",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-event",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        Surveillance and analysis of firearm injuries to identify risk factors, causes, and possible prevention strategies",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_59_38843=[""].join("\n");
var outline_f37_59_38843=null;
var title_f37_59_38844="Diff diagnosis pheo spells";
var content_f37_59_38844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F63617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F63617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of pheochromocytoma type spells",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Endocrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pheochromocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Hyperandrenergic spells\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyrotoxicosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary hypogonadism (menopausal syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medullary thyroid carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic tumors (eg, insulinoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbohydrate intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Labile essential hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular deconditioning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orthostatic hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paroxysmal cardiac arrhythmia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Psychologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anxiety and panic attacks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Somatization disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factitious (eg, drugs, valsalva)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pharmacologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Withdrawal of andernergic-inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MAO-inhibitor RX + decongestant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sympathomimetic ingestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Illegal drug ingestion (cocaine, PCP, LSD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorpropamide-alcohol flush",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vancomycin (\"red man syndrome\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postural orthostatic tachycardia syndrome (POTS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autonomic neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Migraine headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diencephalic epilepsy (autonomic seizures)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebrovascular insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unexplained flushing spells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mast cell disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carcinoid syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent idiopathic anaphylaxis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Young, WF Jr. Pheochromocytoma and primary aldosteronism. Cancer Treat Res 1997; 89:239. Copyright &copy; 1997 Springer Science and Business Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_59_38844=[""].join("\n");
var outline_f37_59_38844=null;
var title_f37_59_38845="Nutrition and diaphragm function";
var content_f37_59_38845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of nutrition on diaphragmatic length-tension relationship",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 359px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Undernutrition (calorie-restricted group) decreases the tension produced at any given muscle length in response to tetanic stimulation (50 Hz). Muscle length is expressed as a percentage of the length at which tension was maximal (Lo).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Kelsen SG, Ference M, Dapoor S, J Appl Phsiol 1985; 58:1354.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_59_38845=[""].join("\n");
var outline_f37_59_38845=null;
var title_f37_59_38846="Neonate step pain therapy";
var content_f37_59_38846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 580px\">",
"   <div class=\"ttl\">",
"    Proposed steps for neonatal analgesia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 560px; height: 395px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_59_38846=[""].join("\n");
var outline_f37_59_38846=null;
var title_f37_59_38847="Craniopharyngioma Plain film";
var content_f37_59_38847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Craniopharyngioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain film in a 36 year-old patient with craniopharyngioma shows sella turcica expansion with amorphous calcification projecting over the anterior clinoids.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lawrence Recht, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_59_38847=[""].join("\n");
var outline_f37_59_38847=null;
